Study GUID,Reference,,,,,,,
CG15AdultST1,"Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabetic Medicine 1995; 12 :1068–76.",,,,,,,
CG15AdultST2,"Currie C, Peters J. Costs of insulin-dependent diabetes mellitus. Diabetic Medicine 1996; 13 :684–5.",,,,,,,
CG15AdultST3,"Evans JM, MacDonald TM, Leese GP et al . Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care 2000; 23 :770–4.",,,,,,,
CG15AdultST4,"National Institute for Clinical Excellence. Information for National Collaborating Centres and Guideline Development Groups . The Guideline Development Process Series No. 3. London: NICE, 2004.",,,,,,,
CG15AdultST5,"Home PD, Coles J, Goldacre M et al . Health outcome indicators: Diabetes. A report of a working group to the Department of Health . Oxford: National Centre for Health Outcomes Development, 1999.",,,,,,,
CG15AdultST6,"Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technology Assessment 2001; 5 :1–69.",,,,,,,
CG15AdultST7,"Murphy MK, Black NA, Lamping DL et al . Consensus development methods and their use in clinical guideline development , 1998.",,,,,,,
CG15AdultST8,"World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus . Geneva: WHO, 1999.",,,,,,,
CG15AdultST9,"Delahanty L, Simkins SW, Camelon K. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. The DCCT Research Group. Journal of the American Dietetic Association 1993; 93 :758–64, 767.",,,,,,,
CG15AdultST10,"Loveman E, Royle P, Waugh N. Specialist nurses in diabetes mellitus . The Cochrane Library, 2003.",,,,,,,
CG15AdultST11,"Sadur CN, Moline N, Costa M et al . Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care 1999; 22 :2011–7.",,,,,,,
CG15AdultST12,"Thompson DM, Kozak SE, Sheps S. Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients: a randomized trial. Canadian Medical Association Journal 1999; 161 :959–62.",,,,,,,
CG15AdultST13,"Hearnshaw H, Hopkins J, Wild A et al . Mandatory, multidisciplinary education in diabetes care. Can it meet the needs of primary care organisations? Practical Diabetes International 2001; 18 :274–80.",,,,,,,
CG15AdultST14,"Koblik T, Sieradzki J, Friedlein J, Legutko J. First Polish multidisciplinary diabetic foot team: results of the first three years of operation – the Cracow study. Diabetologia Polska 1999; 6 :233–8.",,,,,,,
CG15AdultST15,"Larsson J, Apelqvist J, Agardh CD, Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabetic Medicine 1995; 12 :770–6.",,,,,,,
CG15AdultST16,"Brink SJ, Miller M, Moltz KC. Education and multidisciplinary team care concepts for pediatric and adolescent diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 2002; 15 :1113–30.",,,,,,,
CG15AdultST17,"Yokoyama KK, Cryar AK, Griffin KC et al . Cost-effectiveness of a multidisciplinary diabetes care clinic. Drug Benefit Trends 2002; 14 :36–44.",,,,,,,
CG15AdultST18,"Dargis V, Pantelejeva O, Jonushaite A et al . Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study. Diabetes Care 1999; 22 :1428–31.",,,,,,,
CG15AdultST19,"Cox D, Gonder-Frederick L, Polonsky W et al . A multicenter evaluation of blood glucose awareness training – II. Diabetes Care 1995; 18 :523–8.",,,,,,,
CG15AdultST20,"Apelqvist J, Ragnarson-Tennvall G, Persson U, Larsson J. Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation. Journal of Internal Medicine 1994; 235 :463–71. 153",,,,,,,
CG15AdultST21,Frykberg RG. Team approach toward lower extremity amputation prevention in diabetes. Journal of the American Podiatric Medical Association 1997; 87 :305–12.,,,,,,,
CG15AdultST22,"Riazi A, Hammersley S, Eiser C et al . Patients’ experiences of the diabetes annual review. Practical Diabetes International 2000; 17 :226–30.",,,,,,,
CG15AdultST23,"Braid E, Campbell B, Curtis S et al . The diabetes annual review as an educational tool: assessment and learning integrated with care, screening, and audit. Diabetic Medicine 1992; 9 :389–94.",,,,,,,
CG15AdultST24,"International Diabetes Foundation. A guide to type 1 (insulin dependent) diabetes mellitus . Brussels: IDF, 1998.",,,,,,,
CG15AdultST25,"Grabert M, Schweiggert F, Holl RW. A framework for diabetes documentation and quality management in Germany: 10 years of experience with DPV. Computer Methods and Programs in Biomedicine 2002; 69 : 115–21.",,,,,,,
CG15AdultST26,"Azzopardi J, Fenech FF, Junoussov Z et al . A computerized health screening and follow-up system in diabetes mellitus. Diabetic Medicine 1995; 12 :271–6.",,,,,,,
CG15AdultST27,"Burnett SD, Woolf CM, Yudkin JS. Developing a district diabetic register. British Medical Journal 1992; 305 :627–30.",,,,,,,
CG15AdultST28,"Burnett SD, Press M, Yudkin JS. Compiling a district diabetic register: theoretical and practical considerations. Diabetic Medicine 1993; 10 :199–200.",,,,,,,
CG15AdultST29,"Elwyn GJ, Vaughan NJ, Stott NC. District diabetes registers: more trouble than they’re worth? Review. Diabetic Medicine 1998; 15 (Suppl 3):S44–8.",,,,,,,
CG15AdultST30,"Harris MF, Priddin D, Ruscoe W et al . Quality of care provided by general practitioners using or not using division-based diabetes registers. Medical Journal of Australia 2002; 177 :250–2.",,,,,,,
CG15AdultST31,"Howitt AJ, Cheales NA. Diabetes registers: a grassroots approach. British Medical Journal 1993; 307 :1046–8.",,,,,,,
CG15AdultST32,"Kelly W, Bilous R, Murray G. A comprehensive register for diabetic outpatients: experience with desktop computing from 1987–1996. Computer Methods and Programs in Biomedicine 1998; 56 :205–10.",,,,,,,
CG15AdultST33,"Coppell K, Manning P; Otago Diabetes Team. Establishing a regional diabetes register and a description of the registered population after one year. New Zealand Medical Journal 2002; 115 :U146.",,,,,,,
CG15AdultST34,"Kleschen MZ, Holbrook J, Rothbaum AK et al . Improving the pneumococcal immunization rate for patients with diabetes in a managed care population: a simple intervention with a rapid effect. Joint Commission Journal on Quality Improvement 2000; 26 :538–46.",,,,,,,
CG15AdultST35,"Kopelman PG, Michell JC, Sanderson AJ. DIAMOND: a computerized system for the management and evaluation of district-wide diabetes care. Diabetic Medicine 1995; 12 :83–7.",,,,,,,
CG15AdultST36,"Vaughan NJ, Shaw M, Boer F et al . Creation of a District Diabetes Register using the DIALOG system. Review. Diabetic Medicine 1996; 13 :175–81.",,,,,,,
CG15AdultST37,"Day JL, Metcalfe J, Johnson P. Benefits provided by an integrated education and clinical diabetes centre: a follow-up study. Diabetic Medicine 1992; 9 :855–9.",,,,,,,
CG15AdultST38,"Bridgford A, Davis TM. A comprehensive patient-held record for diabetes. Part one: Initial development of the Diabetes Databank. Practical Diabetes International 2001; 18 :241–5.",,,,,,,
CG15AdultST39,"Davis TM, Bridgford A. A comprehensive patient-held record for diabetes. Part two: Large-scale assessment of the diabetes databank by patients and health care workers. Practical Diabetes International 2001; 18 :311–4.",,,,,,,
CG15AdultST40,"Engelbrecht R, Hildebrand C, Kuhnel E et al . A chip card for patients with diabetes. Computer Methods and Programs in Biomedicine 1994; 45 :33–5.",,,,,,,
CG15AdultST41,"Engelbrecht R, Hildebrand C, Brugues E et al . DIABCARD – an application of a portable medical record for persons with diabetes. Medical Informatics 1996; 21 :273–82.",,,,,,,
CG15AdultST42,"Engelbrecht R, Hildebrand C. DIABCARD a smart card for patients with chronic diseases. Clinical Performance and Quality Health Care 1997; 5 :67–70.",,,,,,,
CG15AdultST43,"Engelbrecht R, Hildebrand C. Telemedicine and diabetes. Studies in Health Technology and Informatics 1999; 64 :142–54.",,,,,,,
CG15AdultST44,"Fischer U, Salzsieder E, Menzel R et al . Primary health care of diabetic patients in a specialized outpatient setting: a DIABCARE-based analysis. Diabète et Métabolisme 1993; 19 :188–94.",,,,,,,
CG15AdultST45,"Chiarelli F, Verrotti A, Di Ricco L, LaPorte RE. Information superhighway, Internet and diabetes. Diabetes, Nutrition and Metabolism – Clinical and Experimental 1998; 11 :219–24.",,,,,,,
CG15AdultST46,"Gorman C, Looker J, Fisk T et al . A clinically useful diabetes electronic medical record: lessons from the past; pointers toward the future. Review. European Journal of Endocrinology 1996; 134 :31–42.",,,,,,,
CG15AdultST47,"Piwernetz K, Renner R, Mohrlein A et al . Analysis and processing of data in a hospital-based diabetes management system. Hormone and Metabolic Research Supplement 1990; 24 :109–15.",,,,,,,
CG15AdultST48,"Smith SA, Murphy ME, Huschka TR et al . Impact of a diabetes electronic management system on the care of patients seen in a subspecialty diabetes clinic. Diabetes Care 1998; 21 :972–6.",,,,,,,
CG15AdultST49,"Stroebel RJ, Scheitel SM, Fitz JS et al . A randomized trial of three diabetes registry implementation strategies in a community internal medicine practice. Joint Commission Journal on Quality Improvement 2002; 28 :441–50.",,,,,,,
CG15AdultST50,"Biermann E, Dietrich W, Rihl J, Standl E. Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial. Computer Methods and Programs in Biomedicine 2002; 69 :137–46.",,,,,,,
CG15AdultST51,"McGill M, Constantino M, Yue DK. Integrating telemedicine into a National Diabetes Footcare Network. Practical Diabetes International 2000; 17 :235–8.",,,,,,,
CG15AdultST52,"Cummings DM, Morrissey S, Barondes MJ et al . Screening for diabetic retinopathy in rural areas: the potential of telemedicine. Journal of Rural Health 2001; 17 :25–31.",,,,,,,
CG15AdultST53,"McCulloch DK. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Diabetes Spectrum 1996; 9 :180–1. [Commentary on Levetan CS, Salas R, Wiltes IF et al . American Journal of Medicine 1995; 99 :22–8].",,,,,,,
CG15AdultST54,"Levetan CS, Salas JR, Wilets IF, Zumoff B. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. American Journal of Medicine 1995; 99 :22–8.",,,,,,,
CG15AdultST55,"Koproski J, Pretto Z, Poretsky L. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care 1997; 20 :1553–5.",,,,,,,
CG15AdultST56,"Hentinen M, Kyngas H. Diabetic adolescents’ compliance with health regimens and associated factors. International Journal of Nursing Studies 1996; 33 :325–37.",,,,,,,
CG15AdultST57,"Kaplan RM, Hartwell SL. Differential effects of social support and social network on physiological and social outcomes in men and women with type II diabetes. Health Psychology 1987; 6 :387–98.",,,,,,,
CG15AdultST58,"Fisher L, Chesla CA, Bartz RJ et al . The family and type 2 diabetes: a framework for intervention. Diabetes Educator 1998; 24 :599–607.",,,,,,,
CG15AdultST59,"Hanson CL, Henggeler SW, Burghen GA. Social competence and parental support as mediators of the link between stress and metabolic control in adolescents with insulin-dependent diabetes mellitus. Journal of Consulting and Clinical Psychology 1987; 55 :529–33.",,,,,,,
CG15AdultST60,"Schafer LC, McCaul KD, Glasgow RE. Supportive and nonsupportive family behaviors: relationships to adherence and metabolic control in persons with type I diabetes. Diabetes Care 1986; 9 :179–85.",,,,,,,
CG15AdultST61,"Bailey BJ, Kahn A. Apportioning illness management authority: how diabetic individuals evaluate and respond to spousal help. Qualitative Health Research 1993; 3 :55–73.",,,,,,,
CG15AdultST62,"The DAWN (Diabetes Attitudes, Wishes and Needs) Study. Practical Diabetes International 2002; 19 :22a–4a.",,,,,,,
CG15AdultST63,"Diabetes UK and Care Interventions Team. Needs of the recently diagnosed. Listening project. Report and recommendations . London: Diabetes UK, 2001. 155 References",,,,,,,
CG15AdultST64,"Hiscock J, Legard R, Snape D. Listening to Diabetes Service Users: Qualitative findings for the Diabetes National Service Framework . London: Department of Health, 2003.",,,,,,,
CG15AdultST65,Assessing the benefit of support groups. New England Journal of Medicine 2001; 345 :1719–68.,,,,,,,
CG15AdultST66,"Knight BG, Lutzky SM, Macofsky-Urban F. A meta-analytic review of interventions for caregiver distress: recommendations for future research. Gerontologist 1993; 33 :240–8.",,,,,,,
CG15AdultST67,"Toseland RW, Labrecque MS, Gobel ST, Whitney MH. An evaluation of a group program for spouses of frail elderly veterans. Gerontologist 1992; 32 :382–90. 67a. Data obtained from an email from Debbie Hammond, Diabetes UK patients representative on the Guideline Development Group, August 2003.",,,,,,,
CG15AdultST68,"Labrecque MS, Peak T. Long-term effectiveness of a group program for caregivers of frail elderly veterans. American Journal of Orthopsychiatry 1992; 62 :575–88.",,,,,,,
CG15AdultST69,"Ostwald SK, Hepburn KW, Caron W et al . Reducing caregiver burden: a randomized psychoeducational intervention for caregivers of persons with dementia. Gerontologist 1999; 39 :299–309.",,,,,,,
CG15AdultST70,"Hanestad BR, Albrektsen G. The effects of participation in a support group on self assessed quality of life in people with insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice 1993; 19 :163–73.",,,,,,,
CG15AdultST71,"Maxwell AE, Hunt IF, Bush MA. Effects of a social support group, as an adjunct to diabetes training, on metabolic control and psychosocial outcomes. Diabetes Educator 1992; 18 :303–9.",,,,,,,
CG15AdultST72,"Fisher EB, Auslander WF, Munro JF et al . Neighbors for a smoke free north side: Evaluation of a community organization approach to promoting smoking cessation among African Americans. American Journal of Public Health 1998; 88 :1658–63.",,,,,,,
CG15AdultST73,Morris DB. A rural diabetes support group. Diabetes Educator 1998; 24 :493–7.,,,,,,,
CG15AdultST74,"Nuffield Trust. Sharing, stories: a feasibility study of facilitated small group learning by the oral tradition in diabetes education for British Bangladeshis in Tower Hamlets. 2000.",,,,,,,
CG15AdultST75,"Home P, Coles J, Goldacre M et al (eds). Health outcome indicators: diabetes mellitus . Report of a working group to the Department of Health. Oxford: National Centre for Health outcomes Development, 1999.",,,,,,,
CG15AdultST76,American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 (Suppl 1):S33–50.,,,,,,,
CG15AdultST77,"Carpentier WS, Piziak VK, Bratcher T, Hejl J. Efficacy of diabetes education: classroom versus individualized instruction. HMO Practice 1990; 4 :30–3.",,,,,,,
CG15AdultST78,"Kim JY, Phillips TL. The effectiveness of two forms of corrective feedback in diabetes education. Journal of Computer-Based Instruction 1991; 18 :14–8.",,,,,,,
CG15AdultST79,"Mensing C, Boucher J, Cypress M. National standards for diabetes self-management education. Diabetes Care 2003; 26 (Suppl 1):S149–56.",,,,,,,
CG15AdultST80,"Rapid Reviews Team, Southampton Health Technology Assessment Centre, University of Southampton. Patient education models for diabetes . London: National Institute for Clinical Excellence, 2002.",,,,,,,
CG15AdultST81,"de Weerdt I, Visser AP, Kok GJ et al . Randomized controlled multicentre evaluation of an education programme for insulin-treated diabetic patients: effects on metabolic control, quality of life, and costs of therapy. Diabetic Medicine 1991; 8 :338–45.",,,,,,,
CG15AdultST82,"Lennon GM, Taylor KG, Debney L, Bailey CJ. Knowledge, attitudes, technical competence, and blood glucose control of Type 1 diabetic patients during and after an education programme. Diabetic Medicine 1990; 7 :825–32.",,,,,,,
CG15AdultST83,"Valk GD, Kriegsman DM, Assendelft WJ. Patient education for preventing diabetic foot ulceration: a systematic review. Endocrinology and Metabolism Clinics of North America 2002; 31 :633–58.",,,,,,,
CG15AdultST84,"Norris SL, Nichols PJ, Caspersen CJ et al . Increasing diabetes self-management education in community settings. A systematic review. American Journal of Preventive Medicine 2002; 22 :39–66. 156 Type 1 diabetes in adults: national clinical guideline for diagnosis and management",,,,,,,
CG15AdultST85,Jones PM. Use of a course on self-control behavior techniques to increase adherence to prescribed frequency for self-monitoring blood glucose. Diabetes Educator 1990; 16 :296–303.,,,,,,,
CG15AdultST86,"Matam P, Kumaraiah V, Munichoodappa C et al . Behavioural intervention in the management of compliance in young type-I diabetics. Journal of the Association of Physicians of India 2000; 48 :967–71.",,,,,,,
CG15AdultST87,"Korhonen T, Huttunen JK, Aro A et al . A controlled trial on the effects of patient education in the treatment of insulin-dependent diabetes. Diabetes Care 1983; 6 :256–61.",,,,,,,
CG15AdultST88,"Halimi S, Charpentier G, Grimaldi A et al . Effect on compliance, acceptability of blood glucose self-monitoring and HbA(1c) of a self-monitoring system developed according to patient’s wishes. The ACCORD study. Diabetes and Metabolism 2001; 27 :681–7.",,,,,,,
CG15AdultST89,"Coster S, Gulliford MC, Seed PT et al . Monitoring blood glucose control in diabetes mellitus: a systematic review. Health Technology Assessment 2000; 4 :No.12.",,,,,,,
CG15AdultST90,"Germer S, Campbell IW. Home-monitoring of blood glucose – patient preference for ‘BM-Test Glycemie 20–800’ strips or ‘Glucometer’. British Journal of Clinical Practice 1985; 39 :225–7.",,,,,,,
CG15AdultST91,"Edelman SV, Callahan P, Deeb LC. Multisite evaluation of a new diabetes self-test for glucose and glycated protein (fructosamine) [including commentary by Riddle MC]. Diabetes Technology and Therapeutics 2000; 2 :233–40.",,,,,,,
CG15AdultST92,"Cefalu WT, Wang ZQ, Redmon E et al . Clinical validity of a self-test fructosamine in outpatient diabetic management [including commentary by Hom F]. Diabetes Technology and Therapeutics 1999; 1 :435–45.",,,,,,,
CG15AdultST93,"Gordon D, Semple CG, Paterson KR. Do different frequencies of self-monitoring of blood glucose influence control in type 1 diabetic patients? Diabetic Medicine 1991; 8 :679–82.",,,,,,,
CG15AdultST94,"Giacco R, Parillo M, Rivellese AA et al . Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. Diabetes Care 2000; 23 :1461–6.",,,,,,,
CG15AdultST95,"Hansen HP, Christensen PK, Tauber LE et al . Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Kidney International 1999; 55 :621–8.",,,,,,,
CG15AdultST96,"Chantelau EA, Frenzen A, Gosseringer G et al . Intensive insulin therapy justifies simplification of the diabetes diet: a prospective study in insulin-dependent diabetic patients. American Journal of Clinical Nutrition 1987; 45 :958–62.",,,,,,,
CG15AdultST97,"McCulloch DK, Mitchell RD, Ambler J, Tattersall RB. A prospective comparison of ‘conventional’ and high carbohydrate/high fibre/low fat diets in adults with established type 1 (insulin-dependent) diabetes. Diabetologia 1985; 28 :208–12.",,,,,,,
CG15AdultST98,"Yale JF, Begg I, Gerstein H et al . 2001 Canadian Diabetes Association clinical practice guidelines for the prevention and management of hypoglycemia in diabetes. Canadian Journal of Diabetes Care 2001; 26 :22–35.",,,,,,,
CG15AdultST99,"Amiel S, Beveridge S, Bradley C et al . Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. British Medical Journal 2002; 325 :746–9.",,,,,,,
CG15AdultST100,"Muhlhauser I, Bott U, Overmann H et al . Liberalized diet in patients with type 1 diabetes. Journal of Internal Medicine 1995; 237 :591–7.",,,,,,,
CG15AdultST101,"National Institute for Clinical Excellence. Guidance on the use of patient-education models for diabetes . London: NICE, 2003.",,,,,,,
CG15AdultST102,"Laaksonen DE, Atalay M, Niskanen LK et al . Aerobic exercise and the lipid profile in type 1 diabetic men: a randomized controlled trial. Medicine and Science in Sports and Exercise 2000; 32 :1541–8.",,,,,,,
CG15AdultST103,"Ligtenberg PC, Blans M, Hoekstra JB et al . No effect of long-term physical activity on the glycemic control in type 1 diabetes patients: a cross-sectional study. Netherlands Journal of Medicine 1999; 55 :59–63.",,,,,,,
CG15AdultST104,"Lehmann R, Kaplan V, Bingisser R et al . Impact of physical activity on cardiovascular risk factors in IDDM. Diabetes Care 1997; 20 :1603–11. 157 References",,,,,,,
CG15AdultST105,"Perry TL, Mann JI, Lewis-Barned NJ et al . Lifestyle intervention in people with insulin-dependent diabetes mellitus (IDDM). European Journal of Clinical Nutrition 1997; 51 :757–63.",,,,,,,
CG15AdultST106,"Schneider SH, Khachadurian AK, Amorosa LF et al . Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 1992; 15 :1800–10.",,,,,,,
CG15AdultST107,"Connor H, Annan F, Bunn E et al . The implementation of nutritional advice for people with diabetes. Diabetic Medicine 2003; 20 :786–807.",,,,,,,
CG15AdultST108,Larsen ML. The clinical usefulness of glucated haemoglobin in diabetes care evaluated by use of a medical technology assessment strategy. Review. Danish Medical Bulletin 1997; 44 :303–15.,,,,,,,
CG15AdultST109,"Gross TM, Bode BW, Einhorn D et al . Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technology and Therapeutics 2000; 2 :49–56.",,,,,,,
CG15AdultST110,"Gross TM, Ter Veer A. Continuous glucose monitoring in previously unstudied population subgroups. Diabetes Technology and Therapeutics 2000; 2 (Suppl 1):S27–34.",,,,,,,
CG15AdultST111,"Maran A, Crepaldi C, Tiengo A et al . Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 2002; 25 :347–52.",,,,,,,
CG15AdultST112,"Grieve R, Beech R, Vincent J, Mazurkiewicz J. Near patient testing in diabetes clinics: appraising the costs and outcomes. Health Technology Assessment 1999; 3 :1–74.",,,,,,,
CG15AdultST113,"Wang PH, Lau J, Chalmers TC, Zinman B. Intensive blood-glucose control and diabetes: a meta-analysis. Annals of Internal Medicine 1993; 119 :71.",,,,,,,
CG15AdultST114,"Alberti KG, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabetic Medicine 1988; 5 :275–81.",,,,,,,
CG15AdultST115,European Diabetes Policy Group. A desktop guide to Type 1 (insulin-dependent) diabetes mellitus. 1998. Diabetic Medicine 1999; 16 :253–66.,,,,,,,
CG15AdultST116,"Rohlfing CL, Wiedmeyer HM, Little RR et al . Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25 :275–8.",,,,,,,
CG15AdultST117,The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993; 329 :977–86.,,,,,,,
CG15AdultST118,The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44 :968–83.,,,,,,,
CG15AdultST119,"Stratton IM, Kohner EM, Aldington SJ et al . UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44 :156–63.",,,,,,,
CG15AdultST120,"McCance DR, Hadden DR, Atkinson AB et al . Long-term glycaemic control and diabetic retinopathy. Lancet 1989; ii :824–8.",,,,,,,
CG15AdultST121,"Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 1993; 329 :304–9.",,,,,,,
CG15AdultST122,"Krolewski AS, Laffel LM, Krolewski M et al . Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. New England Journal of Medicine 1995; 332 :1251–5.",,,,,,,
CG15AdultST123,"Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. Journal of the American Medical Association 1996; 276 : 1246–52.",,,,,,,
CG15AdultST124,"McCance DR, Hanson RL, Charles MA et al . Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. British Medical Journal 1994; 308 :1323–8. 158 Type 1 diabetes in adults: national clinical guideline for diagnosis and management",,,,,,,
CG15AdultST125,"Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. New England Journal of Medicine 1984; 310 :341–6.",,,,,,,
CG15AdultST126,"Richter B, Neises G, Bergerhoff K. Human versus animal insulin in people with diabetes mellitus: a systematic review. Endocrinology and Metabolism Clinics of North America 2002; 31 :723–49.",,,,,,,
CG15AdultST127,"George E, Bedford C, Peacey SR et al . Further evidence for a high incidence of nocturnal hypoglycaemia in IDDM: no effect of dose for dose transfer between human and porcine insulins. Diabetic Medicine 1997; 14 :442–8.",,,,,,,
CG15AdultST128,"Karlson B, Agardh CD. Influence of intensified insulin regimen on quality of life and metabolic control in insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice 1994; 25 :111–5.",,,,,,,
CG15AdultST129,"Egger M, Davey G, Stettler SC, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabetic Medicine 1997; 14 :919–28.",,,,,,,
CG15AdultST130,"Haakens K, Hanssen KF, Dahl-Jorgensen K et al . Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics. Scandinavian Journal of Clinical and Laboratory Investigation 1989; 49 :653–9.",,,,,,,
CG15AdultST131,"Tunbridge FK, Newens A, Home PD et al . Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens. Diabetes Care 1989; 12 :115–9.",,,,,,,
CG15AdultST132,"National Institute for Clinical Excellence. Guidance on the use of long-acting analogues for the treatment of diabetes – insulin glargine . Technology Appraisal Guidance No.53. London: NICE, 2002.",,,,,,,
CG15AdultST133,"Vignati L, Anderson JH Jr, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clinical Therapeutics 1997; 19 :1408–21.",,,,,,,
CG15AdultST134,"Nielsen FS, Jorgensen LN, Ipsen M et al . Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 1995; 38 :592–8.",,,,,,,
CG15AdultST135,"Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22 :801–5.",,,,,,,
CG15AdultST136,"Del Sindaco P, Ciofetta M, Lalli C et al . Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabetic Medicine 1998; 15 :592–600.",,,,,,,
CG15AdultST137,"Davey P, Grainger D, MacMillan J et al . Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clinical Therapeutics 1997; 19 :656–74.",,,,,,,
CG15AdultST138,"Lalli C, Ciofetta M, Del Sindaco P et al . Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22 :468–77.",,,,,,,
CG15AdultST139,"Anderson JH Jr, Brunelle RL, Koivisto VA et al . Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46 :265–70.",,,,,,,
CG15AdultST140,"Pfutzner A, Kustner E, Forst T et al . Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Experimental and Clinical Endocrinology and Diabetes 1996; 104 :25–30.",,,,,,,
CG15AdultST141,"Renner R, Pfutzner A, Trautmann M et al . Use of insulin lispro in continuous subcutaneous insulin infusion treatment: results of a multicenter trial. Diabetes Care 1999; 22 :784–8.",,,,,,,
CG15AdultST142,"Ebeling P, Jansson PA, Smith U et al . Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997; 20 :1287–9.",,,,,,,
CG15AdultST143,"Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. International Journal of Clinical Practice 2001; 55 :177–82. 159 References",,,,,,,
CG15AdultST144,"Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabetic Medicine 2000; 17 :209–14.",,,,,,,
CG15AdultST145,"Roach P, Trautmann M, Arora V et al . Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clinical Therapeutics 1999; 21 :523–34.",,,,,,,
CG15AdultST146,"Holleman F, Schmitt H, Rottiers R et al . Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20 :1827–32.",,,,,,,
CG15AdultST147,"Ahmed AB, Home PD. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care 1998; 21 :32–7.",,,,,,,
CG15AdultST148,"Brunelle RL, Llewelyn J, Anderson JH et al . Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21 :1726–31.",,,,,,,
CG15AdultST149,"Shukla VK, Otten N. Insulin lispro: a critical evaluation . Ottawa: Canadian Coordinating Office for Health Technology Assessment; Issue 5, Feb 1999.",,,,,,,
CG15AdultST150,"Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21 :1904–9.",,,,,,,
CG15AdultST151,"Zinman B, Ross S, Campos RV, Strack T. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen: a double-blind randomized prospective trial. Diabetes Care 1999; 22 :603–8.",,,,,,,
CG15AdultST152,"Hermansen K, Madsbad S, Perrild H et al . Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24 :296–301.",,,,,,,
CG15AdultST153,"Stades AM, Hoekstra JB, van den Tweel I et al ; STABILITY Study Group. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults: a real-life design. Diabetes Care 2002; 25 :712–7.",,,,,,,
CG15AdultST154,"Fanelli CG, Pampanelli S, Porcellati F et al . Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Annals of Internal Medicine 2002; 136 :504–14.",,,,,,,
CG15AdultST155,"Dunbar JM, Madden PM, Gleeson DT et al . Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994; 17 :874–8.",,,,,,,
CG15AdultST156,"DeVries JH, Snoek FJ, Kostense PJ et al ; Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002; 25 :2074–80.",,,,,,,
CG15AdultST157,"Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care 1997; 20 : 248–53.",,,,,,,
CG15AdultST158,"Riccardi G, Giacco R, Parillo M et al . Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabetic Medicine 1999; 16 :228–32.",,,,,,,
CG15AdultST159,"Viviani GL, Camogliano L, Borgoglio MG et al . Acarbose treatment in insulin-dependent diabetics. A double-blind crossover study. Current Therapeutic Research, Clinical Experimental 1987; 42 :1–11.",,,,,,,
CG15AdultST160,"Marena S, Tagliaferro V, Cavallero G et al . Double-blind crossover study of acarbose in type 1 diabetic patients. Diabetic Medicine 1991; 8 :674–8.",,,,,,,
CG15AdultST161,"Gums JG, Curry RW Jr, Montes de Oca G et al . Treatment of type I diabetes with a combination of glyburide and insulin. Annals of Pharmacotherapy 1992; 26 :757–62.",,,,,,,
CG15AdultST162,"Goldman J, Tamayo RC, Whitehouse FW, Kahkonen DM. Effect of glyburide on metabolic control and insulin binding in insulin-dependent diabetes mellitus. Diabetes Care 1984; 7 (Suppl 1):106–12. 160 Type 1 diabetes in adults: national clinical guideline for diagnosis and management",,,,,,,
CG15AdultST163,"Burke BJ, Hartog M, Waterfield MR. Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide. Acta Endocrinologica 1984; 107 :70–7.",,,,,,,
CG15AdultST164,"Fallucca F, Sciullo E, Maldonato A. Combined therapy with insulin and sulfonylurea for the treatment of new-onset insulin-dependent diabetes mellitus. Hormone and Metabolic Research 1996; 28 :86–8.",,,,,,,
CG15AdultST165,"National Institute for Clinical Excellence. Guidance on the use of continuous subcutaneous insulin infusion for diabetes . London: NICE, 2003.",,,,,,,
CG15AdultST166,"Murray DP, Keenan P, Gayer E et al . A randomized trial of the efficacy and acceptability of a pen injector. Diabetic Medicine 1988; 5 :750–4.",,,,,,,
CG15AdultST167,"Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care 1993; 16 :1592–7.",,,,,,,
CG15AdultST168,"de Meijer PH, Lutterman JA, van Lier HJ, van’t Laar A. The variability of the absorption of subcutaneously injected insulin: effect of injection technique and relation with brittleness. Diabetic Medicine 1990; 7 : 499–505.",,,,,,,
CG15AdultST169,"Fleming DR, Jacober SJ, Vandenberg MA et al . The safety of injecting insulin through clothing. Diabetes Care 1997; 20 :244–7.",,,,,,,
CG15AdultST170,"Kinsley BT, Weinger K, Bajaj M et al . Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care 1999; 22 :1022–8.",,,,,,,
CG15AdultST171,"Fritsche A, Stumvoll M, Renn W, Schmulling RM. Diabetes teaching program improves glycemic control and preserves perception of hypoglycemia. Diabetes Research and Clinical Practice 1998; 40 :129–35.",,,,,,,
CG15AdultST172,"Patrick AW, Collier A, Hepburn DA et al . Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department. Archives of Emergency Medicine 1990; 7 :73–7.",,,,,,,
CG15AdultST173,"Collier A, Steedman DJ, Patrick AW et al . Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department. Diabetes Care 1987; 10 :712–5.",,,,,,,
CG15AdultST174,"Scottish Intercollegiate Guidelines Network. Management of diabetes. A national clinical guideline . SIGN Publication No.55. Edinburgh: SIGN, 2001.",,,,,,,
CG15AdultST175,"Kanters SD, Banga JD, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vascular Medicine 1999; 4 :67–75.",,,,,,,
CG15AdultST176,"Pignone MP, Phillips CJ, Atkins D et al . Screening and treating adults for lipid disorders. American Journal of Preventive Medicine 2001; 20 (3 Suppl):77–89.",,,,,,,
CG15AdultST177,"Bayly GR, Bartlett WA, Davies PH et al . Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic. Diabetic Medicine 1999; 16 :697–701.",,,,,,,
CG15AdultST178,"Game FL, Bartlett WA, Bayly GR, Jones AF. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes, Obesity and Metabolism 2001; 3 :279–86.",,,,,,,
CG15AdultST179,"Game FL, Jones AF. Coronary heart disease risk assessment in diabetes mellitus – a comparison of PROCAM and Framingham risk assessment functions. Diabetic Medicine 2001; 18 :355–9.",,,,,,,
CG15AdultST180,"Jones AF, Walker J, Jewkes C et al . Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart 2001; 85 :37–43.",,,,,,,
CG15AdultST181,"Scottish Intercollegiate Guidelines Network. Lipids and the primary prevention of coronary heart disease . SIGN Publication No.40. Edinburgh: SIGN, 1999.",,,,,,,
CG15AdultST182,"Rustemeijer C, Schouten JA, Janssens EN et al . Pravastatin in diabetes associated hypercholesterolemia. Acta Diabetologica 1997; 34 :294–300.",,,,,,,
CG15AdultST183,"Raskin P, Ganda OP, Schwartz S et al . Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. American Journal of Medicine 1995; 99 :362–9. 161 References",,,,,,,
CG15AdultST184,"Goldberg RB, Mellies MJ, Sacks FM et al . Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98 :2513–9.",,,,,,,
CG15AdultST185,"Sartor G, Katzman P, Eizyk E et al . Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1995; 33 :3–6.",,,,,,,
CG15AdultST186,"Hommel E, Andersen P, Gall MA et al . Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35 :447–51.",,,,,,,
CG15AdultST187,"Winocour PH, Durrington PN, Bhatnagar D et al . Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus. Diabetic Medicine 1990; 7 :736–43.",,,,,,,
CG15AdultST188,"NHS Centre for Reviews and Dissemination. Aspirin for the secondary prophylaxis of vascular disease in primary care . Newcastle: University of Newcastle upon Tyne, Centre for Health Services Research; York: University of York, Centre for Health Economics, 1998.",,,,,,,
CG15AdultST189,ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report14. Journal of the American Medical Association 1992; 268 : 1292–300.,,,,,,,
CG15AdultST190,"Roffi M, Chew DP, Mukherjee D et al . Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 23 :2767–71.",,,,,,,
CG15AdultST191,Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355 :253–9.,,,,,,,
CG15AdultST192,"Yusuf S, Dagenais G, Pogue J et al . Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine 2000; 342 :154–60.",,,,,,,
CG15AdultST193,"McAlister FA, Zarnke KB, Campbell NR et al ; Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension. Part two – therapy. Canadian Journal of Cardiology 2002; 18 :625–41.",,,,,,,
CG15AdultST194,"Scottish Intercollegiate Guidelines Network. Hypertension in older people . SIGN Publication No. 49: Edinburgh: SIGN, 2001.",,,,,,,
CG15AdultST195,"Adler AI, Stratton IM, Neil HA et al . Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. British Medical Journal 2000; 321 :412–9.",,,,,,,
CG15AdultST196,"Ramsay L, Williams B, Johnston G et al . Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. Review. Journal of Human Hypertension 1999; 13 : 569–92.",,,,,,,
CG15AdultST197,ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 2002; 288 :2981–97.,,,,,,,
CG15AdultST198,"Schwartz SL, Hanson C, Lucas C et al . Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension. Clinical Therapeutics 1993; 15 :79–87.",,,,,,,
CG15AdultST199,"Ferrier C, Ferrari P, Weidmann P et al . Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients. Drugs 1992; 44 (Suppl 1):74–84.",,,,,,,
CG15AdultST200,"Hutchinson A, McIntosh A, Peters J et al . Effectiveness of screening and monitoring tests for diabetic retinopathy – a systematic review. Diabetic Medicine 2000; 17 :495–506. 162 Type 1 diabetes in adults: national clinical guideline for diagnosis and management",,,,,,,
CG15AdultST201,"National Institute for Clinical Excellence. Management of type 2 diabetes: retinopathy – screening and early management . London: NICE, 2002:2.1.2.",,,,,,,
CG15AdultST202,"Cummins E, Facey K, Macpherson K et al . Health Technology Assessment of Organization of Services for Diabetic Retinopathy Screening (project) . Glasgow: Health Technology Board for Scotland, 2001.",,,,,,,
CG15AdultST203,"Agence d’Evaluation des Technologies et des Modes d’Intervention en Santé. Screening for diabetic retinopathy: validation of a system using telemedicine approach – primary research (project) . Quebec: AETMIS, 2002.",,,,,,,
CG15AdultST204,"Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabetic Medicine 2002; 19 :285–91.",,,,,,,
CG15AdultST205,"Mallamaci F, Zuccala A, Zoccali C et al . The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis. American Journal of Hypertension 2000; 13 :433–7.",,,,,,,
CG15AdultST206,Taylor R. Practical community screening for diabetic retinopathy using the mobile retinal camera: report of a 12 centre study. British Diabetic Association Mobile Retinal Screening Group. Diabetic Medicine 1996; 13 :946–52.,,,,,,,
CG15AdultST207,Frank RN. Aldose reductase inhibition. The chemical key to the control of diabetic retinopathy? Archives of Ophthalmology 1990; 108 :1229–31.,,,,,,,
CG15AdultST208,Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. Archives of Ophthalmology 1990; 108 :1577–83.,,,,,,,
CG15AdultST209,"Pagani A, Greco G, Tagliaferro V et al . Dipyridamole administration in insulin-dependent diabetics with background retinopathy: a 36-month follow-up. Current Therapeutic Research, Clinical and Experimental 1989; 45 :469–75.",,,,,,,
CG15AdultST210,"Mota MC, Leite E, Ruas MA et al . Effect of cyclospasmol on early diabetic retinopathy. International Ophthalmology 1987; 10 :3–9.",,,,,,,
CG15AdultST211,"Bursell SE, Clermont AC, Aiello LP et al . High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999; 22 :1245–51.",,,,,,,
CG15AdultST212,"Tabaei BP, Al Kassab AS, Ilag LL et al . Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2001; 24 :1560–6.",,,,,,,
CG15AdultST213,"Almdal T, Norgaard K, Feldt-Rasmussen B, Deckert T. The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes Care 1994; 17 :120–5.",,,,,,,
CG15AdultST214,"Marshall SM, Collins A, Gregory W et al . Predictors of the development of microalbuminuria in patients with type I diabetes mellitus: a seven-year prospective study. Diabetic Medicine 1999; 16 :918–25.",,,,,,,
CG15AdultST215,"Coonrod BA, Ellis D, Becker DJ et al . Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993; 16 :1376–83.",,,,,,,
CG15AdultST216,"Yip JW, Jones SL, Wiseman MJ et al . Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Diabetes 1996; 45 :1729–33.",,,,,,,
CG15AdultST217,"Mathiesen ER, Feldt-Rasmussen B, Hommel E et al . Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria. A 5-year prospective study. Diabetes Care 1997; 20 :286–9.",,,,,,,
CG15AdultST218,"Ahn CW, Song YD, Kim JH et al . The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. Yonsei Medical Journal 1999; 40 :40–5.",,,,,,,
CG15AdultST219,"Ciavarella A, Silletti A, Forlani G et al . A screening test for microalbuminuria in type 1 (insulin-dependent) diabetes. Diabetes Research and Clinical Practice 1989; 7 :307–12.",,,,,,,
CG15AdultST220,"Zelmanovitz T, Gross JL, Oliveira J, De Azevedo MJ. Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. Diabetes Care 2003; 21 :1076–9.",,,,,,,
CG15AdultST221,"Ellis D, Coonrod BA, Dorman JS et al . Choice of urine sample predictive of microalbuminuria in patients with insulin-dependent diabetes mellitus. American Journal of Kidney Diseases 1989; 13 :321–8.",,,,,,,
CG15AdultST222,"McHardy KC, Gann ME, Ross IS, Pearson DW. A simple approach to screening for microalbuminuria in a type 1 (insulin-dependent) diabetic population. Annals of Clinical Biochemistry 1991; 28 :450–5. 163 References",,,,,,,
CG15AdultST223,"Collins AC, Vincent J, Newall RG et al . An aid to the early detection and management of diabetic nephropathy: assessment of a new point of care microalbuminuria system in the diabetic clinic. Diabetic Medicine 2001; 18 :928–32.",,,,,,,
CG15AdultST224,"Shephard MD, Barratt LJ, Simpson-Lyttle W. Is the Bayer DCA 2000 acceptable as a screening instrument for the early detection of renal disease? Annals of Clinical Biochemistry 1999; 36 :393–4.",,,,,,,
CG15AdultST225,"Webb DJ, Newman DJ, Chaturvedi N, Fuller JH. The use of the Micral-Test strip to identify the presence of microalbuminuria in people with insulin dependent diabetes mellitus (IDDM) participating in the EUCLID study. Diabetes Research and Clinical Practice 1996; 31 :93–102.",,,,,,,
CG15AdultST226,Agardh CD. A new semiquantitative rapid test for screening for microalbuminuria. Practical Diabetes 1993; 10 :146–7.,,,,,,,
CG15AdultST227,"Adamson CL, Kumar S, Sutcliffe H et al . Screening strategies in the detection of microalbuminuria in insulin-dependent diabetic patients. Practical Diabetes 1993; 10 :142–4.",,,,,,,
CG15AdultST228,"Gossain VV, Gunaga KP, Carella MJ et al . Utility of micral test strips in screening for microalbuminuria. Archives of Pathology and Laboratory Medicine 1996; 120 :1015–8.",,,,,,,
CG15AdultST229,"Piehlmeier W, Renner R, Kimmerling T et al . Evaluation of the Micral-Test S, a qualitative immunologic patient self-test for microalbuminuria: the PROSIT project. Proteinuria Screening and Intervention. Diabetic Medicine 1998; 15 :883–5.",,,,,,,
CG15AdultST230,"Kouri TT, Viikari JS, Mattila KS, Irjala KM. Microalbuminuria. Invalidity of simple concentration-based screening tests for early nephropathy due to urinary volumes of diabetic patients. Diabetes Care 1991; 14 :591–3.",,,,,,,
CG15AdultST231,"Le Floch JP, Marre M, Rodier M, Passa P. Interest of Clinitek Microalbumin in screening for micro- albuminuria: results of a multicentre study in 302 diabetic patients. Diabetes and Metabolism 2001; 27 :36–9.",,,,,,,
CG15AdultST232,"Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria . (Cochrane review). Cochrane Database of Systematic Reviews 2002; Issue 2, 2002.",,,,,,,
CG15AdultST233,ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Annals of Internal Medicine 2001; 134 :370–9.,,,,,,,
CG15AdultST234,"Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. Quarterly Journal of Medicine 2001; 94 :89–94.",,,,,,,
CG15AdultST235,"Jerums G, Allen TJ, Campbell DJ et al . Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. American Journal of Kidney Diseases 2001; 37 :890–9.",,,,,,,
CG15AdultST236,"Tarnow L, Rossing P, Jensen C et al . Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000; 23 :1725–30.",,,,,,,
CG15AdultST237,"Kopf D, Schmitz H, Beyer J et al . A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. Diabetes, Nutrition and Metabolism – Clinical and Experimental 2001; 14 :245–52.",,,,,,,
CG15AdultST238,"Waugh NR, Robertson AM. Protein restriction for diabetic renal disease. Cochrane Database of Systematic Reviews 2002; Issue 2, 2002.",,,,,,,
CG15AdultST239,"Zarazaga A, Lopez-Martinez, Lorenzo V et al . Nutritional support in chronic renal failure: systematic review. Clinical Nutrition 2001; 20 :291–9.",,,,,,,
CG15AdultST240,"Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney International 2002; 62 :220–8.",,,,,,,
CG15AdultST241,"Meloni C, Morosetti M, Suraci C et al . Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? Journal of Renal Nutrition 2002; 12 :96–101.",,,,,,,
CG15AdultST242,"Rossing P, Hansen BV, Nielsen FS et al . Fish oil in diabetic nephropathy. Diabetes Care 1996; 19 :1214–9.",,,,,,,
CG15AdultST243,"National Institute for Clinical Excellence. Management of Type 2 diabetes: renal disease – prevention and early management . London: NICE, 2002. 164 Type 1 diabetes in adults: national clinical guideline for diagnosis and management",,,,,,,
CG15AdultST244,"National Institute for Clinical Excellence. Clinical guidelines for Type 2 diabetes: prevention and management of foot problems . London: NICE, 2003:1–164.",,,,,,,
CG15AdultST245,"O’Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technology Assessment 2000; 4 :1–237.",,,,,,,
CG15AdultST246,"Mayfield JA, Sugarman JR. The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. Review. Journal of Family Practice 2000; 49 (11 Suppl):S17–29.",,,,,,,
CG15AdultST247,"Paisley AN, Abbott CA, Van Schie CH, Boulton AJ. A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabetic Medicine 2002; 19 :400–5.",,,,,,,
CG15AdultST248,"Bowering CK. Diabetic foot ulcers. Pathophysiology, assessment, and therapy. Canadian Family Physician 2001; 47 :1007–16.",,,,,,,
CG15AdultST249,"Ackerman MD, D’Attilio JP, Antoni MH, Campbell BM. Assessment of erectile dysfunction in diabetic men: the clinical relevance of self-reported sexual functioning. Journal of Sex and Marital Therapy 1991; 17 :191–202.",,,,,,,
CG15AdultST250,"Wellmer A, Sharief MK, Knowles CH et al . Quantitative sensory and autonomic testing in male diabetic patients with erectile dysfunction. British Journal of Urology International 1999; 83 :66–70.",,,,,,,
CG15AdultST251,"Leedom L, Feldman M, Procci W, Zeidler A. Symptoms of sexual dysfunction and depression in diabetic women. Journal of Diabetic Complications 1991; 5 :38–41.",,,,,,,
CG15AdultST252,"Benbow SJ, Chan AW, Bowsher DR et al . The prediction of diabetic neuropathic plantar foot ulceration by liquid-crystal contact thermography. Diabetes Care 1994; 17 :835–9.",,,,,,,
CG15AdultST253,"Price DE, Gingell JC, Gepi-Attee S et al . Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabetic Medicine 1998; 15 :821–5.",,,,,,,
CG15AdultST254,"Levitt NS, Stansberry KB, Wynchank S, Vinik AI. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of people with IDDM. Diabetes Care 1996; 19 :751–4.",,,,,,,
CG15AdultST255,"Ryder RE, Dent MT, Ward JD. Testing for diabetic neuropathy, part two: autonomic neuropathy. Practical Diabetes 1992; 9 :56–60.",,,,,,,
CG15AdultST256,"Ewing DJ, Clarke BF. Autonomic neuropathy: its diagnosis and prognosis. Review. Clinical Endocrinology and Metabolism 1986; 15 :855–88.",,,,,,,
CG15AdultST257,"Gill JS, Williams G, Ghatei MA et al . Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabète et Métabolisme 1990; 16 :296–302.",,,,,,,
CG15AdultST258,"Faes TJ, Yff GA, DeWeerdt O et al . Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. Journal of Neurology 1993; 240 :156–60.",,,,,,,
CG15AdultST259,"Sundkvist G, Armstrong FM, Bradbury JE et al . Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. Journal of Diabetes and its Complications 1992; 6 :123–30.",,,,,,,
CG15AdultST260,"Didangelos TP, Karamitsos DT, Athyros VG, Kourtoglou GI. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. Journal of Diabetes and its Complications 1998; 12 :201–7.",,,,,,,
CG15AdultST261,"Kontopoulos AG, Athyros VG, Didangelos TP et al . Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997; 20 :355–61.",,,,,,,
CG15AdultST262,"Athyros VG, Didangelos TP, Karamitsos DT et al . Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. Acta Cardiologica 1998; 53 :201–9.",,,,,,,
CG15AdultST263,"Wehrmann T, Lembcke B, Caspary WF. Influence of cisapride on antroduodenal motor function in healthy subjects and diabetics with autonomic neuropathy. Alimentary Pharmacology and Therapeutics 1991; 5 :599–608. 165 References",,,,,,,
CG15AdultST264,"Desautels SG, Hutson WR, Christian PE et al . Gastric emptying response to variable oral erythromycin dosing in diabetic gastroparesis. Digestive Diseases and Sciences 1995; 40 :141–6.",,,,,,,
CG15AdultST265,"Samsom M, Jebbink RJ, Akkermans LM et al . Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care 1997; 20 :129–34.",,,,,,,
CG15AdultST266,"Janssens J, Peeters TL, Vantrappen G et al . Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. New England Journal of Medicine 1990; 322 :1028–31.",,,,,,,
CG15AdultST267,"Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. Journal of Pain and Symptom Management 2000; 20 :449–58.",,,,,,,
CG15AdultST268,"Gorson KC, Schott C, Herman R et al . Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry 1999; 66 :251–2.",,,,,,,
CG15AdultST269,"Eisenberg E, Lurie Y, Braker C et al . Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001; 57 :505–9.",,,,,,,
CG15AdultST270,"Max MB, Kishore-Kumar R, Schafer SC et al . Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45 :3–9.",,,,,,,
CG15AdultST271,"Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabetic Medicine 2003; 20 :114–8.",,,,,,,
CG15AdultST272,"Zhang WY, Po AL The effectiveness of topically applied capsaicin. A meta-analysis. European Journal of Clinical Pharmacology 1994; 46 :517–22.",,,,,,,
CG15AdultST273,"Zeigler D, Lynch SA, Muir J et al . Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992; 48 :403–8.",,,,,,,
CG15AdultST274,"Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain 1995; 60 :267–74.",,,,,,,
CG15AdultST275,"Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabetic Medicine 1990; 7 :319–23.",,,,,,,
CG15AdultST276,"Keen H, Payan J, Allawi J et al . Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care 1993; 16 :8–15.",,,,,,,
CG15AdultST277,"Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002; 25 :1699–703.",,,,,,,
CG15AdultST278,"Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997; 20 :1594–7.",,,,,,,
CG15AdultST279,"Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992; 15 :1550–5.",,,,,,,
CG15AdultST280,"Morello CM, Leckband SG, Stoner CP et al . Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine 1999; 159 :1931–7.",,,,,,,
CG15AdultST281,"Harati Y, Gooch C, Swenson M et al . Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50 :1842–6.",,,,,,,
CG15AdultST282,"Diabetes UK. Recommendations for the management of diabetes in primary care . London: Diabetes UK, 2000. http://www.diabetes.org.uk/infocentre/index.html",,,,,,,
CG15AdultST283,"Department of Veterans Affairs. The management of diabetes mellitus in the primary care setting . US Department of Defense, 1999.",,,,,,,
CG15AdultST284,"Inpatient management guidelines for people with diabetes . Nashville, TN: American Healthways, 2002.",,,,,,,
CG15AdultST285,Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 :S33–50. 166 Type 1 diabetes in adults: national clinical guideline for diagnosis and management,,,,,,,
CG15AdultST286,"Piters KM, Kumar D, Pei E, Bessman AN. Comparison of continuous and intermittent intravenous insulin therapies for diabetic ketoacidosis. Diabetologia 1977; 13 :317–21.",,,,,,,
CG15AdultST287,"Sacks HS, Shahshahani M, Kitabchi AE et al . Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion. Annals of Internal Medicine 1979; 90 :36–42.",,,,,,,
CG15AdultST288,"Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. New England Journal of Medicine 1977; 297 :238–41.",,,,,,,
CG15AdultST289,"Storms FE, Lutterman JA, van’t Laar A. Comparison of efficacy of human and porcine insulin in treatment of diabetic ketoacidosis. Diabetes Care 1987; 10 :49–55.",,,,,,,
CG15AdultST290,"Wiggam MI, O’Kane MJ, Harper R et al . Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care 1997; 20 :1347–52.",,,,,,,
CG15AdultST291,"Gamba G, Oseguera J, Castrejon M, Gomez-Perez FJ. Bicarbonate therapy in severe diabetic ketoacidosis. A double blind, randomized, placebo controlled trial. Revista de Investigacion Clinica 1991; 43 :234–8.",,,,,,,
CG15AdultST292,"Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Annals of Internal Medicine 1986; 105 :836–40.",,,,,,,
CG15AdultST293,"Viallon A, Zeni F, Lafond P et al . Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Critical Care Medicine 1999; 27 :2690–3.",,,,,,,
CG15AdultST294,"Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. Journal of Clinical Endocrinology and Metabolism 1983; 57 :177–80.",,,,,,,
CG15AdultST295,"Wilson HK, Keuer SP, Lea AS et al . Phosphate therapy in diabetic ketoacidosis. Archives of Internal Medicine 1982; 142 :517–20.",,,,,,,
CG15AdultST296,"Yun YS, Lee HC, Park CS et al . Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis. Journal of Diabetes and its Complications 1999; 13 :288–92.",,,,,,,
CG15AdultST297,"Davies M, Dixon S, Currie CJ et al . Evaluation of a hospital diabetes specialist nursing service: a randomized controlled trial. Diabetic Medicine 2001; 18 :301–7.",,,,,,,
CG15AdultST298,"Cavan DA, Hamilton P, Everett J, Kerr D. Reducing hospital inpatient length of stay for patients with diabetes. Diabetic Medicine 2001; 18 :162–4.",,,,,,,
CG15AdultST299,"Rassias AJ, Marrin CA, Arruda J et al . Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesthesia and Analgesia 1999; 88 :1011–6.",,,,,,,
CG15AdultST300,"Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Annals of Thoracic Surgery 1999; 67 :352–60.",,,,,,,
CG15AdultST301,"Raucoules-Aime M, Lugrin D, Boussofara M et al . Intraoperative glycaemic control in non-insulin-dependent and insulin-dependent diabetes. British Journal of Anaesthesia 1994; 73 :443–9.",,,,,,,
CG15AdultST302,"Christiansen CL, Schurizek BA, Malling B et al . Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery. Continuous intravenous infusion compared with subcutaneous administration. Anaesthesia 1988; 43 :533–7.",,,,,,,
CG15AdultST303,"Pezzarossa A, Taddei F, Cimicchi MC et al . Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11 :52–8.",,,,,,,
CG15AdultST304,"Simmons D, Morton K, Laughton SJ, Scott DJ. A comparison of two intravenous insulin regimens among surgical patients with insulin-dependent diabetes mellitus. Diabetes Educator 1994; 20 :422–7.",,,,,,,
CG15AdultST305,"Dazzi D, Taddei F, Gavarini A et al . The control of blood glucose in the critical diabetic patient: a neuro-fuzzy method. Journal of Diabetes and its Complications 2001; 15 :80–7.",,,,,,,
CG15AdultST306,"Malmberg K, Ryden L, Efendic S et al . Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. Journal of the American College of Cardiology 1995; 26 :57–65. 167 References",,,,,,,
CG15AdultST307,"Malmberg KA, Efendic S, Ryden LE. Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction. A report from the multicenter trial: DIGAMI. Diabetes Care 1994; 17 :1007–14.",,,,,,,
CG15AdultST308,"Clark RS, English M, McNeill GP, Newton RW. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. British Medical Journal 1985; 291 :303–5.",,,,,,,
CG15AdultST309,"Davis RE, McCann VJ, Stanton KG. Type 1 diabetes and latent pernicious anaemia. Medical Journal of Australia 1992; 156 :160–2.",,,,,,,
CG15AdultST310,"Talal AH, Murray JA, Goeken JA, Sivitz WI. Celiac disease in an adult population with insulin-dependent diabetes mellitus: use of endomysial antibody testing. American Journal of Gastroenterology 1997; 92 : 1280–4.",,,,,,,
CG15AdultST311,"Sjoberg K, Eriksson KF, Bredberg A et al . Screening for coeliac disease in adult insulin-dependent diabetes mellitus. Journal of Internal Medicine 1998; 243 :133–40.",,,,,,,
CG15AdultST312,"Matteucci E, Cinapri V, Quilici S et al . Screening for coeliac disease in families of adults with Type 1 diabetes based on serological markers. Diabetes, Nutrition and Metabolism – Clinical and Experimental 2001; 14 :37–42.",,,,,,,
CG15AdultST313,"Sategna-Guidetti C, Grosso S, Pulitano R et al . Celiac disease and insulin-dependent diabetes mellitus. Screening in an adult population. Digestive Diseases and Sciences 1994; 39 :1633–7.",,,,,,,
CG15AdultST314,"Johnston SD, Ritchie C, Robinson J. Application of red cell distribution width to screening for coeliac disease in insulin-dependent diabetes mellitus. Irish Journal of Medical Science 1999; 168 :167–70.",,,,,,,
CG15AdultST315,"Van Tilburg MA, McCaskill CC, Lane JD et al . Depressed mood is a factor in glycemic control in type 1 diabetes. Psychosomatic Medicine 2001; 63 :551–5.",,,,,,,
CG15AdultST316,"Lustman PJ, Clouse RE, Carney RM. Depression and the reporting of diabetes symptoms. International Journal of Psychiatry in Medicine 1988; 18 :295–303.",,,,,,,
CG15AdultST317,"Lustman PJ, Anderson RJ, Freedland KE et al . Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23 :934–42.",,,,,,,
CG15AdultST318,"Berlin I, Bisserbe JC, Eiber R et al . Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care 1997; 20 :176–8.",,,,,,,
CG15AdultST319,"Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice 1999; 46 :239–46.",,,,,,,
CG15AdultST320,"Anderson RJ, de Groot M, Grigsby AB et al . Anxiety and poor glycemic control: a meta-analytic review of the literature. International Journal of Psychiatry in Medicine 2002; 32 :235–47.",,,,,,,
CG15AdultST321,"Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24 :1069–78.",,,,,,,
CG15AdultST322,"Lawrenson R, Williams J. Antidepressant use in people with diabetes. Diabetes Primary Care 2001; 3 :70–4.",,,,,,,
CG15AdultST323,"Cox DJ, Gonder-Frederick L, Polonsky W et al . Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001; 24 :637–42.",,,,,,,
CG15AdultST324,"Lustman PJ, Griffith LS, Clouse RE et al . Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosomatic Medicine 1997; 59 :241–50.",,,,,,,
CG15AdultST325,"Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000; 23 :618–23.",,,,,,,
CG15AdultST326,"Spiess K, Sachs G, Pietschmann P, Prager R. A program to reduce onset distress in unselected type I diabetic patients: effects on psychological variables and metabolic control. European Journal of Endocrinology 1995; 132 :580–6.",,,,,,,
CG15AdultST327,"Lustman PJ, Griffith LS, Clouse RE et al . Effects of alprazolam on glucose regulation in diabetes. Results of double-blind, placebo-controlled trial. Diabetes Care 1995; 18 :1133–9. 168 Type 1 diabetes in adults: national clinical guideline for diagnosis and management",,,,,,,
CG15AdultST328,"Bryden KS, Neil A, Mayou RA et al . Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care 1999; 22 :1956–60.",,,,,,,
CG15AdultST329,"Rodin G, Olmsted MP, Rydall AC et al . Eating disorders in young women with type 1 diabetes mellitus. Journal of Psychosomatic Research 2002; 53 :943–9.",,,,,,,
CG15AdultST330,"Herpertz S, Wagener R, Albus C et al . Diabetes mellitus and eating disorders: a multicenter study on the comorbidity of the two diseases. Journal of Psychosomatic Research 1998; 44 :503–15.",,,,,,,
CG15AdultST331,Nielsen S. Eating disorders in females with type 1 diabetes: an update of a meta-analysis. European Eating Disorders Review 2002; 10 :241–54.,,,,,,,
CG15AdultST332,"Alloway SC, Toth EL, McCargar LJ. Effectiveness of a group psychoeducation program for the treatment of subclinical disordered eating in women with type 1 diabetes. Canadian Journal of Dietetic Practice and Research 2001; 62 :188–92.",,,,,,,
CG15AdultST333,"Affenito SG, Kerstetter J. Position of the American Dietetic Association and Dietitians of Canada: women’s health and nutrition. Journal of the American Dietetic Association 1999; 99 :738–51.",,,,,,,
CG15AdultST334,"Rose M, Hildebrandt M, Fliege H et al . Relevance of the treatment facility for disease-related knowledge of diabetic patients. Diabetes Care 2000; 23 :1708–9.",,,,,,,
CG15AdultST335,"Diabetes Integrated Care Evaluation Team. Integrated care for diabetes: clinical, psychosocial, and economic evaluation. British Medical Journal 1994; 308 :1208–12.",,,,,,,
CG15AdultST336,"Fukunishi I, Horikawa N, Yamazaki T et al . Perception and utilization of social support in diabetic control. Diabetes Research and Clinical Practice 1998; 41 :207–11.",,,,,,,
CG15AdultST337,"Connell CM, Davis WK, Gallant MP, Sharpe PA. Impact of social support, social cognitive variables, and perceived threat on depression among adults with diabetes. Health Psycholology 1994; 13 :263–73.",,,,,,,
CG15AdultST338,"Loveman E, Cave C, Green C et al . The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation. Health Technology Assessment . 2003; 7 :iii, 1–iii190.",,,,,,,
CG15AdultST339,"Glasgow RE, La Chance PA, Toobert DJ et al . Long-term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical office. Patient Education and Counseling 1997; 32 :175–84.",,,,,,,
CG15AdultST340,"Kaplan RM, Hartwell SL, Wilson DK, Wallace JP. Effects of diet and exercise interventions on control and quality of life in non-insulin-dependent diabetes mellitus. Journal of General Internal Medicine 1987; 2 :220–8.",,,,,,,
CG15AdultST341,"Starostina EG, Antsiferov M, Galstyan GR et al . Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for type 1 (insulin-dependent) diabetes mellitus in Moscow – blood glucose versus urine glucose self-monitoring. Diabetologia 1994; 37 :170–6.",,,,,,,
CG15AdultST342,"Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix25. Measured by a willingness-to-pay approach. Pharmacoeconomics 2000; 18 :275–87.",,,,,,,
CG15AdultST343,Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Journal of the American Medical Association 1996; 276 :1409–15.,,,,,,,
CG15AdultST344,"Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweizerische medizinische Wochenschrift 2000; 130 :1034–40.",,,,,,,
CG15AdultST345,"Herman WH, Dasbach EJ, Songer TJ, Eastman RC. The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinology and Metabolism Clinics of North America 1997; 26 :679–95.",,,,,,,
CG15AdultST346,"Stern Z, Levy R. Analysis of direct cost of standard compared with intensive insulin treatment of insulin- dependent diabetes mellitus and cost of complications. Acta Diabetolica 1996; 33 :48–52.",,,,,,,
CG15AdultST347,"Graff MR,. McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clinical Therapeutics 1998; 20 :486–96. 169 References",,,,,,,
CG15AdultST348,"Hornquist JO, Wikby A, Stenstrom U, Andersson PO. Change in quality of life along with type 1 diabetes. Diabetes Research and Clinical Practice 1995; 28 :63–72.",,,,,,,
CG15AdultST349,"Hornquist JO, Wikby A, Andersson PO, Dufva AM. Insulin-pen treatment, quality of life and metabolic control: retrospective intra-group evaluations. Diabetes Research and Clinical Practice 1990; 10 :221–30.",,,,,,,
CG15AdultST350,"Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42 :1293–301.",,,,,,,
CG15AdultST351,"Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated? Circulation 2000; 102 :722–7.",,,,,,,
CG15AdultST352,"Grover SA, Coupal L, Zowall H et al . How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001; 24 :45–50.",,,,,,,
CG15AdultST353,"Grover SA, Levinton C, Paquet S. Identifying adults at low risk for significant hyperlipidemia: a validated clinical index. Journal of Clinical Epidemiology 1999; 52 :49–55.",,,,,,,
CG15AdultST354,"Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology 1989; 96 :255–64.",,,,,,,
CG15AdultST355,"Javitt JC, Canner JK, Frank RG et al . Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology 1990; 97 :483–94.",,,,,,,
CG15AdultST356,"Javitt JC, Aiello LP, Bassi LJ et al . Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology 1991; 98 :1565–73.",,,,,,,
CG15AdultST357,"Fendrick AM, Javitt JC, Chiang YP. Cost-effectiveness of the screening and treatment of diabetic retinopathy. What are the costs of underutilization? International Journal of Technology Assessment in Health Care 1992; 8 :694–707.",,,,,,,
CG15AdultST358,"Javitt JC,.Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Annals of Internal Medicine 1996; 124 :164–9.",,,,,,,
CG15AdultST359,"Crijns H, Casparie AF, Hendrikse F. Continuous computer simulation analysis of the cost-effectiveness of screening and treating diabetic retinopathy. International Journal of Technology Assessment in Health Care 1999; 15 :198–206.",,,,,,,
CG15AdultST360,"Polak BC, Crijns H, Casparie AF, Niessen LW. Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy. Health Policy 2003; 64 :89–97.",,,,,,,
CG15AdultST361,"Bjorvig S, Johansen MA, Fossen K. An economic analysis of screening for diabetic retinopathy. Journal of Telemedicine and Telecare 2002; 8 :32–5.",,,,,,,
CG15AdultST362,"Maberley D, Walker H, Koushik A, Cruess A. Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. Canadian Medical Association Journal 2003; 168 :160–4.",,,,,,,
CG15AdultST363,"Pegoraro A, Singh A, Bakir AA, Arruda JA, Dunea G. Simplified screening for microalbuminuria. Annals of Internal Medicine 1997; 127 :817–9.",,,,,,,
CG15AdultST364,Lewis JB. Microalbuminuria: accuracy or economics. American Journal of Kidney Diseases 1998; 32 :524–8.,,,,,,,
CG15AdultST365,"Faronato P, de Bigontina G. A cost-benefit analysis of two mass screening strategies for albuminuria in diabetic patients. Diabetes, Nutrition & Metabolism: Clinical and Experimental 1994; 7 (6):325–329.",,,,,,,
CG15AdultST366,Le Floch JP. Cost effectiveness of screening for microalbuminuria. Diabetic Medicine 1994; 11 :349–356: (Abstract),,,,,,,
CG15AdultST367,"Hendry BM, Viberti GC, Hummel S et al . Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. Quarterly Journal of Medicine 1997; 90 :277–82.",,,,,,,
CG15AdultST368,"Garattini L, Brunetti M, Salvioni F, Barosi M. Economic evaluation of ACE Inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. Pharmacoeconomics 1997; 12 :67–75. 170 Type 1 diabetes in adults: national clinical guideline for diagnosis and management",,,,,,,
CG15AdultST369,"Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996; 19 :1051–61.",,,,,,,
CG15AdultST370,"Clark WF, Churchill DN, Forwell L et al . To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Canadian Medical Association Journal 2000; 162 :195–8.",,,,,,,
CG15AdultST371,"van Os N, Niessen LW, Bilo HJ et al . Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. Health Policy 2000; 51 :135–47.",,,,,,,
CG15AdultST372,"Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? British Medical Journal 1993; 306 :1722–5.",,,,,,,
CG15AdultST373,"Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. British Medical Journal 1995; 311 :1595–9.",,,,,,,
CG15AdultST374,"Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. Journal of the American Society of Nephrology 1992; 3 :S111–S119.",,,,,,,
CG15AdultST375,"Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G et al . The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000; 43 :13–26.",,,,,,,
CG15AdultST376,"Allenet B, Paree F, Lebrun T, Carr L, Posnett J, Martini J et al . Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes and Metabolism 2000; 26 :125–32.",,,,,,,
CG15AdultST377,"University of York Health Economics Consortium. Evaluation of the cost-effectiveness of Dermagraft for the treatment of diabetic foot ulcers in the UK . York: YHEC, 1997.",,,,,,,
CG15AdultST378,"Kowalske KJ, Agre JC. Neuromuscular rehabilitation and electrodiagnosis.3. Generalized peripheral neuropathy. Archives of Physical Medicine and Rehabilitation 2000; 81 :S20–S26.",,,,,,,
CG15AdultST379,"Javor KA, Kotsanos JG, McDonald RC et al . Diabetic ketoacidosis charges relative to medical charges of adult patients with type I diabetes. Diabetes Care 1997; 20 :349–54.",,,,,,,
CG15AdultST380,"Davey P, Grainger D, MacMillan J et al . Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics 1998; 13 :347–58.",,,,,,,
CG15AdultST381,"Wu SY, Lung BC, Chang S et al . Evaluation of drug usage and expenditure in a hospital diabetes clinic. Journal of Clinical Pharmacy and Therapeutics 1998; 23 :49–56.",,,,,,,
CG15AdultST382,"McIntosh A, Hutchinson A, Home PD et al . Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose . Sheffield: ScHARR, University of Sheffield, 2001.",,,,,,,
CG10ST1,"Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM (1998) Multicentre study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 21: 1071–76.",,,,,,,
CG10ST2,"Adler AI, Boyko EJ, Ahroni JH, Smith DG, (1999) Lower-extremity amputation in diabetes. Diabetes Care 22: 1029-1035.",,,,,,,
CG10ST3,"Ahroni JH, Boyko EJ, Pecoraro RE (1993) Diabetic foot ulcer healing: extrinsic vs intrinsic factors. Wounds 5: 245–55.",,,,,,,
CG10ST4,"Albert, S. 2002, Cost-effective management of recalcitrant diabetic foot ulcers""", Clinics in Podiatric Medicine & Surgery, vol. 19, no. 4," pp. 483-491.""",,,
CG10ST5,"Allenet, B., Paree, F., Lebrun, T., Carr, L., {psmett, J., Martini, J., & Yvon, C.(2000), Cost- effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context""", Diabetes & Metabolism, vol. 26, no. 2," pp. 125-132.""",,,
CG10ST6,American Diabetes Association (1991) Position statement: Foot care guidelines. Alexandria. VA: American Diabetes Association.,,,,,,,
CG10ST7,"Apelqvist, J., Ragnarson, T. G., & Larsson, J. (1995), Topical treatment for diabetic foot ulcers: an economic analysis of treatment alternatives and strategies""", Diabetic Medicine, vol. 12, no. 2," pp. 123-128.""",,,
CG10ST8,"Apelqvist, J., Ragnarson, T. G., Larsson, J., & Persson, U. (1995), Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting""", Foot & Ankle International, vol. 16, no. 7," pp. 388-394.""",,,
CG10ST9,"Apelqvist, J., Ragnarson, T. G., Persson, U., & Larsson, J. (1994), Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation""", Jounral of Internal Medicine, vol. 235, no. 55," pp. 463-471.""",,,
CG10ST10,"Apelqvist J, Agardh C-D (1992) The association between clinical risk factors and outcome of diabetic foot ulcers. Diabetes Research and Clinical Practice 18: 43–45.",,,,,,,
CG10ST11,"Apelqvist J, Castenfors J, Larsson J, Stenstrom A, Persson G (1990) Ketanserin in the treatment of diabetic foot ulcers with severe PVD. International Angiology 9: 120–24.",,,,,,,
CG10ST12,"Apelqvist J, Tennvall GR (1996) Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. Acta Derm Venereol (Stockh) 76: 231–35.",,,,,,,
CG10ST13,"Armstrong D G, Nguyen H C (2000) Improvement in healing with aggressive edema reduction after debridement of foot infection in persons with diabetes. Arch Surg 135: 1405-1409.",,,,,,,
CG10ST14,"Armstrong D G, Nguyen, H C, Lavery L A, van Schie C H M, Boulton A J M, Harkless L B (2001) Off-loading the diabetic foot wound. A randomized clinical trial. Diabetes Care, 24: 1019-1022.",,,,,,,
CG10ST15,Baker N (unpublished). Allevyn vs sorbsan in the treatment of diabetic foot ulcers.,,,,,,,
CG10ST16,"Barth R, Campbell LV, Allen S, Jupp JJ, Chisholm DJ (1991) Intensive education improves knowledge, compliance and foot problems in Type 2 diabetes. Diabetic Medicine 8: 111– 17.",,,,,,,
CG10ST17,"Benbow SJ, Walsh A, Gill GV (1997) Diabetes in institutionalised elderly people: a forgotten population? British Medical Journal 314: 1868–69.",,,,,,,
CG10ST18,"Blackman JD, Senseng D, Quinn L, Mazzone T (1994) Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetes foot ulcers. Diabetes Care 17: 322–25.",,,,,,,
CG10ST19,"Bland JM, Jones DR, Bennett S, Haines AP, MacFarlane AJ (1985) Is the clinical trial evidence about new drugs statistically adequate? British Journal of Clinical Pharmacology 19: 155–60.",,,,,,,
CG10ST20,"Bloomgarden ZT, Karmally W, Metzger J, Brothers M, Nechemias C, Bookman J, et al (1987) Randomized control trial of diabetic patient education: improved knowledge without improved metabolic status. Diabetes Care 10: 263–72.",,,,,,,
CG10ST21,Booth J Young MJ (2000) Differences in the performance of commercially available 10g monofilaments Diabetes Care 23: 984-988,,,,,,,
CG10ST22,"Boulton AJM, Gries FA, Jervell JA (1998) Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabetic Medicine 15: 508–14.",,,,,,,
CG10ST23,"Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle diabetic foot study. Diabetes Care 22: 1036-1042",,,,,,,
CG10ST24,"Bradsher RW, Snow RM (1984) Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. American Journal of Medicine October 19: 63–67.",,,,,,,
CG10ST25,"British National Formulary Number 35 (March 1998). The British Medical Association and the Royal Pharmaceutical Society of Great Britain, London.",,,,,,,
CG10ST26,Cabezas-Cerrato for the Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS) (1998) The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia 41: 1263-1269,,,,,,,
CG10ST27,"Caddick SL, McKinnon M, Payne N, Ward TJ, Thornton-Jones H, Kells J, Ward JD (1994) Hospital admissions and social deprivation of patients with diabetes mellitus. Diabetic Medicine 11: 981–83.",,,,,,,
CG10ST28,"Campbell E M, Redman S, Moffitt P S, Sanson-Fisher R W (1996) The relative effectiveness of educational and behavioural instruction programs for patients with NIDDM: A randomized trial. The Diabetes Educator 22: 379-386.",,,,,,,
CG10ST29,"Caravaggi C, Faglia E, De Giglio R, Mantero M, Quarantiello A, Sommariva E, Gino M, Pritelli C, Morabito A (2000) Effectiveness and safety of a nonremovable fibreglass off- bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers. A randomized study. Diabetes Care 23: 1746-1751.",,,,,,,
CG10ST30,"Cavanagh PR, Vickers KL, Young MJ, Boulton AJM, Adams JE (1994) Radiographic abnormalities in the feet of patients with diabetic neuropathy. Diabetes Care 17: 201–209.",,,,,,,
CG10ST31,"Cesarone M R, Incandela L, Belcaro G, Sanctis M T, Ricci A, Griffin M, (2001) Two-week topical treatment with essaven gel in patients with diabetic microangiopathy. A placebo- controlled, randomized study. Angiology 52: S43-S48.",,,,,,,
CG10ST32,"Chantelau E, Tanudjaja T, Altenhöfer F, Ersanli Z, Lacigova S, Metzger C (1996) Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial.Diabetic Medicine 13: 156–59.",,,,,,,
CG10ST33,"Chaturvedi N, Stephenson JM, Fuller JH (1996) The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM complications study. Diabetes Care 19: 423–30.",,,,,,,
CG10ST34,"Clever HU, Dreyer M (1996) Comparing two wound dressings for the treatment of neuropathic diabetic foot ulcers. Proceedings of the 5th European Conference on Advances in Wound Management. London: MacMillan: 201–203.",,,,,,,
CG10ST35,Cohen S (1983) Potential barriers to diabetes care. Diabetes Care 6: 499–500.,,,,,,,
CG10ST36,"Colagiuri S, Marsden LL, Naidu V, Taylor L (1995) The use of orthotic devices to correct plantar callus in people with diabetes. Diabetes Research and Clinical Practice 28: 29–34.",,,,,,,
CG10ST37,Collier BN (1971) Comparative study of diabetes knowledge among juvenile diabetics and their parents. Diabetes 20: 51–57.,,,,,,,
CG10ST38,"Connor H (1987) The economic impact of diabetic foot disease. In: Connor H, Boulton AJM, Ward JD (eds). The foot in diabetes. Chichester: Wiley: 145–49.",,,,,,,
CG10ST39,"Cook TD, Campbell DT (1979) Quasi-experimentation: design and analysis issues for field settings. Chicago: Rand McNally.",,,,,,,
CG10ST40,"Currie, C. J., Morgan, C. L., & Peters, J. R. (1998), The epidemiology and cost of inpatient care for peripheral vascular disease", infection, neuropathy," and ulceration in diabetes""", Diabetes Care, vol. 21, no. 1," pp. 42-48."""
CG10ST41,"Day JL, Humphreys H, Alban-Davies H (1987) Problems of comprehensive shared diabetes care. British Medical Journal 294: 1590–92.",,,,,,,
CG10ST42,"Deerochanawong C, Home PD, Alberti KGMM (1992) A survey of lower limb amputation in diabetic patients. Diabetic Medicine 9: 942–46.",,,,,,,
CG10ST43,"De Lalla F, Pellizzer G, Strazzabosco M, Martini Z, Jardin G D, Lora L, Fabris P, Benedetti P, Erle G, (2001) Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrobial Agents and Chemotherapy 45: 1094-1098.",,,,,,,
CG10ST44,Department of Health (2002) Current and Future Research on Diabetes: A review for the Department of Health and the Medical Research Council London: Department of Health,,,,,,,
CG10ST45,Department of Health (2001a) National Service Framework for Diabetes: Standards London: Department of Health,,,,,,,
CG10ST46,"Department of Health (2001b) National Service Framework for Diabetes: Supplementary Material, Intervention details and draft service models London: Department of Health",,,,,,,
CG10ST47,"DerSimonian R, Laird N (1986) Meta analysis in clinical trials. Controlled Clinical Trials 7: 177–88.",,,,,,,
CG10ST48,"De Sanctis M T, Cesarone M R, Incandela L, Belcaro G, Ricci A, Griffin M, (2001) Four- week treatment with essaven gel in diabetic microangiopathy. A placebo-controlled, randomized study. Angiology 52: S49-S55.",,,,,,,
CG10ST49,"de Sonnaville JJJ, Colly LP, Wijkel D, Heine RJ (1997) The prevalence and determinants of foot ulceration in Type 2 diabetic patients in a primary health care setting. Diabetes Research and Clinical Practice 35: 149–56.",,,,,,,
CG10ST50,"Di Mauro C, Ossino AM, Trefiletti M, Polosa P, Beghe F (1991) Lyophilized collagen in the treatment of diabetic ulcers. Drugs and Experimental Clinical Research XVII: 371–73.",,,,,,,
CG10ST51,Diabetes Control and Complications Trial Research Group (DCCT) (1993) The effect of intensive treatment of diabetics on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329: 977–86.,,,,,,,
CG10ST52,"Diabetes Integrated Care Evaluation (DICE) (1994) Diabetes Integrated Care Evaluation Team. Integrated care for diabetes: clinical, psychosocial, and economic evaluation. British Medical Journal 308: 1208–12.",,,,,,,
CG10ST53,"Donaghue VM, Chrzan JS, Rosenblum BI et al (1996) A clinical evaluation of a collagen- alginate topical wound dressing in the management of diabetic foot ulcers. Diabetes Electronic Highlights Bulletin (A daily summary of selected presentations made at the 56th annual meeting and scientific sessions of the American Diabetes Association, No 2: June 9, 1996).",,,,,,,
CG10ST54," Donaghue V M, Chrzan J S, Rosenblum B I, Giurini J M, Habershaw G M, Veves A, (1998) Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. Advances in Wound Care 11: 114-119.",,,,,,,
CG10ST55,"Donohoe M E, Fletton J A, Hook A, Powell R, Robinson I, Stead J W, Sweeney K, Taylor R, Tooke J E (2000) Improving foot care for people with diabetes mellitus – a randomized controlled trial of an integrated care approach. Diabetic Medicine 17: 581-587.",,,,,,,
CG10ST56,"Dornan TL, Peck GM, Dow JDC, Tattersall RB (1992) A community survey of diabetes in the elderly. Diabetic Medicine; 9: 860–65.",,,,,,,
CG10ST57,"Dunn NR, Bough P (1996) Standards of care of diabetic patients in a typical English community. British Journal of General Practice; 46: 401–405.",,,,,,,
CG10ST58,"Eckman, M. H., Greenfield, S., Mackey, W. C., Wong, J. B., Kaplan, S., Sullivan, L., Dukes, K., & Pauker, S. G. (1995), Foot infections in diabetic patients Decision and cost- effectiveness analyses""", JAMA, vol. 273, no. 9," pp. 712-720.""",,,
CG10ST59,"Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan L, Dukes K, Pauker SG (1995) Foot infections in diabetic patients: decision and cost-effectiveness analyses. Journal of the American Medical Association 273: 712–20.",,,,,,,
CG10ST61,"Edmonds, M., Gough, A., Solovera, J., & Standaert, B. (1999), Filgrastim in the treatment of infected diabetic foot ulcers - Retrospective cast analysis of a phase II randomised clinical trial""", Clinical Drug Investigation, vol. 17, no. 4," pp. 275-286.""",,,
CG10ST62,"Edmonds ME, Blundell MP, Morris ME, Cotton LT, Watkins PI (1986) Improved survival of the diabetic foot: the role of the specialised foot clinic. Quarterly Journal of Medicine 60: 763–71.",,,,,,,
CG10ST63,"Edmonds M, Boulton A, Buckenham T, Every N et al (1996) Report of the diabetic foot and amputation group. Diabetic Medicine 13: S27–42.",,,,,,,
CG10ST64,"El-Shazly M, Abdel-Fattah M, Scorpiglione N, Benedetti MM, Capani F, Carinci F, Carta  Q, Cavaliere D, De Feo EM, Taboga C, Tognoni G, Nicolucci A on behalf of the The Italian Study Group for the Implementation of the St Vincent Declaration (1998) Risk factors for lower limb complications in diabetic patients. Journal of Diabetes and Its Complications  12: 10-17",,,,,,,
CG10ST65,"Faglia E, Favales F, Aldeghi A, Patrizia C, Quarantiello A, Oriani G, Michael M, Campiagnoli P, Morabito A (1996) Adjunctive systemic hyperbaric oxygen therapy in the treatment of severe prevalently ischemic diabetic foot ulcers. Diabetes Care; 19: 1338–43.",,,,,,,
CG10ST66,"File TM, Tan JS (1983) Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections). American Journal of Medicine 75: 100–105.",,,,,,,
CG10ST67,"Fletcher AK, Dolben J (1996) A hospital survey of the care of elderly patients with diabetes mellitus. Age and ageing: 25: 349–52.",,,,,,,
CG10ST68,"Foster AVM, Greenhill MT, Edmonds ME (1994) Comparing two dressings in the treatment of diabetic foot ulcers. Journal of Wound Care 3: 224–28.",,,,,,,
CG10ST69,"Frykberg RG, Lavery LA, Pham H, Harvey C, Harkless L, Veves A (1998) Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care 21: 1714- 1719.",,,,,,,
CG10ST70,"Gaster B, Hirsch IB (1998) The effects of improved glycemic control on complications in Type 2 diabetes. Archives of Internal Medicine 158: 134–40.",,,,,,,
CG10ST71,"Gentzkow G, Iawaski S, Hershon K, Mengel M, Prendergast J, Ricotta J, Steed D, Lipkin S (1996) Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 19: 350–54.",,,,,,,
CG10ST72,"Ghatnekar, O., Willis, M., & Persson, U. (2002), Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries""", Journal of Wound Care, vol. 11, no. 2," pp. 70-74.""",,,
CG10ST73,"Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J, Edmonds ME (1997) Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 350: 855–59.",,,,,,,
CG10ST74,"Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin C, Karchmer AW (1994) Use of ampicillin/sulbactam versus imipenem/cilastitin in the treatment of limb-threatening foot infections in diabetic patients. Clinical Infectious Diseases 18: 683–93.",,,,,,,
CG10ST75,"Greenhalgh T (1994) Shared care for diabetes – a systematic review. Royal College of General Practitioners Occasional Paper 67. London, RCGP.",,,,,,,
CG10ST76,"Griffin S, Kinmonth AL (1998) Diabetes care: the effectiveness of systems for routine surveillance for people with diabetes. In Williams R, Bennett P, Nicolucci A, Krans HMJ, Ramirez G (eds). Diabetes module of the cochrane database of systematic reviews, (updated 01 December 1997). Available in the Cochrane Library, 1998, Issue 1.",,,,,,,
CG10ST77,"Gurlek A, Bayraktar M, Savas C, Gedik O (1998) Amputation rate in 147 Turkish patients with diabetic foot. Experimental and Clinical Endocrinology & Diabetes 106: 404-409.",,,,,,,
CG10ST78,"Hampson JP, Roberts RI, Morgan DA (1996) Shared care: a review of the literature. Family Practice 13: 264–79.",,,,,,,
CG10ST79,"Hamalainen H, Ronnemaa T, Toikka T, Liukkonen I (1998) Long-term effects of one year   of intensified podiatric activities on foot-care knowledge and self-care habits in patients with diabetes. The Diabetes Educator 24: 734-740.",,,,,,,
CG10ST80,"Hamalainen H, Ronnemaa T, Halonen J-P & Toikka T (1999) Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: a population-based 7-year follow-up study. Journal of Internal Medicine 246: 97-103.",,,,,,,
CG10ST81,"Hayes TM, Harries JM (1984) Randomised controlled trial of routine hospital clinic care versus routine general practice care for Type II diabetics. British Medical Journal 289: 728–30.",,,,,,,
CG10ST82,"Health Survey for England ’96; Volume 1: Findings. (ed.) Prescott-Clarke P, Primatesta P (1996) London: The Stationery Office.",,,,,,,
CG10ST83,"Heng M C Y, Harker J, Csathy G, Marshall C, Brazier J, Sumampong S, Gomez E P (2000) Angiogenesis in necrotic ulcers treated with hyperbaric oxygen. Ostomy Wound Management 46: 18-28.",,,,,,,
CG10ST84,"Hickman M, Drummond N and Grimshaw J (1994) A taxonomy of shared care for chronic disease. Journal of Public Health Medicine 16: 447–54.",,,,,,,
CG10ST85,"Holloway G, Steed D, DeMarco M, Masmuto T, Moosa H, Webster M, Bunt T, Polansky M (1993) A randomised controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, non-healing diabetic wounds. Wounds 5: 198–206.",,,,,,,
CG10ST86,"Holstein P, Ellitsgaard N, Olsen B B, Ellitsgaard V, (2000) Decreasing incidence of major amputations in people with diabetes. Diabetologia 43: 844-847.",,,,,,,
CG10ST87,"Hoskins PL, Fowler PM, Constantino M, Forrest J, Yue DK, Turtle JR (1993) Sharing the care of diabetic patients between hospital and general practitioners: does it work? Diabetic Medicine 10: 81–86.",,,,,,,
CG10ST88,"Hughes CE, Johnson CC, Bamberger DM, Reinhardt JF, Peterson LR, Mulligan ME, Gerding DN, George WL, Finegold SM (1987) Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clinical Therapeutics 10: 36–49.",,,,,,,
CG10ST89,"Hurwitz B, Goodman C, Yudkin J (1993) Prompting the clinical care of non-insulin dependent (Type II) diabetic patients in an inner city area: one model of community care. British Medical Journal 306: 624–30.",,,,,,,
CG10ST90,"Hutchinson A, McIntosh A, Feder G, Home PD, et al (2000) Clinical Guidelines and Evidence Review for Type 2 Diabetes: Prevention and Management of Foot Problems London: Royal College of General Practitioners",,,,,,,
CG10ST91,"Incandela L, Belcaro G, Cesarone M R, De Sanctis M T, Griffin M, (2001) Microvascular alterations in diabetic microangiopathy: topical treatment with essaven gel. A placebo- controlled, randomized study. Angiology 52: S35-S41.",,,,,,,
CG10ST92,"Janssen H, Rooman R, Donecker P, Cauwenbergh G, Degreef H, Lapiere C, Roseeuw D, Dockx P, Bersaques J, Decroix J, Cuyper C, Karavani I, Janssen P (unpublished) Topical ketanserin accelerates the wound healing process in decubitus, arterial and diabetic skin ulcers.",,,,,,,
CG10ST93," Jensen J L, Seeley J, Gillin B, (1998) Diabetic foot ulcerations. A controlled, randomized comparison of two moist wound healing protocols: carrasyn hydrogel wound dressing and wet-to-moist saline gauze. Research Digest 11: 1-4.",,,,,,,
CG10ST94,"Kastenbauer T, Sauseng S, Sokol G, Auinger M, Irsigler K (2001) A prospective study of predictors for foot ulceration in type 2 diabetes. Journal of the American Podiatric Medical Association 91: 343-350.",,,,,,,
CG10ST95,"Klenerman L, McCabe C, Cogley D, Crerand S, Laing P, White M (1996) Screening for patients at risk of diabetic foot ulceration in a general diabetic outpatient clinic. Diabetic Medicine 13: 561–63.",,,,,,,
CG10ST96,"Koblik T, Sieradzki J, Sendur R, Biernat J, Czarnobilski K, Gryz E, Pawlik W, Szczudlik A, Gaddi A (2001) The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome. Pilot study in elderly patients. Journal of Diabetes and its Complications 15:69-74.",,,,,,,
CG10ST97,"Kruger S, Guthrie D (1992) Foot care: knowledge retention and self-care practices. The Diabetes Educator 18(6): 487–90.",,,,,,,
CG10ST98,"Kumar S, Ashe HA, Parnell LN, Fernando DJS, Tsigos C, Young RJ, Ward JD, Boulton AJM (1994) The prevalence of foot ulceration and its correlates in Type 2 diabetic patients: a population based study. Diabetic Medicine 11: 480–84.",,,,,,,
CG10ST99,"Kumar S, Fernando DJS, Veves A, Knowles EA, Young MJ, Boulton AJM (1991) Semmes- Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Research and Clinical Practice 13: 63–68.",,,,,,,
CG10ST100,"Laing W, Williams R (1989) Diabetes: a model for health care management. London: Office of Health Economics, No 2.",,,,,,,
CG10ST101,Leese B (1995a) Diabetes mellitus and the Saint Vincent declaration: the economic implications. Pharmaco Economics 7(4): 292–307.,,,,,,,
CG10ST102,Leese B (1995b) Economic evaluations of Type II diabetes. Pharmaco Economics 8 (Suppl 1): 23–27.,,,,,,,
CG10ST103,"Lehto S, Ronnemaa T, Pyorala K, Laakso M (1996) Risk factors predicting lower extremity amputations in patient with NIDDM. Diabetes Care 19: 607-612.",,,,,,,
CG10ST104,"Leslie C, Sapico F, Ginunas V, Adkins R (1988) Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 11(2): 111–15.",,,,,,,
CG10ST105,Levin ME (1987) Understanding your diabetic patient. Clinics in Podiatric Medicine and Surgery 4: 315–30.,,,,,,,
CG10ST106,"Liniger C, Albeanu A, Assal J-P (1990a) Measuring diabetic neuropathy: “low tech” vs. “high tech”. Diabetes Care 13: 180–81.",,,,,,,
CG10ST107,"Liniger C, Albeanu A, Bloise D, Assal J-P (1990b) The tuning fork revisited. Diabetic Medicine 7: 859–64.",,,,,,,
CG10ST108,"Lipsky BA, Baker PD, Landon GC, Fernau R. (1996) Antibiotic therapy for diabetic foot infections: a comparison of two parenteral-to oral regimens. Clinical Infectious Diseases 24: 643–48.",,,,,,,
CG10ST109,"Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH (1990) Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Archives of Internal Medicine 150: 790–97.",,,,,,,
CG10ST110,"Lishner M, Lang R, Kedar I, Ravid M (1985) Treatment of diabetic perforating ulcers (mal perforant) with local dimethylsulfoxide. Journal of the American Geriatrics Society 33: 41– 43.",,,,,,,
CG10ST111,Lithner FG (1992) The diabetic foot: epidemiology and economic impact. IDF Bulletin 38: 7–9.,,,,,,,
CG10ST112,"Litzelman DK, Marriott DJ, Vinicor F (1997a) The role of footwear in the prevention of foot lesions in patients with NIDDM. Diabetes Care 20: 156–62.",,,,,,,
CG10ST113,"Litzelman DK, Marriott DJ, Vinicor F (1997b) Independent physiological predictors of foot lesions in patients with NIDDM. Diabetes Care 20: 1272–78.",,,,,,,
CG10ST114,"Litzelman DK, Slemenda CW, Langefeld CD, Hays LM, Walch MA, Bild DE, et al (1993) Reduction of lower extremity clinical abnormalities in patients with non insulin dependent diabetes. Ann Intern Med 119: 36–41.",,,,,,,
CG10ST115,"McCabe CJ, Stevenson RC, Dolan AM (1998) Evaluation of a diabetic foot screening and protection programme. Diabetic Medicine 15: 80–84.",,,,,,,
CG10ST116,"McCormick A, Fleming D, Charlton J (1995) Morbidity statistics in general practice: fourth national study 1991-1992 series MB5 No 3. London HMSO.",,,,,,,
CG10ST117,"McKinnon, P. S., Paladino, J. A., Grayson, M. L., Gibbons, G. W., & Karchmer, A. W. (1997), Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients""", Clinical Infectious Diseases, vol. 24, no. 1," pp. 57-63.""",,,
CG10ST118,"Majid M, Cullum N, Fletcher A, O’Meara S, Sheldon T. Systematic review of interventions for the prevention and treatment of diabetic foot ulceration. Pre-Publication Copy. York: NHS Centre for Reviews and Dissemination.",,,,,,,
CG10ST119,"Malone JM, Snyder M, Anderson G, Bernhard VM, Holloway GA, Bunt TJ (1989) Prevention of amputation by diabetic education. American Journal of Surgery 158: 520–24.",,,,,,,
CG10ST120,"Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA, (2000) Risk factors for delayed healing of neuropathic diabetic foot ulcers. A pooled analysis. Arch Dermatol 136: 1531- 1535.",,,,,,,
CG10ST121,"Margolis DJ, Kantor J, Berlin JA, (1999) Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22: 692-695.",,,,,,,
CG10ST122,Marks L (1996) Counting the cost: the real impact of non-insulin dependent diabetes. London: Kings Fund Policy Institute.,,,,,,,
CG10ST123,"Martinez-de Jesus FR, Morales-Guzman M, Castañeda M, Perez-Morales A, Garcia-Alonso J, Mendiola-Segura I (1997) Randomised single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers. Archives of Medical Research 28: 95–99.",,,,,,,
CG10ST124,"Maser RE, Nielsen VK, Bass EB, Manjoo Q, Dorman JS, Kelsey SF, Becker DJ, Orchard MS (1989) Measuring diabetic neuropathy: assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 12: 270–75.",,,,,,,
CG10ST125,"Masson EA, Angle S, Roseman P, Soper C, Wilson I, Cotton M, Boulton AJM (1989) Diabetic foot ulcers: do patients know how to protect themselves? Practical Diabetes 6: 22–25.",,,,,,,
CG10ST126,"Mayfield J A, Reiber G E, Nelson R G, Greene T, (2000) Do foot examinations reduce the risk of diabetic amputation? The Journal of Family Practice 49:499-504.",,,,,,,
CG10ST127,"Meijer J-W G, Van Sonderen E, Blaauwwiekel E E, Smit A J, Groothoff J W, Eisma W H, Links T P (2000) Diabetic Neuropathy Examination. A hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care 23: 750-753.",,,,,,,
CG10ST128,"Morris A D, McAlpine R, Steinke D, Boyle D I R, Ebrahim A-R, Vasudev N, Stewart C P U, Jung R T, Leese G P, MacDonald T M, Newton R W, (1998) Diabetes and lower-limb amputations in the community. A retrospective cohort study. Diabetes Care 21: 738-743.",,,,,,,
CG10ST129,"Moss S E, Klein R, Klein B E K, (1999) The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care 22: 951-959.",,,,,,,
CG10ST130,"Moss S E, Klein R, Klein B E K (1996) Long-term incidence of lower-extremity amputations in a diabetic population. Arch Fam Med 5: 391-398.",,,,,,,
CG10ST131,"Mueller M J, Diamond J E, Sinacore D R, Delitto A, Blair III V, Drury D, Rose S (1989) Total contact casting in treatment of diabetic planter ulcers. Controlled clinical trial. Diabetes Care 12: 384–88.",,,,,,,
CG10ST132,"Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW (1994) Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl- L-histidyl-L-lysine copper. Wound Repair and Regeneration 2: 259–69.",,,,,,,
CG10ST133,"Murray HJ, Young MJ, Hollis S, Boulton AJM (1996) The association between callus formation, high pressures and neuropathy in diabetic foot ulceration. Diabetic Medicine 13: 979–82.",,,,,,,
CG10ST134,"Muthukumarasamy MG, Sivakumar G, Manoharan G (1991) Topical phenytoin in diabetic foot ulcers. Diabetes Care 14: 909–11.",,,,,,,
CG10ST135,National Service Framework for Diabetes: Standards: London Department of Health 2001 Ib ,,,,,,,
CG10ST136,"Naughton G, Mansbridge J, Gentzkow G (1997) A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs 21: 1203–10.",,,,,,,
CG10ST137,NICE: The Guideline Development Process– Information for National Collaborating Centres and Guideline Development Groups (www.nice.org.uk),,,,,,,
CG10ST138,"Neil HAW, Thompson AV, Thorogood M, et al (1989) Diabetes in the elderly: the Oxford community diabetes study. Diabetic Medicine 6: 608–13.",,,,,,,
CG10ST139,"New J P, MdDowell D, Burns E, Young R J, (1998) Problem of amputations in patients with newly diagnosed diabetes mellitus. Diabetes Medicine 15: 760-764.",,,,,,,
CG10ST140,Office for National Statistics (1996) Key health statistics from general practice: studies on medical and population subjects No 60. London: The Stationery Office.,,,,,,,
CG10ST141,"Ollendorf, D. A., Kotsanos, J. G., Wishner, W. J., Friedman, M., Cooper, T., Bittoni, M., & Oster, G. (1998), Potential economic benefits of lower-extremity amputation prevention strategies in diabetes""", Diabetes Care, vol. 21, no. 8," pp. 1240-1245.""",,,
CG10ST142,"III Pacaud D, Singer D, McConnell B, Yale J-F, (1999) Assessment of screening practices for peripheral neuropathy in people with diabetes. Canadian Journal of Diabetes Care 23: 21- 25.",,,,,,,
CG10ST143,"Paisley A N, Abbott C A, van Schie C H M, Boulton A J M, (2002) A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabetic Medicine 19: 400-405.",,,,,,,
CG10ST144,"Pecoraro RE, Reiber GE, Burgess EM (1990) Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 13: 513.",,,,,,,
CG10ST145,"Peters E J, Lavery L A, Armstrong D G, Fleischli J G, (2001) Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial. Arch Phys Med Rehabil 82: 721-725.",,,,,,,
CG10ST146,"Peters E J, Lavery L A, (2001) Effectiveness of the diabetic foot risk classification system of the international working group on the diabetic foot. Diabetes Care 24: 1442-1447.",,,,,,,
CG10ST147,"Pham H, Armstrong D G, Harvey C, Harkless L B, Giurini J M, Veves A, (2000) Screening techniques to identify people at high risk for diabetic foot ulceration. A prospective multicenter trial. Diabetes Care 23: 606-611.",,,,,,,
CG10ST148,"Pham HT, Exelbert L, Segal-Owens AC, Veves A, (2002) A prospective, randomized, controlled double-blind study of a moisturizer for xerosis of the feet in patients with diabetes. Ostomy Wound Management 48: 30-36.",,,,,,,
CG10ST149,"Piagessi A, Baccetti F, Rizzo L, Romanelli M, Navalesi R, Benzi L, (2001) Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot. Diabetic Medicine 18: 320-324.",,,,,,,
CG10ST150,"Pieber TR, Holler A, Siebenhofer A, Brunner GA, Semlitsch B, Schattenberg S, Zapotoczky H, Rainer W, Krejs GJ (1995) Evaluation of a structured teaching programme for Type 2 diabetes in general practice in a rural area of Austria. Diabetic Medicine 12: 349–54.",,,,,,,
CG10ST151,"Pierce M, Agarwal G, Ridout D (2000) A survey of diabetes care in general practice in England and Wales British Journal of General Practice 50: 542-545.",,,,,,,
CG10ST152,Porter AMD (1982) Organisation of diabetic care. British Medical Journal 285: 1121.,,,,,,,
CG10ST153,"Ramsey, S. D., Sandhu, N., Newton, K., Reiber, G. E., Waggner, E. H., & McCullough, D.",,,,,,,
CG10ST154,"K. (1999), Incidence", outcomes," and cost of foot ulcers in patients with diabetes""", Diabetes Care, vol. 22, no. 3," pp. 382-387.""",
CG10ST155,"Reiber G E, Smith D G, Wallace C, Sullivan K, Hayes S, Vath C, Maciejewski M L, Yu O, Heagerty P J, LeMaster J, (2002) Effect of therapeutic footwear on foot reulceration in patients with diabetes. A randomized controlled trial. JAMA 287: 2552-2559",,,,,,,
CG10ST156,"Reichard P, Nilsson B-Y, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 329: 304–309.",,,,,,,
CG10ST157,"Rettig BA, Shrauger DG, Recker RR, Gallagher TF, Wiltse H (1986) A randomized study of the effects of a home diabetes education program. Diabetes Care 9: 173–78.",,,,,,,
CG10ST158,"Richard J, Richard C, Daures J, Clouet S, Vannereau D, Bringer J, Rodier M, Jacob C, Comte-Bardonnet M (1995) Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. Diabetes Care 18: 64–69.",,,,,,,
CG10ST159,"Rith-Najarian SJ, Stolusky T, Gohdes DM (1992) Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting: a prospective evaluation of simple screening criteria. Diabetes Care 15: 1386–89.",,,,,,,
CG10ST160,"Selby PL, Young MJ, Boulton AJM (1994) Bisphosphonates: A new treatment for diabetic charcot neuroarthropathy? Diabetic Medicine 11: 28–31.",,,,,,,
CG10ST161,"Shin J B, Seong Y J, Lee H J, Kim S H, Park J R, (2000) Foot screening technique in a diabetic population. J Korean Med Sci 15: 78-82.",,,,,,,
CG10ST162,"Sinclair AJ, Barnett AH (1993) Special needs of elderly diabetic patients. British Medical Journal 306: 1142–43.",,,,,,,
CG10ST163,"Smith S A, Murphy M E, Huschka T R, Dinneen S F, Gorman C A, Zimmerman B R, Rizza R A, Naessens J M, (1998) Impact of a diabetes electronic management system on the care of patients seen in a subspecialty diabetes clinic. Diabetes Care 21: 972-976.",,,,,,,
CG10ST164,"Smith J, (2002) Debridement of diabetic foot ulcers (Cochrane Review). The Cochrane Library 4.",,,,,,,
CG10ST165,Songer TJ (1992) The economic costs of NIDDM. Diabetes/Metabolism Reviews 8: 389– 404.,,,,,,,
CG10ST166,"Sriussadaporn S, Makanandha P, Vannasaeng S, Nitiyanant W, Komoltri C, Ploybutr S, Yamwong P, Peerapatdit T, Vichayanrat, (1996) Factors associated with diabetic foot ulceration in Thailand: a case-control study. Diabetic Medicine 14: 50-56.",,,,,,,
CG10ST167,"Steed D, Donohoe D, Webster M, Lindsley L and the Diabetic Ulcer Group (1995b) Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery 21: 71–81.",,,,,,,
CG10ST168,"Steed D, Goslen J, Holloway G, Malone J, Bunt T, Webster M (1992) Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. Diabetes Care 15: 1598–1604.",,,,,,,
CG10ST169,"Steed D, Ricotta J, Prendergast J, Kaplan R, Webster M, McGill J, Schwartz S and the RGD Study Group (1995a) Promotion and acceleration of diabetic ulcer healing by arginine- glycine-aspartic acid (RGD) peptide matrix. Diabetes Care 18: 1–8.",,,,,,,
CG10ST170,"Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW (1993) Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-taxobactam versus ticarcillin-clavulanate. Antimicrobial Agents and Chemotherapy 37: 1580–86.",,,,,,,
CG10ST171,"Tennvall G R, Apelqvist J, (2000) Health-related quality of life in patients with diabetes mellitus and foot ulcers. Journal of Diabetes and its Complications 14: 235-241.",,,,,,,
CG10ST172,"Thivolet C, El Farkh J, Petiot A, Simonet C, Tourniaire J (1990) Measuring vibration sensations with graduated tuning fork: simple & reliable means to detect diabetic patients at risk of neuropathic foot ulceration. Diabetes Care 13: 1077–80.",,,,,,,
CG10ST173,"Thomson FJ, Masson EA (1992) Can elderly diabetic patients cooperate in routine foot care? Age and Ageing 21: 333–37.",,,,,,,
CG10ST174,"Thomson FJ, Veves A, Ashe H, et al (1991) A team approach to diabetic foot care – the Manchester experience. The Foot 1: 75–82.",,,,,,,
CG10ST175,"Uccioli L, Aldeghi A, Faglia E, Quarantiello A, Monticone G, Calia P, Favales F,  Menzinger G, Durola L (1995) Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care 18: 1376–78.",,,,,,,
CG10ST176,"UK Prospective Diabetes Study Group (1995) Perspectives in diabetes, U.K. prospective diabetes study 16. Overview of 6 years’ therapy of Type II diabetes: a progressive disease. Diabetes 44: 1249–58.",,,,,,,
CG10ST177,UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes British Medical Journal 317: 703–13,,,,,,,
CG10ST178,"Ia Valk G D, Kriegsman D M W, Assendelft W J J, (2002) Patient education for preventing diabetic foot ulceration. A systematic review. Endocrinology and Metabolism Clinics of North America. 31: 633-658.",,,,,,,
CG10ST180,"Valk G D, Kriegsman D M W, Assendelft W J J, (2001) Patient education for preventing diabetic foot ulceration (Cochrane Review). The Cochrane Library 4.",,,,,,,
CG10ST181,"Van Schie C H M, Whalley A, Vileikyte L, Wignall T, Hollis S, Boulton A J M (2000) Efficacy of injected liquid silicone in the diabetic foot to reduce risk factors for ulceration. A randomized double-blind placebo-controlled trial. Diabetes Care 23: 634-638.",,,,,,,
CG10ST182,"Veves A, Falanga V, Armstrong D G, Sabolinski M L, (2001) Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. A prospective randomized multicenter clinical trial. Diabetes Care 24: 290-295.",,,,,,,
CG10ST183,"Veves A, Sheeha P, Pham H T, (2002) A randomized, controlled trial of promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 137: 822-827.",,,,,,,
CG10ST184,"Vileikyte L, Hutchings G, Hollis S, Boulton AJM (1997) The tactile circumferential discriminator: A new, simple screening device to identify diabetic patients at risk of foot ulceration. Diabetes Care 20: 623–26.",,,,,,,
CG10ST185,"Wagner FW (1983) Algorithms of diabetic foot care. In Levin ME, O’Neal FW (eds). The diabetic foot. St Louis, MO: CV Mosby, 290.",,,,,,,
CG10ST186,"Walters DA, Gatling W, Mullee MA, Hill RD (1992) The distribution and severity of diabetic foot disease: a community based study with comparison to a non-diabetic group. Diabetic Med 9: 354–58.",,,,,,,
CG10ST187,Ward JD (1994) Wealthy means healthy: diabetes and social deprivation. Diabetic Medicine 11: 334–35.,,,,,,,
CG10ST188,"Welsh Office, Health Statistics & Analysis Unit (1996) Welsh Health Survey 1995. Cardiff: Welsh Office",,,,,,,
CG10ST189,"Yonem A, Cakir B, Guler S, Azal O, Corakci A, (2001) Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes, Obesity and Metabolism 3: 332-337",,,,,,,
CG10ST190,West R (1992) Assessment of evidence versus consensus or prejudice. Journal of Epidemiology and Community Health 46: 321–22.,,,,,,,
CG10ST191,"Wieman TJ, Smiell JM, Yachin S (1998) Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 21: 822–27.",,,,,,,
CG10ST192,"Wilkes E, Lawtin EE (1980) The diabetic, the hospital and primary care. Journal of the Royal College of General Practitioners 30: 199–206.",,,,,,,
CG10ST193,"Williams R (1994) Diabetes mellitus. In: Health care needs assessment: the epidemiologically based needs assessment reviews. Volume 1. (eds): Stevens A, Raftery J. Radcliffe Medical Press, Oxford.",,,,,,,
CG10ST194,World Health Organisation (Europe) and International Diabetes Federation (Europe) (1990) Diabetes care and research in Europe: the St Vincent Declaration. Diabetic Med 7: 360.,,,,,,,
CG10ST195,"World Health Organisation. Diabetes care and research in Europe: the St Vincent Declaration Action Programme Implementation Document (2nd edition). Krans HMJ, Porta M, Keen H, Staehr Johansen K (eds). Copenhagen: World Health Organisation, 1995.",,,,,,,
CG10ST196,"Young MJ, Breddy JL, Veves A, Boulton AJM (1994) The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. Diabetes Care 17: 557– 60.",,,,,,,
CG10ST197,"Young MJ, Boulton AJM, MacLeod AF et al (1993) A multicenter study of the prevalence of diabetic peripheral neuropathy in the United kingdom hospital clinic population Diabetologia 36: 150-54",,,,,,,
PH38ST1,"Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med. 2007 May;24(5):451-63",,,,,,,
PH38ST2,Centre for Reviews and Dissemination (CRD) Systematic Reviews: CRD’s guidance for undertaking reviews in health care. CRD. York: 2009,,,,,,,
PH38ST3,Department of Health (2002) National service framework for diabetes: standards London: Department of Health,,,,,,,
PH38ST4,Diabetes UK (2006) Diabetes and the disadvantaged: reducing health inequalities in the UK. A report by the All Party Parliamentary Group for Diabetes and Diabetes UK [online]. Available from  www.diabetes.org.uk/Documents/Reports/Diabetes_disadvantaged_Nov2006.pdf,,,,,,,
PH38ST5,"Griffin SJ, Little PS., Hales CN., Kinmomth AL., Wareham NJ. Diabetes risk score: wards earlier detection of type 2 diabetes in general practice. Diabetes Metab. Res. Rev. 2000: 16; 164 – 171.",,,,,,,
PH38ST6,"Hippisley – Cox J., Coupland C., Vinogradova Y., Robson J., May M., Brindle. P.Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. 2009: bmj.com doi:10.1136/bmj.39261.471806.55",,,,,,,
PH38ST7,"Lindstrom J, Eriksson JG, Valle TT et al. (2003a) Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society Nephrology 14 (supplement 2): 108–13",,,,,,,
PH38ST8,"Lindstrom J., Tuomilehto J. (2003b) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26; 725 – 731.",,,,,,,
PH38ST9,Model Group (2007) Diabetes: finding excellence? Facing the multi-faceted challenge of diabetes [online]. Available from  www.diabetes.nhs.uk/downloads/diabetes_finding_excellence.pdf,,,,,,,
PH38ST10,"National Institute for Health and Clinical Excellence 2009. Methods for development of NICE public health guidance (second edition) National Institute for Health and Clinical Excellence, London.",,,,,,,
PH38ST11,National Institute for Health and Clinical Excellence 2009b. Developing NICE Guidance. http://www.nice.org.uk/nicemedia/live/12067/45087/45087.pdf (Accessed 13.05.10).   http://www.nice.org.uk/guidance/index.jsp?action=download&o=34605 Accessed 10/01/2012,,,,,,,
PH38ST12,"Reinauer H., Home P.D., Kanagasabapathy A.S., Heuck C-C. Laboratory Diagnosis and Monitoring of Diabetes Mellitus. 2002: World Health Organization.",,,,,,,
PH38ST13,"Sandbaek A., Griffin SJ., Rutten G., Davies M., Stolk R., Khunti K., Borch-Johnsen K., N. J. Wareham NJ., Lauritzen T. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk: the ADDITION study. Diabetologia. 2008 51:1127–1134",,,,,,,
PH38ST14,"The Health and Social Care Information Centre (2009) Statistics on obesity, physical activity and diet: England February 2009. London: The Information Centre.",,,,,,,
PH38ST15,"Tuomeilheto J., Lindstrom J., Eriksson JG., Valle TT., Hamaleinen H., Hanne-Parikka P. et al. 2001 Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001 344: 1343-1350",,,,,,,
PH38ST16,"UK National Screening Committee. The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management. University of Leicester; UK. 2008.",,,,,,,
PH38ST17,"Waugh N, Scotland G, McNamee P et al (2007) Screening for type 2 diabetes literature review and economic modelling. Health Technology Assessment 11: 17 [online]. Available from www.ncbi.nlm.nih.gov/pubmed/17462167",,,,,,,
PH38ST18,"Whiting P., Rutjes AWS., 2 Reitsma JB., Bossuyt PMM., Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology 2003, 3:25",,,,,,,
PH38ST19,"Williamsom DF., Venkat Narayan KM. Identification of persons with dysglycaemia: Terminology and practical significance. Primary Care Diabetes 2009, 3: 211-217.",,,,,,,
PH38ST20,World Health Organisation.Screening for Type 2 Diabetes: Report of a WHO/IDF meeting. (2003) WHO Geneva,,,,,,,
PH38ST21,World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF Consultation (2006) WHO / IDF,,,,,,,
PH38ST22,World Health Organisation. Use of Glycated Haemoglobin (HbA1c) in the diagnosis of Diabetes Mellitus. (Addendum to ?Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia?) 2011 WHO / IDF,,,,,,,
PH38ST23,"Colagiuri S.Hussain Z., Zimmet P., Cameron A., Shaw J. Screening for type 2 diabetes and impaired glucose metabolism. The Australian experience. Diabetes Care 2004; 27(2):367-371.",,,,,,,
PH38ST24,"Franciosi M, De Berardis G, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care 2005 28(5):1187-1194",,,,,,,
PH38ST25,"Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish Diabetes Risk Score for Targeted Screening: The Inter99 study. Diabetes Care 2004 Mar:  27(3):727 – 733",,,,,,,
PH38ST26,"Gomyo MS., Sakane N., Kamae I., Sato S., Suzuki K., Tominaga S et al Effects of sex, age and BMI on screening tests for impaired glucose tolerance. Diabetes research and clinical practice 2004; 64(2):129-136.",,,,,,,
PH38ST27,"Gray LJ., Taub NA., Khunti K., Gardiner E., Hilest S., Webb DR., Srinivasan BT., Davies MJ. The Leicester Risk Assessment Score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabetic Medicine 2010 27: 887-895",,,,,,,
PH38ST28,"Greaves CJ., Stead JW., Hattersley AT., Ewings P., Brown P., Evans PH. A simple pragmatic system for detecting new cases of type 2 diabetes and impaired fasting glycaemia in primary care. Family Practice 2004: 21: 57-62",,,,,,,
PH38ST29,"Guerrero-Romero FR-M., Rodriguez-Moran M. Lowered criterion for normal fasting plasma glucose: Impact on the detection of impaired glucose tolerance and metabolic syndrome. Archives of Medical Research 2006: 37(1):140-144.",,,,,,,
PH38ST30,"Heikes KE, Eddy DM, Arondekar B, Schlessinger L, Heikes KE, Eddy DM et al. Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre- diabetes. Diabetes Care 2008: 31(5):1040-1045.",,,,,,,
PH38ST31,"Heldgaard, PE., Griffin SJ. Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome. Diabetic Medicine 2006. 23(9): 996-1002",,,,,,,
PH38ST32,"Herdzik E., Safranow K., Ciechanowski K. Diagnostic value of fasting capillary glucose, fructosamine and glycosylated haemoglobin in detecting diabetes and other glucose tolerance abnormalities compared to oral glucose tolerance test. Acta Diabetol 2002; 39(1):15-22.",,,,,,,
PH38ST33,"Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, et al Combined use of fasting plasma glucose and glycated haemoglobin A1c in the screening of diabetes and impaired glucose tolerance Acta Diabetol 2010: 47:231–236",,,,,,,
PH38ST34,"Lidfeldt, J., Nerbrand C., Samsioe G., Schersten B., Agardh C-D. A screening procedure detecting high-yield candidates for OGTT. The Women's Health in the Lund Area (WHILA) study: A population based study of middle-aged Swedish women. European journal of epidemiology 2001: 17(10):  943-951.",,,,,,,
PH38ST35,"Luders S., Hammersen F., Kulschewski A., Venneklass U., Zuchner C., Gansz A., et al Diagnosis of impaired glucose tolerance in hypertensive patients in daily practice. Int J Clin Practice 2005: 59 (6) 632-8",,,,,,,
PH38ST36,"Mannucci E, Ognibene A., Sposato I., Brogi M., Gallori G., Bardini G, et al. Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 2003: 40: 181-186",,,,,,,
PH38ST37,"Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007 May 30(5):1120 -1124",,,,,,,
PH38ST38,"Mohan V, Vijayachanrika V, Gokulakrishnan K, Anjana RM, Ganesan A, Weber MB, Venkat Narayan KM. A1c cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010 33 (3); 515-519",,,,,,,
PH38ST39,"Mostafa SA., Khunti K., Srinivasan BT., Webb D., Gray LJ., Davies MJ. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Research and Clinical Practice 2010: 90; 100 - 108",,,,,,,
PH38ST40,"Phillips LS, Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009 Sep 52 (9):1798-807.",,,,,,,
PH38ST41,"Rolka DB, Narayan KM, Thompson TJ, Goldman D, Lindenmayer J, Alich K, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001 24(11):1899 -1903",,,,,,,
PH38ST42,"Rush E. Crook N., Simmons D. Point-of-care testing as a tool for screening for diabetes and pre-diabetes. Diabet Med 2008: 25(9):1070-1075.",,,,,,,
PH38ST43,"Saaristo TP., Peltonen M., Lindstrom J., Saarikoski L., Sundvall J., Eriksson JG., Tuomilehto J. Cross-sectional evaluation of the Finnish Diabetes Risk Score: A tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diabetes and Vascular Disease Research 2005: 2(2):67-72.",,,,,,,
PH38ST44,"Saydah SH., Byrd-Holt D., Harris MI. Projected impact of implementing the results of the Diabetes Prevention Programme in the US population. Diabetes Care 2002: 25; 1940-45",,,,,,,
PH38ST45,"Schwarz PEH., Li J., Reimann M., Schutte AE., Bergmann A., Hanefeld M., et al The Finnish Diabetes Risk Score is associated with insulin resistance and progression toward Type 2 diabetes. J Clin Endocrinol Metab 2009: 94: 920-6",,,,,,,
PH38ST46,"Simmons D., Thompson CF., Engelgau MM. Controlling the diabetes epidemic: how should we screen for undiagnosed diabetes and dysglycaemia?  Diabetic Medicine 2005: 22; 207-212",,,,,,,
PH38ST47,"Somannavar, S., Ganesan A., Deepa M., Datta M., Mohan V. Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community- based opportunistic screening in India. Diabetes Care 2009:32(4) 641-643.",,,,,,,
PH38ST48,"Thomas C, Hypponen E, Power C. Type 2 diabetes mellitus in midlife estimated from the Cambridge Risk Score and body mass index. Arch Intern Med 2006: 166(6):682- 688.",,,,,,,
PH38ST49,"Woolthuis EPK., de Grauw WJC., van Gerwen WHEM., van den Hoogen HJM., van de Lisdonk EH., Metsemakers JFM., van Weel C. Identifying people at risk for undiagnosed type 2 diabetes using the GP‘s electronic medical record. Family Practice June 14, 2007",,,,,,,
PH38ST50,"Zhou XH, Ji LN, Luo YY, Zhang XY, Han XY, Qiao Q et al. Performance of HbA1c for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing. Diabet Med 2009; 26(12):1262-1268.",,,,,,,
PH38ST51,"Zhou X, Pang Z, Gao W, Wang S, Zhang L, Ning F et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre- diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care 2010: 33(3) 545-550.",,,,,,,
CG66ST1,"1 National Institute for Health and Clinical Excellence. Guidelines manual. London: NICE, 2006.",,,,,,,
CG66ST2,"2 International Diabetes Federation. Definition and diagnosis of diabetes mellitus and immediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organisation, 2006.",,,,,,,
CG66ST3,"3 Department of Health. Health survey for England 2004. London: DH, 2005.",,,,,,,
CG66ST4,"4 International Diabetes Federation. Diabetes atlas. Brussels: IDF, 2006.",,,,,,,
CG66ST5,"5 Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care 2000;23(8):1103–1107.",,,,,,,
CG66ST6,"6 Anon. British National Formulary for Children (3). UK: BMJ Publishing Group Ltd and RPS Publishing, 2007. http://bnfc.org/bnfc",,,,,,,
CG66ST7,"7 National Collaborating Centre for Chronic Conditions. Type 2 diabetes: methodology pack. London: NCC-CC, 2006.",,,,,,,
CG66ST8,"8 Healthcare Commission. Managing diabetes: improving services for people with diabetes. London: Commission for Healthcare Audit and Inspection, 2007.",,,,,,,
CG66ST9,"9 Christensen NK, Williams P, Pfister R. Cost savings and clinical effectiveness of an extension service diabetes program. Diabetes Spectrum 2004;17(3):171–175.",,,,,,,
CG66ST10,"10 Mortimer D, Kelly J. Economic evaluation of the good life club intervention for diabetes self-management.Australian Journal of Primary Health 2006;12(1):91–100. ",,,,,,,
CG66ST11,"11 Connor H, Annan F, Bunn E et al. The implementation of nutritional advice for people with diabetes. Diabetic Medicine 2003;20(10):786–807.",,,,,,,
CG66ST12,"12 National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children (CG43). London: NICE, 2006.",,,,,,,
CG66ST13,"13 Li Z, Hong K, Saltsman P et al. Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: Relative effects on weight loss, metabolic parameters, and C-reactive protein. European Journal of Clinical Nutrition 2005;59(3):411–418.",,,,,,,
CG66ST14,"14 Barnard ND, Cohen J, Jenkins DJA et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care 2006; 29(8):1777–1783.",,,,,,,
CG66ST15,"15 Brinkworth GD, Noakes M. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia 2004;47(10):1677–1686.",,,,,,,
CG66ST16,"16 Daly ME, Paisey R. Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes – a randomized controlled trial. Diabetic Medicine 2006;23(1):15–20.",,,,,,,
CG66ST17,"17 Redmon JB, Susan KR, Kristell PR et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: A randomized trial. Diabetes Care 2003;26(9):2505.",,,,,,,
CG66ST18,"18 Stern L, Iqbal N, Seshadri P et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Annals of Internal Medicine 2004; 140(10):778–785.",,,,,,,
CG66ST19,"19 The Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu). Diabetes nutrition and complications trial: adherence to the ADA nutritional recommendations, targets of metabolic control, and onset of diabetes complications. A 7-year, prospective, population-based, observational multicenter study. Journal of Diabetes & its Complications 2006;20(6):361–366.",,,,,,,
CG66ST20,"20 Van ST, Van de Laar FA, Van Leeuwe JF et al. The dieting dilemma in patients with newly diagnosed type 2 diabetes: does dietary restraint predict weight gain 4 years after diagnosis? Health Psychology 2007; 26(1):105–112.",,,,,,,
CG66ST21,"21 Anderson RJ, Freedland KE, Clouse RE et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24(6):1069–1078.",,,,,,,
CG66ST22,"22 Rubin RR, Ciechanowski P, Egede LE et al. Recognizing and treating depression in patients with diabetes. Current Diabetes Reports 2004;4(2):119–125.",,,,,,,
CG66ST23,"23 de Groot M, Anderson R, Freedland KE et al. Association of depression and diabetes complications: a meta-analysis. Psychosomatic Medicine 2001;63(4):619–630.",,,,,,,
CG66ST24,"24 Lin EH, Katon W, Von KM et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004;27(9):2154–2160.",,,,,,,
CG66ST25,"25 Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002;25(3):464–470.",,,,,,,
CG66ST26,"26 National Institute for Health and Clinical Excellence. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15). London: NICE, 2004.",,,,,,,
CG66ST27,"27 National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care (CG23). London: NICE, 2004.",,,,,,,
CG66ST28,"28 Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 2000;321(7258):405–412.",,,,,,,
CG66ST29,"29 Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine 2004;141(6):421–431.",,,,,,,
CG66ST30,"30 Gerstein HC, Pogue J. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005;48(9):1749–1755.",,,,,,,
CG66ST31,"31 Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103(22):2668–2673.",,,,,,,
CG66ST32,"32 Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: A retrospective analysis. Cost Effectiveness & Resource Allocation 2006;4:1.",,,,,,,
CG66ST33,"33 Clarke PM, Gray AM, Briggs A et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48(5):868–877.",,,,,,,
CG66ST34,"34 Clarke P, Gray A, Adler A et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS no. 51). Diabetologia 2001;44(3):298–304.",,,,,,,
CG66ST35,35 ACCORD. ACCORD Study Announcement www.accordtrial.org. Date of message: 6 February 2008.,,,,,,,
CG66ST36,"36 Sarol JN, Nicodemus NA, Tan KM et al. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004). Current Medical Research & Opinion 2005;21(2):173–184.",,,,,,,
CG66ST37,"37 Welschen LM, Bloemendal E, Nijpels G et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005;28(6):1510–1517.",,,,,,,
CG66ST38,"38 Welschen LM, Bloemendal E, Nijpels G et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database of Systematic Reviews 2005;(2):CD005060.",,,,,,,
CG66ST39,39 Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Current Medical Research & Opinion 2006;22(4):671–681.,,,,,,,
CG66ST40,"40 Farmer A, Wade A, French DP et al. The DiGEM trial protocol: a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes. BMC Family Practice 2005;6(25)",,,,,,,
CG66ST41,"41 Moreland EC, Volkening LK, Lawlor MT et al. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial. Archives of Internal Medicine 2006;166(6):689–695.",,,,,,,
CG66ST42,"42 Siebolds M, Gaedeke O, Schwedes U et al. Self-monitoring of blood glucose – psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication. Patient Education & Counseling 2006;62(1):104–110.",,,,,,,
CG66ST43,"43 Karter AJ, Chan J, Parker MM et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29(8).",,,,,,,
CG66ST44,"44 Martin S, Schneider B, Heinemann L et al. Self-monitoring of blood glucose in type 2 diabetes and longterm outcome: an epidemiological cohort study. Diabetologia 2006;49(2):271–278.",,,,,,,
CG66ST45,"45 Wen L, Parchman ML, Linn WD et al. Association between self-monitoring of blood glucose and glycemic control in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy 2004; 61(22):2401–2405.",,,,,,,
CG66ST46,"46 Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 2006;29(8):1764–1770.",,,,,,,
CG66ST47,"47 Schutt M, Kern W, Krause U et al. Is the frequency of self-monitoring of blood glucose related to longterm metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Experimental & Clinical Endocrinology & Diabetes 2006;114(7):384–388.",,,,,,,
CG66ST48,"48 Kalergis M, Nadeau J, Pacaud D et al. Accuracy and reliability of reporting self-monitoring of blood glucose results in adults with type 1 and type 2 diabetes. Canadian Journal of Diabetes 2006;30(3):241–247.",,,,,,,
CG66ST49,"49 Lawton J, Peel E, Douglas M et al. ‘Urine testing is a waste of time’: newly diagnosed type 2 diabetes patients’ perceptions of self-monitoring. Diabetic Medicine 2004;21(9):1045–1048.",,,,,,,
CG66ST50,"50 Peel E, Parry O, Douglas M et al. Blood glucose self-monitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients’ perspectives. British Journal of General Practice 2004;54(500):183–188.",,,,,,,
CG66ST51,"51 Palmer AJ, Dinneen S, Gavin JR, III et al. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Current Medical Research & Opinion 2006;22(5):861–872.",,,,,,,
CG66ST52,"52 Gray A, Clarke P, Farmer A et al. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: Cost analysis (UKPDS 63). British Medical Journal 2002; 325(7369):860–863.",,,,,,,
CG66ST53,53 UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UKPDS Group. Lancet 1998;352(9131):837–853.,,,,,,,
CG66ST54,"54 Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 2006;355(23):2427–2443.",,,,,,,
CG66ST55,55 UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44(11):1249–1258.,,,,,,,
CG66ST56,"56 Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005;(3):CD002966.",,,,,,,
CG66ST57,"57 Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2003;(2):CD002967.",,,,,,,
CG66ST58,"58 Cryer DR, Nicholas SP, Henry DH et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005;28(3):539–543.",,,,,,,
CG66ST59,"59 Schernthaner G, Matthews DR, Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology & Metabolism 2004;89(12):6068–6076.",,,,,,,
CG66ST60,"60 Derosa G, Franzetti I, Gadaleta G et al. Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes: comparison between glimepiride and metformin. Diabetes, Nutrition & Metabolism – Clinical & Experimental 2004;17(3):143–150.",,,,,,,
CG66ST61,"61 Weissman P, Goldstein BJ, Rosenstock J et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Current Medical Research & Opinion 2005;21(12):2029–2035.",,,,,,,
CG66ST62,"62 Bailey CJ, Bagdonas A, Rubes J et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clinical Therapeutics 2005;27(10):1548–1561.",,,,,,,
CG66ST63,"63 Marre M, Van GL, Usadel KH et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes, Obesity & Metabolism 2002;4(3):177–186.",,,,,,,
CG66ST64,"64 Kvapil M, Swatko A, Hilberg C et al. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes, Obesity & Metabolism 2006;8(1):39–48.",,,,,,,
CG66ST65,"65 Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twicedaily immediate-release metformin to a once-daily extended-release formulation. Clinical Therapeutics 2003;25(2):515–529.",,,,,,,
CG66ST66,"66 Fujioka K, Brazg RL, Raz I et al. Efficacy, dose-response relationship and safety of once-daily extendedrelease metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes, Obesity & Metabolism 2005;7(1):28–39.",,,,,,,
CG66ST67,"67 Blonde L, Dailey G, Jabbour SA et al. Gastrointerstinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research & Opinion 2006;20(4):565–572.",,,,,,,
CG66ST68,"68 Mohammad F, Fenna I, Leong K et al. Audit of metformin sustained release (SR) in patients intolerant of immediate release metformin. Diabetic Medicine 2006;23(Suppl 2):111.",,,,,,,
CG66ST69,"69 Nagle A, Brake J, Hopkins M et al. Glucophage SR. Can it really make a difference? Diabetic Medicine 2006;23(Suppl 2):110.",,,,,,,
CG66ST70,"70 Thomas Z, Phillips SM, Hogan D et al. The tolerability of prolonged-release metformin (Glucophage SR) in previously metformin intolerant patients – review of local experience. Diabetic Medicine 2006; 23(Suppl 2):111.",,,,,,,
CG66ST71,"71 Yousseif A, Roberts S, Malik S et al. Patient reported side effects and compliance with Glucophage SR. Diabetic Medicine 2006;23(Suppl 2):111.",,,,,,,
CG66ST72,"72 Palmer AJ, Roze S, Lammert M et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic",,,,,,,
CG66ST73,control: an application of the CORE Diabetes Model in type 2 diabetes. Current Medical Research & Opinion 2004;20(Suppl 1):S41–S51.,,,,,,,
CG66ST74,"73 Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes  Clinical Therapeutics 2002;24(10):1690–1705.mellitus.",,,,,,,
CG66ST75,"74 Ward AJ, Salas M, Caro JJ, Owens D. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK. Cost Effectiveness & Resource Allocation 2004;2:2.",,,,,,,
CG66ST76,"75 Caro JJ, Salas M, Ward AJ et al. Combination therapy for type 2 diabetes: what are the potential health and cost implications in Canada? Canadian Journal of Diabetes 2003;27(1):33–41.",,,,,,,
CG66ST77,"76 Alvarsson M, Sundkvist G, Lager I et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26(8):2231–2237.",,,,,,,
CG66ST78,"77 Tong PC, Chow CC, Jorgensen LN et al. The contribution of metformin to glycaemic control in patients with type 2 diabetes mellitus receiving combination therapy with insulin. Diabetes Research & Clinical Practice 2002;57(2):93–98.",,,,,,,
CG66ST79,"78 Inukai K, Watanabe M, Nakashima Y et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Research & Clinical Practice 2005;68(3):250–257.",,,,,,,
CG66ST80,"79 Jibran R, Suliman MI, Qureshi F et al. Safety and efficay of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. Pakistan Journal of Medical Sciences 2006;22(4): 385–390.",,,,,,,
CG66ST81,"80 Saloranta C, Hershon K, Ball M et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. Journal of Clinical Endocrinology & Metabolism 2002;87(9):4171–4176.",,,,,,,
CG66ST82,"81 Bengel FM, Abletshauser C, Neverve J et al. Effects of nateglinide on myocardial microvascular reactivity in type 2 diabetes mellitus: a randomized study using positron emission tomography. Diabetic Medicine 2005;22(2):158–163.",,,,,,,
CG66ST83,"82 Moses RG, Gomis R, Frandsen KB et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001;24(1):11–15.",,,,,,,
CG66ST84,"83 Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27(6):1265–1270.",,,,,,,
CG66ST85,"84 Derosa G, Mugellini A, Ciccarelli L et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clinical Therapeutics 2003;25(2):472–484.",,,,,,,
CG66ST86,"85 Madsbad S, Kilhovd B, Lager I et al. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabetic Medicine 2001;18(5):395–401.",,,,,,,
CG66ST87,"86 Esposito K, Giugliano D, Nappo F et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110(2):214–219.",,,,,,,
CG66ST88,"87 Furlong NJ, Hulme SA, O’Brien SV et al. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabetic Medicine 2003;20(11):935–941.",,,,,,,
CG66ST89,"88 Raskin P, Klaff L, McGill J et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26(7):2063–2068.",,,,,,,
CG66ST90,"89 Gerich J, Raskin P, Jean LL et al. PRESERVE-beta: two-year efficacy and safety of initial combination versus nateglinide plus metformin. Diabetes Care 2003;26(7):2063–2068. ",,,,,,,
CG66ST91,"90 Ristic S, ColloberMaugeais C, Pecher E et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine 2006;23(7):757–762.",,,,,,,
CG66ST92,"91 Horton ES, Foley JE, Shen SG et al. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Current Medical Research & Opinion 2004;20(6):883–889.",,,,,,,
CG66ST93,"92 Dashora UK, Sibal L, Ashwell SG et al. Insulin glargine in combination with nateglinide in people withtype 2 diabetes: a randomized placebo-controlled trial. Diabetic Medicine 2007;24(4):344–349.",,,,,,,
CG66ST94,"93 Schernthaner G, Grimaldi A, Di MU et al. GUIDE study: double-blind comparison of once-daily gliclazideMR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation 2004;34(8):535–542.",,,,,,,
CG66ST95,"94 Lu CH, Chang CC, Chuang LM et al. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Diabetes, Obesity & Metabolism 2006;8(2):184–191.",,,,,,,
CG66ST96,"95 Charpentier G, Fleury F, Kabir M et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine 2001;18(10):828–834.",,,,,,,
CG66ST97,"96 Forst T, Eriksson JW, Strotmann HJ et al. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes 2003;111(2): 97–103.",,,,,,,
CG66ST98,"97 Wright AD, Cull CA, Macleod KM et al. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis (UKPDS 73). Journal of Diabetes & its Complications 2006;20(6):395–401.",,,,,,,
CG66ST99,"98 Gray A, Raikou M, McGuire A et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41). British Medical Journal 2000;320(7246):1373–1378.",,,,,,,
CG66ST100,"99 Van de Laar FA, Lucassen PL, Akkermans RP et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005;(2):CD003639.",,,,,,,
CG66ST101,"100 Ko GTC, Tsang CC, Ng CW et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation 2001;21(6):401–408.",,,,,,,
CG66ST102,"101 Goke B, German Pioglitazone Study Group. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Treatments in Endocrinology 2002;1(5):329–336.",,,,,,,
CG66ST103,"102 Feinbock C, Luger A, Klingler A et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose",,,,,,,
CG66ST104,"compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Diabetes, Nutrition & Metabolism - Clinical & Experimental 2003;16(4):214–221.",,,,,,,
CG66ST105,"103 Hwu CM, Ho LT, Fuh MM et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Diabetes Research & Clinical Practice 2003;60(2):111–118.",,,,,,,
CG66ST106,"104 Phillips P, Karrasch J, Scott R et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Diabetes Care 2003;26(2):269–273.",,,,,,,
CG66ST107,"105 Bachmann W, Petzinna D, Raptis SA et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation 2003;23(10):679–686.",,,,,,,
CG66ST108,"106 Lin BJ, Wu HP, Huang HS et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Journal of Diabetes & its Complications 2003;17(4):179–185.",,,,,,,
CG66ST109,"107 Segal P, Eliahou HE, Petzinna D et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation 2005;25(9):589–595.",,,,,,,
CG66ST110,"108 White TJ, Vanderplas A, Chang E et al. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Disease Management and Health Outcomes 2004;12(3):181–188.",,,,,,,
CG66ST111,"109 Quilici S, Chancellor J, Maclaine G et al. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden. International Journal of Clinical Practice 2005;59(10):1143–1152.",,,,,,,
CG66ST112,"110 Huang ES, Shook M, Jin L et al. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care 2006;29(2):259–264.",,,,,,,
CG66ST113,"111 Johnson JA, Simpson SH, Toth EL et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabetic Medicine 2005;22(4):497–502.",,,,,,,
CG66ST114,"112 Evans JMM, Ogston SA, EmslieSmith A et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49(5):930–936.",,,,,,,
CG66ST115,"113 National Institute for Health and Clinical Excellence. Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21). (TA63). London: NICE, 2003.",,,,,,,
CG66ST116,114 European Medicines Agency. 2007. www.emea.europa.eu,,,,,,,
CG66ST117,"115 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007;356(24):2457–2471.",,,,,,,
CG66ST118,"116 Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. New England Journal of Medicine 2007;357(1):28–38.",,,,,,,
CG66ST119,"117  Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. The Journal of the American Medical Association 2007;298(10):1180–1188.",,,,,,,
CG66ST120,"118 Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 2007;147(8):578–581.",,,,,,,
CG66ST121,"119 Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis [see comment]. The Journal of the American Medical Association 2007;298(10):1189–1195.",,,,,,,
CG66ST122,"120 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370(9593):1129–1136.",,,,,,,
CG66ST123,"121 GlaxoSmithKline. Coronary heart disease outcomes in patients receiving antidiabetic agents. Uxbridge, Middlesex: GlaxoSmithKline, 2008.",,,,,,,
CG66ST124,"122 Richter B, Bandeira-Echtler E, Bergerhoff K et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007;(3):CD006063.",,,,,,,
CG66ST125,"123 Derosa G, Gaddi AV, Piccinni MN et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes, Obesity & Metabolism 2006;8(2):197–205.",,,,,,,
CG66ST126,"124 Rosenstock J, Goldstein BJ, Vinik AI et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes, Obesity & Metabolism 2006;8(1):49–57.",,,,,,,
CG66ST127,"125 Raskin P, McGill J, Saad MF et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabetic Medicine 2004;21(4):329–335.",,,,,,,
CG66ST128,"126 Bakris GL, Ruilope LM, McMorn SO et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension 2006;24(10):2047–2055.",,,,,,,
CG66ST129,"127 Vongthavaravat V, Wajchenberg BL, Waitman JN et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Current Medical Research & Opinion 2002;18(8):456–461.",,,,,,,
CG66ST130,"128 St John SM, Rendell M, Dandona P et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11): 2058–2064.",,,,,,,
CG66ST131,"129 Hanefeld M, Patwardhan R, Jones NP et al. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutrition Metabolism & Cardiovascular Diseases  2007;17(1):13–23.",,,,,,,
CG66ST132,"130 Kerenyi Z, Samer H, James R et al. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Research & Clinical Practice 2004;63(3):213–223.",,,,,,,
CG66ST133,"131 Derosa G, Gaddi AV, Piccinni MN et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.  Pharmacotherapy  2005;25(5):637–645.",,,,,,,
CG66ST134,"132 Baksi A, James RE, Zhou B et al. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide  in patients  with type  2 diabetes  inadequately controlled  on half-maximal  doses of  a sulphonylurea. Acta Diabetologica 2004;41(2):63–69.",,,,,,,
CG66ST135,"133 Derosa G, D’Angelo A, Ragonesi PD et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal 2007;37(2): 79–86.",,,,,,,
CG66ST136,"134 Rosenstock J, Rood J, Cobitz A et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes, Obesity & Metabolism 2006;8(6):650–660.",,,,,,,
CG66ST137,"135 Stewart MW, Cirkel DT, Furuseth K et al. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabetic Medicine 2006;23(10): 1069–1078.",,,,,,,
CG66ST138,"136 Home PD, Jones NP, Pocock SJ et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine 2007;24(6):626–634.",,,,,,,
CG66ST139,"137 Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24(7):1226–1232.",,,,,,,
CG66ST140,"138 Home PD, Bailey CJ, Donaldson J et al. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabetic Medicine 2007;24(6):618–625.",,,,,,,
CG66ST141,"139 Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29(3):554–559.",,,,,,,
CG66ST142,"140 Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007;30(4):795–800.",,,,,,,
CG66ST143,"141 Richter B, Bandeira-Echtler E, Bergerhoff K et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006;(4):CD006060.",,,,,,,
CG66ST144,142 Dormandy JA. PROactive study. Lancet 2006;367(9405):26–27.,,,,,,,
CG66ST145,"143 Yudkin J.S., Freemantle N. PROactive study. Lancet 2006;367(3504):24–25.",,,,,,,
CG66ST146,144 PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study. Lancet 2006;367(9515):982.,,,,,,,
CG66ST147,"145 Mattoo V, Eckland D, Widel M et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clinical Therapeutics 2005;27(5):554–567.",,,,,,,
CG66ST148,"146 Davidson JA, Perez A, Zhang J. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes, Obesity & Metabolism 2006;8(2):164–174.",,,,,,,
CG66ST149,"147 Raz I, Stranks S, Filipczak R et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clinical Therapeutics 2005;27(9):1432–1443.",,,,,,,
CG66ST150,"148 Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48(6):1093–1104.",,,,,,,
CG66ST151,"149 Jain R, Osei K, Kupfer S et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006;26(10):1388–1395.",,,,,,,
CG66ST152,"150 Erdmann E, Dormandy JA, Charbonnel B et al. The effect of pioglitazone on  recurrent  myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. Journal of the American College of Cardiology 2007;49(17):1772–1780.",,,,,,,
CG66ST153,"151 Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. The Journal of the American Medical Association 2006;296(21):2572–2581.",,,,,,,
CG66ST154,"152 Wilcox R, Bousser MG, Betteridge DJ et al. effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38(3):865–873.",,,,,,,
CG66ST155,"153 Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Research & Clinical Practice 2007;76(2):279–289.",,,,,,,
CG66ST156,"154 Czoski-Murray C, Warren E, Chilcott J et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation (structured abstract). Health Technology Assessment 2004;8(13)",,,,,,,
CG66ST157,"155 National Institute for Health and Clinical Excellence. Diabetes (type 2) – pioglitazone (replaced by TA63) (TA21). London: NICE, 2001.",,,,,,,
CG66ST158,"156 Beale S, Bagust A, Shearer AT et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2006;24(Suppl 1):21–34.",,,,,,,
CG66ST159,"157 Tilden DP, Mariz S, O’BryanTear G et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007;25(1):39–54.",,,,,,,
CG66ST160,"158 Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279–1289.",,,,,,,
CG66ST161,"159 Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628–2635.",,,,,,,
CG66ST162,"160 DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over",,,,,,,
CG66ST163,30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092–1100.,,,,,,,
CG66ST164,"161 Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083–1091.",,,,,,,
CG66ST165,"162 Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2006;8(4):436–447.",,,,,,,
CG66ST166,"163 Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technology & Therapeutics 2005;7(3):467–477.",,,,,,,
CG66ST167,"164 Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2005;143(8):559–569.",,,,,,,
CG66ST168,"165 Secnik BK, Matza LS, Oglesby A et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health & Quality of Life Outcomes 2006;4(80).",,,,,,,
CG66ST169,"166 Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non- inferiority study. Diabetologia 2007;50(2):259–267.",,,,,,,
CG66ST170,"167 Zinman B, Hoogwerf BJ, Duran GS et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2007;146(7): 477–485.",,,,,,,
CG66ST171,168 European Medicines Agency. EPARs for authorised medicinal products for human use. Available from: www.emea.europa.eu. Last accessed on: 19 January 2008.,,,,,,,
CG66ST172,"169 Ray JA, Boye KS, Yurgin N et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Current Medical Research & Opinion 2007;23(3): 609–622.",,,,,,,
CG66ST173,"170 Goudswaard AN, Furlong NJ, Rutten GE et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2004;(4):CD003418.",,,,,,,
CG66ST174,171 Kokic SB. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Collegium Antropologicum 2003;27(1):181–187.,,,,,,,
CG66ST175,"172 Olsson PO, Lindstrom T. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes & Metabolism 2002;28(4:Pt 1):272–277.",,,,,,,
CG66ST176,"173 Altuntas Y, Ozen B, Ozturk B et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes, Obesity & Metabolism 2003;5(6):371–378.",,,,,,,
CG66ST177,"174 Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Annals of Pharmacotherapy 2003;37(11):1572–1576.",,,,,,,
CG66ST178,"175 Zargar AH, Masoodi SR, Laway BA et al. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure. Journal of the Association of Physicians of India 2002;50(5):641–646.",,,,,,,
CG66ST179,"176 Douek IF, Allen SE, Ewings P et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabetic Medicine 2005;22(5):634–640.",,,,,,,
CG66ST180,"177 Goudswaard AN, Stolk RP, Zuithoff P et al. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. Journal of Family Practice 2004;53(5):393–399.",,,,,,,
CG66ST181,"178 Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28(2):254–259.",,,,,,,
CG66ST182,"179 Stehouwer MH, DeVries JH, Lumeij JA et al. Combined bedtime insulin – daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and  hypo- glycaemia rate – a randomised trial. Diabetes/Metabolism Research and Reviews 2003;19(2):148–152.",,,,,,,
CG66ST183,"180 Lechleitner M, Roden M, Haehling E et al. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wiener Klinische Wochenschrift 2005;117(17):593–598.",,,,,,,
CG66ST184,"181 Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for economic evaluation of health care programmes, 2nd edn. Oxford: Oxford University Press, 2003.",,,,,,,
CG66ST185,"182 Christiansen JS, Vaz JA, Metelko Z. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2003;5(6):446–454.",,,,,,,
CG66ST186,"183 Kilo C, Mezitis N, Jain R et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. Journal of Diabetes & its Complications 2003;17(6):307–313.",,,,,,,
CG66ST187,"184 Ceriello A, Del PS, Bue VJ et al. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. Journal of Diabetes & its Complications 2007;21(1):20–27.",,,,,,,
CG66ST188,"185 Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006;(2):CD003287.",,,,,,,
CG66ST189,"186 Boehm BO, Home PD, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients [erratum appears in Diabetic Medicine. 2002 Sep;19(9):797]. Diabetic Medicine 2002;19(5):393–399.",,,,,,,
CG66ST190,"187 Boehm BO, Vaz JA, Brondsted L et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. European Journal of Internal Medicine 2004;15(8):496–502.",,,,,,,
CG66ST191,"188 Abrahamian H, Ludvik B, Schernthaner G et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). Hormone & Metabolic Research 2005;37(11):684–689.",,,,,,,
CG66ST192,"189 Schernthaner G, Kopp HP, Ristic S et al. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Hormone & Metabolic Research 2004;36(3):188–193.",,,,,,,
CG66ST193,"190 Ligthelm RJ, Mouritzen U, Lynggaard H et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes 2006;114(9):511–519.",,,,,,,
CG66ST194,"191 Joshi SR, Kalra S, Badgandi M et al. Designer insulins regimens in clinical practice – pilot multicenter Indian study. Journal of the Association of Physicians of India 2005;53(Sept):775–779.",,,,,,,
CG66ST195,"192 Davies M, Storms F, Shutler S. Initiation of Insulin Glargine in type 2 patients with suboptimal glycaemic control on twice-daily premix insulin: results from the AT.LANTUS trial. Diabetologia 2004;47(Suppl 1): 319.",,,,,,,
CG66ST196,"193 National Institute for Clinical Excellence. The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes (TA53). London: NICE, 2002.",,,,,,,
CG66ST197,"194 Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: a meta- analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28(4):950–955.",,,,,,,
CG66ST198,"195 Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007;(2):CD005613.",,,,,,,
CG66ST199,"196 Yki JH, Kauppinen MR, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49(3):442–451.",,,,,,,
CG66ST200,"197 Herman WH, Ilag LL, Johnson SL et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28(7):1568–1573.",,,,,,,
CG66ST201,"198 Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260–265.",,,,,,,
CG66ST202,"199 Eliaschewitz FG, Calvo C, Valbuena H et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research 2006;37(4):495–501.",,,,,,,
CG66ST203,200 Rosskamp R. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabetic Medicine 2003;20(7):545–551.,,,,,,,
CG66ST204,"201 Malone JK, Kerr LF, Campaigne BN et al. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clinical Therapeutics 2004;26(12):2034–2044.",,,,,,,
CG66ST205,"202 Malone JK, Bai S, Campaigne BN et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabetic Medicine 2005;22(4): 374–381.",,,,,,,
CG66ST206,"203 Jacober SJ, Scism BJ, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes, Obesity & Metabolism 2006;8(4):448–455.",,,,,,,
CG66ST207,"204 Kann PH, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Experimental & Clinical Endocrinology & Diabetes 2006;114(9):527–532.",,,,,,,
CG66ST208,"205 Kazda C, Hulstrunk H, Helsberg K et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. Journal of Diabetes & its Complications 2006;20(3):145–152.",,,,,,,
CG66ST209,"206 Pan CY, Sinnassamy P, Chung KD et al. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research & Clinical Practice 2007;76(1):111–118.",,,,,,,
CG66ST210,"207 Raskin PR, Hollander PA, Lewin A et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. European Journal of Internal Medicine 2007;18(1):56–62.",,,,,,,
CG66ST211,"208 Yokoyama H, Tada J, Kamikawa F et al. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research & Clinical Practice 2006;73(1):35–40.",,,,,,,
CG66ST212,"209 Standl E, Maxeiner S, Raptis S et al. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Hormone & Metabolic Research 2006;38(3):172–177.",,,,,,,
CG66ST213,"210 Gerstein HC, Yale JF, Harris SB et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabetic Medicine 2006;23(7):736–742.",,,,,,,
CG66ST214,"211 Fritsche A, Schweitzer MA, Haring HU et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine 2003;138(12):952–959.",,,,,,,
CG66ST215,"212 Massi BM, Humburg E, Dressler A et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone & Metabolic Research 2003;35(3):189–196.",,,,,,,
CG66ST216,"213 Riddle MC, Rosenstock J, Gerich J et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080–3086.",,,,,,,
CG66ST217,"214 Rosenstock J, Schwartz SL, Clark CM Jr et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631–636.",,,,,,,
CG66ST218,"215 Warren E, Weatherley-Jones E, Chilcott J et al. Systematic review and economic evaluation of a long- acting insulin analogue, insulin glargine. Health Technology Assessment 2004;8(45):iii, 1–57.",,,,,,,
CG66ST219,"216 McEwan P, Poole CD, Telow T et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research & Opinion 2007;23(1): S7–S19.",,,,,,,
CG66ST220,"217 National Institute for Health and Clinical Excellence. The clinical effectiveness and cost effectiveness of insulin pump therapy (TA57). London: NICE, 2003.",,,,,,,
CG66ST221,"218 Little RR, Rohilfing CL, Wiedmeyer HM et al. The National Glycohaemoglobin Standardization Program (NGSP): a five-year progress report. Clinical Chemistry 2001;47:1985–1992.",,,,,,,
CG66ST222,"219 Coscelli C. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Research & Clinical Practice 1995;28(3):173–177.",,,,,,,
CG66ST223,"220 Fox C, McKinnon C, Wall A et al. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Practical Diabetes International 2002;19(4):104–107.",,,,,,,
CG66ST224,"221 Kadiri A, Chraibi A, Marouan F et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Research & Clinical Practice 1998;41(1):15–23.",,,,,,,
CG66ST225,"222 Korytkowski M, Bell D, Jacobsen C et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clinical Therapeutics 2003;25(11):2836–2848.",,,,,,,
CG66ST226,223 Shelmet J. Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Research & Clinical Practice 2004;63(1):27–35.,,,,,,,
CG66ST227,"224 Stockl K, Ory C, Vanderplas A et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Current Medical Research & Opinion 2007;23(1):133–146.",,,,,,,
CG66ST228,"225 Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technology & Therapeutics 2005;7(4):620–626.",,,,,,,
CG66ST229,"226 Turner R, Holman R, Stratton I et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). British Medical Journal 1998;317:703–713.",,,,,,,
CG66ST230,"227 Sibal L, Law HN, Gebbie J et al. Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. Annals of the New York Academy of Sciences 2006;1084:304–318.",,,,,,,
CG66ST231,"228 Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. Journal of the American Society of Nephrology 2005;16(10):3027–3037.",,,,,,,
CG66ST232,"229 Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. Journal of the American Society of Nephrology 2005;16(7):2170–2179.",,,,,,,
CG66ST233,"230 Matthews DR, Stratton IM, Aldington SJ et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus (UKPDS 69). Archives of Opthalmology 2004;122(11):1631–1640.",,,,,,,
CG66ST234,"231 Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Archives of Internal Medicine 2003;163(13):1555–1565.",,,,,,,
CG66ST235,"232 Estacio RO, Coll JR, Tran ZV et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American Journal of Hypertension 2006;19(12):1241–1248.",,,,,,,
CG66ST236,"233 Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney International 2002;61(3):1086–1097.",,,,,,,
CG66ST237,"234 Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Archives of Internal Medicine 2005;165(12):1410–1419.",,,,,,,
CG66ST238,"235 Torffvit O, Agardh CD. A blood pressure cut-off level identified for renal failure, but not for macro- vascular complications in type 2 diabetes: a 10-year observation study. Hormone & Metabolic Research 2002;34(1):32–35.",,,,,,,
CG66ST239,"236 Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews 2005;(4):CD004136.",,,,,,,
CG66ST240,"237 Strippoli GF, Bonifati C, Craig M et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006;(4):CD006257.",,,,,,,
CG66ST241,"238 Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502): 2026–2033.",,,,,,,
CG66ST242,"239 Mann JF, Gerstein HC, Yi QL et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases 2003;42(5):936–942.",,,,,,,
CG66ST243,"240 Mann JF, Gerstein HC, Yi QL et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. Journal of the American Society of Nephrology 2003;14(3):641–647.",,,,,,,
CG66ST244,241 Bosch J. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005;112(9):1339–1346.,,,,,,,
CG66ST245,"242 Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine 2004;351(19):1952–1961.",,,,,,,
CG66ST246,"243  Sengul AM, Altuntas Y, Kurklu A et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Research & Clinical Practice 2006;71(2):210–219.",,,,,,,
CG66ST247,"244 Dalla VM, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes, Nutrition & Metabolism – Clinical & Experimental 2004;17(5):259–266.",,,,,,,
CG66ST248,"245 Fogari R, Preti P, Zoppi A et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. American Journal of Hypertension 2002;15(12):1042–1049.",,,,,,,
CG66ST249,"246 Ruggenenti P, Perna A, Ganeva M et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. Journal of the American Society of Nephrology 2006;17(12):3472–3481.",,,,,,,
CG66ST250,"247 Whelton PK, Barzilay J, Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2005;165(12): 1401–1409.",,,,,,,
CG66ST251,"248 Fernandez R, Puig JG, Rodriguez PJ et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. Journal of Human Hypertension 2001;15(12):849–856.",,,,,,,
CG66ST252,"249 Holzgreve H, Nakov R, Beck K et al. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. American Journal of Hypertension 2003;16(5:Pt 1):381–386.",,,,,,,
CG66ST253,"250 Derosa G, Cicero AF, Gaddi A et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. Journal of Cardiovascular Pharmacology 2005;45(6):599–604.",,,,,,,
CG66ST254,"251 Derosa G, Cicero AF, Bertone G et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clinical Therapeutics 2004;26(8):1228–1236.",,,,,,,
CG66ST255,"252 Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106(6):672–678.",,,,,,,
CG66ST256,"253 Appel GB, Radhakrishnan J, Avram MM et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003;26(5):1402–1407.",,,,,,,
CG66ST257,"254 Remuzzi G, Ruggenenti P, Perna A et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. Journal of the American Society of Nephrology 2004;15(12):3117–3125.",,,,,,,
CG66ST258,"255 Andersen S, Bröchner-Mortensen J, Parving HH et al. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003;26(12):3296–3302.",,,,,,,
CG66ST259,"256 Lindholm LH, Ibsen H. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):1004–1010.",,,,,,,
CG66ST260,"257 Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 2001; 345(12):851–860.",,,,,,,
CG66ST261,"258 Zanchetti A, Julius S, Kjeldsen S et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. Journal of Hypertension 2006;24(11):2163–2168.",,,,,,,
CG66ST262,"259 Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil- Trandolapril Study (INVEST): a randomized controlled trial. The Journal of the American Medical Association 2003;290(21):2805–2816.",,,,,,,
CG66ST263,"260 Bakris GL, Fonseca V. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. The Journal of the American Medical Association 2004;292(18):2227–2236.",,,,,,,
CG66ST264,"261 Black HR, Elliott WJ, Grandits G et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. The Journal of the American Medical Association 2003; 289(16):2073–2082.",,,,,,,
CG66ST265,"262 Dahlöf B. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895–906.",,,,,,,
CG66ST266,"263 Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus (structured abstract). Journal of Medical Economics  2001;4:199–205.",,,,,,,
CG66ST267,"264 Schadlich PK, Brecht JG, Rangoonwala B et al. Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective. Pharmacoeconomics 2004;22(15):955–973.",,,,,,,
CG66ST268,"265 Gray A, Clarke P, Raikou M et al. An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54). Diabetic Medicine 2001;18(6):438–444.",,,,,,,
CG66ST269,"266 Palmer AJ, Annemans L, Roze S et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. Journal of Human Hypertension 2004;18:733–738.",,,,,,,
CG66ST270,"267 Rodby RA, Chiou CF, Borenstein J et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clinical Therapeutics 2003;25(7):2102–2119.",,,,,,,
CG66ST271,"268 Coyle D, Rodby RA. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Canadian  Journal  of  Cardiology 2004;20(1):71–79.",,,,,,,
CG66ST272,"269 Vora J, Carides G, Robinson P. Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom. Current Therapeutic Research, Clinical & Experimental 2005;66(6):475–485.",,,,,,,
CG66ST273,"270 Smith DG, Nguyen AB, Peak CN et al. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. Journal of Managed Care Pharmacy 2004;10(1):26–32.",,,,,,,
CG66ST274,271 International currency rates. Available from: Financial Times. Last accessed on: 13 March 2007.,,,,,,,
CG66ST275,"272 National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (CG34). London: NICE, 2006.",,,,,,,
CG66ST276,"273 Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine 1998;339(4):229–234.",,,,,,,
CG66ST277,"274 Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 2003;26(11): 3102–3110.",,,,,,,
CG66ST278,"275 Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDSrisk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine 2004;21(3):238–245. ",,,,,,,
CG66ST280,"276 Stephens JW, Ambler G, Vallance P et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? European Journal of Cardiovascular Prevention and Rehabilitation 2004;11(6): 521–528.",,,,,,,
CG66ST281,"277 Guzder RN, Gatling W, Mullee MA et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabetic Medicine 2005;22(5):554–562.",,,,,,,
CG66ST282,"278 Coleman RL, Stevens RJ, Renakaran R et al. Framington, SCORE and DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007;30(5):1292–1293.",,,,,,,
CG66ST283,"279 Stevens RJ, Kothari V, Adler AI et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clinical Science 2001;101(6):671–679.",,,,,,,
CG66ST284,"280 Tuomilehto J, Rastenyte D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. International textbook of diabetes mellitus, 2nd edn. Chichester: John Wiley, 1997: 1559–1583.",,,,,,,
CG66ST285,"281 Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493): 1267–1278.",,,,,,,
CG66ST286,"282 Vijan S, Hayward RA, American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine 2004;140(8):650–658.",,,,,,,
CG66ST287,"283 National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease (TA94). London: NICE, 2006.",,,,,,,
CG66ST288,"284 National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia (TA132). London: NICE, 2007.",,,,,,,
CG66ST289,"285 Insull W, Kafonek S, Goldner D et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. American Journal of Cardiology 2001;87(5):554–559.",,,,,,,
CG66ST290,"286 van Venrooij FV, van de Ree MA, Bots ML et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002;25(7):1211–1216.",,,,,,,
CG66ST291,"287 Miller M, Dobs A, Yuan Z et al. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Current Medical Research & Opinion 2004;20(7):1087–1094.",,,,,,,
CG66ST292,"288 Berne C, Siewert DA, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology 2005;4:7.",,,,,,,
CG66ST293,"289 Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005;48(12):2482–2485.",,,,,,,
CG66ST294,"290 Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28(5):1151–1157.",,,,,,,
CG66ST295,"291 Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29(6):1220–1226.",,,,,,,
CG66ST296,"292 Steiner G, Hamsten A, Hosking J et al. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357(9260):905–910.",,,,,,,
CG66ST297,"293 Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107(13):1733–1737.",,,,,,,
CG66ST298,"294 Keech A, Simes R, Barter P et al. Effects of long–term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366(9500):1849–1861.",,,,,,,
CG66ST299,"295 Derosa G, Cicero AE, Bertone G et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical Therapeutics 2004;26(10):1599–1607.",,,,,,,
CG66ST300,"296 Athyros VG, Papageorgiou VV, Athyrou DS et al. Atorvastatin and micronized fenofibrate alone and in combination, in type-2 diabetes mellitus with combined hyperlipidemia. Atherosclerosis 2002;3(2):70.",,,,,,,
CG66ST301,"297 Durrington PN, Tuomilehto J, Hamann A et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Research & Clinical Practice 2004;64(2):137–151.",,,,,,,
CG66ST302,"298 Muhlestein JB, May HT, Jensen JR et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology 2006;48(2):396–401.",,,,,,,
CG66ST303,"299 Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Archives of Internal Medicine 2002;162(22):2597–2604.",,,,,,,
CG66ST304,"300 Ashraf R, Amir K, Shaikh AR. Comparison between duration dependent effects of simvastatin and gemfibrozil on dyslipidemia in patients with type 2 diabetes. Journal of the Pakistan Medical Association 2005;55(8):324–327.",,,,,,,
CG66ST305,"301 Schweitzer M, Tessier D, Vlahos WD et al. A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 2002;162(1):201–210.",,,,,,,
CG66ST306,"302 Wagner AM, Jorba O, Bonet R et al. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. Journal of Clinical Endocrinology & Metabolism 2003;88(7):3212–3217.",,,,,,,
CG66ST307,"303 Feher MD, Langley-Hawthorne CE, Byrne CD. Cost-outcome benefits of fibrate therapy in type 2 diabetes. British Journal of Diabetes & Vascular Disease 2003;3(2):124–130.",,,,,,,
CG66ST308,"304 Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. The Journal of the American Medical Association 2000;284(10):1263–1270.",,,,,,,
CG66ST309,"305 Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Archives of Internal Medicine 2002;162(14):1568–1576.",,,,,,,
CG66ST310,"306 Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in  non-insulin-dependent  diabetes mellitus. The Journal of the American Medical Association 1990;264(6):723–726.",,,,,,,
CG66ST311,"307 Tsalamandris C, Panagiotopoulos S, Sinha A et al. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. Journal of Cardiovascular Risk 1994;1(3):231–239.",,,,,,,
CG66ST312,"308 Armstrong EP, Zachry WM III, Malone DC. Cost-effectiveness analysis of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. Journal of Managed Care Pharmacy 2004;10(3):251–258.",,,,,,,
CG66ST313,"309 Olson BM, Malone DC, Armstrong EP. Modeling the cost-effectiveness of doubling atorvastatin’s dose versus adding niacin ER. Formulary 2001;36(10):730–746.",,,,,,,
CG66ST314,"310 Roze S, Wierzbicki AS, Liens D et al. Cost-effectiveness of adding prolonged-release nicotinic acid in statin-treated patients who achieve LDL cholesterol goals but remain at risk due to low HDL cholesterol: a UK-based economic evaluation. British Journal of Cardiology 2006;13(6):411–418.",,,,,,,
CG66ST315,"311 Farmer A, Montori V, Dinneen S et al. Fish oil in people with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2001;(3):CD003205.",,,,,,,
CG66ST316,"312 Hartweg J, Farmer AJ, Holman RR et al. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 2007;50(2):250–258.",,,,,,,
CG66ST317,"313 Jain S, Gaiha M, Bhattacharjee J et al. Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress – a prospective preliminary study. Journal of the Association of Physicians of India 2002;50(Aug):1028–1033.",,,,,,,
CG66ST318,"314 Woodman RJ, Mori TA, Burke V et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. American Journal of Clinical Nutrition 2002;76(5):1007–1015.",,,,,,,
CG66ST319,"315 Pedersen H, Petersen M, Major-Pedersen A et al. Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes. European Journal of Clinical Nutrition  2003;57(5):713–720.",,,,,,,
CG66ST320,"316 Petersen M, Pedersen H, Major-Pedersen A et al. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002;25(10):1704–1708.",,,,,,,
CG66ST321,"317 Dunstan DW, Mori TA, Puddey IB et al. Exercise and fish intake: effects on serum lipids and glycemic control for type 2 diabetics. Cardiology Review 1998;15(8):34–37.",,,,,,,
CG66ST322,"318 Hooper L, Thompson RL, Harrison RA et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. British Medical Journal 2006;332(7544):752–760.",,,,,,,
CG66ST323,"319 Wood D, Durrington P, McInnes G et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl 2):1S–29S.",,,,,,,
CG66ST324,"320 McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A. Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose. Sheffield: School of Health and Related Research, 2001.",,,,,,,
CG66ST325,"321 National Institute for Health and Clinical Excellence. Clopidogrel and modified release dipyridamole in the prevention of occlusive vascular events. (TA90). London: NICE, 2005.",,,,,,,
CG66ST326,"322 Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology & Nephrology 2002;36(2):145–148.",,,,,,,
CG66ST327,"323 Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26(12):3264–3272.",,,,,,,
CG66ST328,"324 Neri Serneri GG, Coccheri S, Marubini E et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study. European Heart Journal 2004;25(20):1845–1852.",,,,,,,
CG66ST329,"325 Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364(9431):331–337.",,,,,,,
CG66ST330,"326 Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology 2002;90(6):625–628.",,,,,,,
CG66ST331,"327 Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001;345(7): 494–502.",,,,,,,
CG66ST332,"328 Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine 2006;354(16):1706–1717.",,,,,,,
CG66ST333,"329 Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. The Journal of the American Medical Association 2002;288(19):2411–2420.",,,,,,,
CG66ST334,"330 Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527–533.",,,,,,,
CG66ST335,"331 Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine 2003;253(4):472–480.",,,,,,,
CG66ST336,"332 National Institute for Health and Clinical Excellence. Clopidogrel in the treatment of non-ST-segment- elevation acute coronary syndrome. (TA80). London: NICE, 2004.",,,,,,,
CG66ST337,"333 Weintraub WS, Mahoney EM, Lamy A et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. Journal of the American College of Cardiology 2005;45(6):838–845.",,,,,,,
CG66ST338,"334 Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics 2005;6(4):354–362.",,,,,,,
CG66ST339,"335 Cowper PA, Udayakumar K, Sketch MH Jr et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. Journal of the American College of Cardiology 2005;45(3):369–376.",,,,,,,
CG66ST340,336 Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current Opinion in Nephrology & Hypertension 2003;12(3):317–322.,,,,,,,
CG66ST341,"337  Banerjee S, Ghosh US, Saha SJ. Role of GFR estimation in assessment of the status of nephropathy in type 2 diabetes mellitus. Journal of the Association of Physicians of India 2005;53:181–4.",,,,,,,
CG66ST342,"338 Baskar V, Venugopal H, Holland MR et al. Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district diabetes population. Diabetic Medicine 2006;23(10):1057–1060.",,,,,,,
CG66ST343,"339 Cortes SL, Martinez RH, Hernandez JL et al. Utility of the Dipstick Micraltest II in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension. Revista de Investigacion Clinica 2006;58(3):190–197.",,,,,,,
CG66ST344,"340 Incerti J, Zelmanovitz T, Camargo JL et al. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrology Dialysis Transplantation 2005;20(11):2402–2407.",,,,,,,
CG66ST345,"341 MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004;27(1):195–200.",,,,,,,
CG66ST346,"342 Middleton RJ, Foley RN, Hegarty J et al. The unrecognized prevalence  of  chronic  kidney  disease  in diabetes. Nephrology Dialysis Transplantation 2006;21(1):88–92.",,,,,,,
CG66ST347,"343 Parikh CR, Fischer MJ, Estacio R et al. Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity [erratum appears in Nephrol Dial Transplant 2004;19(9):2425]. Nephrology Dialysis Transplantation 2004;19(7):1881–1885.",,,,,,,
CG66ST348,"344 Poggio ED, Wang X, Greene T et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. Journal of the American Society of Nephrology 2005;16(2):459–466.",,,,,,,
CG66ST349,"345 Rigalleau V, Lasseur C, Perlemoine C et al. A simplified Cockcroft-Gault formula to improve the prediction of the glomerular filtration rate in diabetic patients. Diabetes & Metabolism 2006;32(1):56–62.",,,,,,,
CG66ST350,"346 Younis N, Broadbent DM, Vora JP et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361(9353):195–200.",,,,,,,
CG66ST351,347 UK National Screening Committee. Essential elements in developing a diabetic retinopathy screening programme. Workbook 4:(1–79). Available from: UK National Screening Committee.,,,,,,,
CG66ST352,"348 Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. New England Journal of Medicine 1992;326(19):1250–1256.",,,,,,,
CG66ST353,"349 Sindrup SH, Gram LF, Skjold T et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. British Journal of Clinical Pharmacology 1990;30(5):683–691.",,,,,,,
CG66ST354,"350 Sindrup SH, Tuxen C. Lack of effect of mianserin on the symptoms of diabetic neuropathy. European Journal of Clinical Pharmacology 1992;43(3):251–255.",,,,,,,
CG66ST355,"351 Morello CM, Leckband SG, Stoner CP et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine 1999;159(16):1931–1937.",,,,,,,
CG66ST356,"352 Jose VM, Bhansali A, Hota D et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Medicine 2007;24(4):377–383.",,,,,,,
CG66ST357,"353 Kvinesdal B, Molin J, Froland A et al. Imipramine treatment of painful diabetic neuropathy. The Journal of the American Medical Association 1984;251(13):1727–1730.",,,,,,,
CG66ST358,"354 Max MB, Kishore KR, Schafer SC et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo- controlled trial. Pain 1991;45(1):3–9.",,,,,,,
CG66ST359,"355 Max MB, Culnane M, Schafer SC et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37(4):589–596.",,,,,,,
CG66ST360,"356 Sindrup SH, Ejlertsen B. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. European Journal of Clinical Pharmacology 1989;37(2):151–153.",,,,,,,
CG66ST361,"357 Raskin J, Smith TR, Wong K et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. Journal of Palliative Medicine 2006;9(1):29–40.",,,,,,,
CG66ST362,"358 Raskin J, Pritchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine 2005;6(5): 346–356.",,,,,,,
CG66ST363,"359 Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain  2005;116(1–2):109–118.",,,,,,,
CG66ST364,"360 Hardy T, Sachson R, Shen S et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007;30(1):21–26.",,,,,,,
CG66ST365,"361 Raskin J, Wang F, Pritchett YL et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Medicine 2006;7(5):373–385.",,,,,,,
CG66ST366,"362 Wernicke JF, Pritchett YL, D’Souza DN et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67(8):1411–1420.",,,,,,,
CG66ST367,"363 Wernicke JF, Raskin J, Rosen A et al. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. Current Therapeutic Research, Clinical & Experimental 2006;67(5):283–304.",,,,,,,
CG66ST368,"364 Gomez-Perez FJ, PerezMonteverde A, Nascimento O et al. Gabapentin for  the  treatment  of  painful diabetic neuropathy: dosing to achieve optimal clinical response. British Journal of Diabetes & Vascular Disease 2004;4(3):173–178.",,,,,,,
CG66ST369,"365 Gorson KC, Schott C, Herman R et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery, and Psychiatry 1999;66(2):251–252.",,,,,,,
CG66ST370,"366 Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. The Journal of the American Medical Association 1998;280(21):1831–1836.",,,,,,,
CG66ST371,367 Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease 2001;3(2):53–62.,,,,,,,
CG66ST372,"368 Lesser H, Sharma U, Lamoreaux L et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63(11):2104–2110.",,,,,,,
CG66ST373,"369 Richter RW, Portenoy R, Sharma U et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. Journal of Pain 2005;6(4):253–260.",,,,,,,
CG66ST374,"370 Rosenstock J, Tuchman M, Lamoreaux L et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110(3):628–638.",,,,,,,
CG66ST375,"371 Rull JA, Quibrera R, Gonzalez MH et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5(4):215–218.",,,,,,,
CG66ST376,372 Wilton  TD.  Tegretol  in  the  treatment  of  diabetic  neuropathy.  South  African  Medical  Journal 1974;48(20):869–872.,,,,,,,
CG66ST377,"373 Gomez-Perez FJ, Choza R, Rios JM et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research 1996;27(4):525–529.",,,,,,,
CG66ST378,"374 Beydoun  A, Kobetz SA,  Carrazana EJ. Efficacy of oxcarbazepine  in the treatment of  painful diabetic neuropathy. Clinical Journal of Pain 2004;20(3):174–178.",,,,,,,
CG66ST379,"375 Dogra S, Beydoun S, Mazzola J et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. European Journal of Pain 2005;9(5):543–554.",,,,,,,
CG66ST380,"376 Grosskopf J, Mazzola J, Wan Y et al. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica 2006;114(3):177–180.",,,,,,,
CG66ST381,"377 Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. Journal of Pain 2006;7(2):119–128.",,,,,,,
CG66ST382,"378 Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. American Family Physician 2005;71(3):483–490.",,,,,,,
CG66ST383,"379 Wu EQ, Birnbaum HG, Mareva MN et al. Cost-effectiveness of duloxetine versus routine treatment for  U.S. patients with diabetic peripheral neuropathic pain. Journal of Pain 2006;7(6):399–407",,,,,,,
CG66ST384,"380 National Institute for Health and Clinical Excellence. Type 2 diabetes: prevention and management of foot problems (CG10). London: NICE, 2004.",,,,,,,
CG66ST385,381 Braun AP. Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients. Advances in Therapy 1989;6(2):51–62.,,,,,,,
CG66ST386,"382 Samsom M. Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care 1997; 20(2):129–134.",,,,,,,
CG66ST387,"383 Janssens J, Peeters TL, Vantrappen G et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. New England Journal of Medicine 1990;322(15):1028–1031.",,,,,,,
CG66ST388,"384 McCallum RW, Ricci DA, Rakatansky H et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6(5):463–467.",,,,,,,
CG66ST389,"385 Ricci DA, Saltzman MB, Meyer C et al. Effect of metoclopramide in diabetic gastroparesis. Journal of Clinical Gastroenterology 1985;7(1):25–32.",,,,,,,
CG66ST390,"386 Farup CE, Leidy NK, Murray M et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998;21(10):1699–1706.",,,,,,,
CG66ST391,"387 Erbas T, Varoglu E, Erbas B et al. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16(11):1511–1514.",,,,,,,
CG66ST392,"388 Patterson D, Abell T, Rothstein R et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. American Journal of Gastroenterology 1999;94(5):1230–1234.",,,,,,,
CG66ST393,"389 McCulloch DK, Campbell IW, Wu FC et al. The prevalence of diabetic impotence. Diabetologia 1980;18(4):279–283.",,,,,,,
CG66ST394,"390 Price DE, Gingell JC, Gepi AS et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabetic Medicine 1998;15(10):821–825.",,,,,,,
CG66ST395,"391 Rendell MS, Rajfer J. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. The Journal of the American Medical Association. 1999;281(5):421–426.",,,,,,,
CG66ST396,"392 Boulton AJM, Selam JL, Sweeney M et al. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001;44(10):1296–1301.",,,,,,,
CG66ST397,"393 Saenz de Tejada I, Anglin G, Knight JR et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25(12):2159–2164.",,,,,,,
CG66ST398,"394 Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26(3):777–783.",,,,,,,
CG66ST399,"395 Stuckey BGA, Jadzinsky MN, Murphy LJ et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26(2):279–284.",,,,,,,
CG66ST400,396 Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. Journal of Diabetes & its Complications 2004;18(4):205–210.,,,,,,,
CG66ST401,"397 Ishii N, Nagao K, Fujikawa K et al. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. International Journal of Urology 2006;13(8):1066–1072.",,,,,,,
CG66ST402,"398 Ziegler D, Merfort F, van Ahlen et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. Journal of Sexual Medicine 2006;3(5):883–891.",,,,,,,
CG66ST403,"399 Buvat J, van Ahlen, Schmitt H et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. Journal of Sexual Medicine 2006;3(3):512–520.",,,,,,,
CG66ST404,"400 Weinstein MC, O’Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value in Health 2003;6:9–17.",,,,,,,
CG66ST405,"401 Clarke PM, Gray AM, Briggs A et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47(10):1747–1759.",,,,,,,
CG66ST406,"402 Clarke P, Gray A, Legood R et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine 2003; 20(6):442–450.",,,,,,,
CG66ST407,"403 Curtis L, Netten A. Unit costs of health and social care 2006. Canterbury: Personal Social Services Research Unit, 2006.",,,,,,,
CG66ST408,"404 Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. British Journal of General Practice 2007; 57(539):455–460.",,,,,,,
CG66ST409,405 Scottish Medicines Consortium. Glasgow. New product assessment form – exenatide 2006. Personal communication.,,,,,,,
CG66ST410,"406 Melanie Davies, 31 May 2007. Personal communication.",,,,,,,
CG66ST411,"407 Warren E. The cost-effectiveness of long-acting insulin analogue, insulin glargine. Sheffield: ScHARR, 16 August 2002.",,,,,,,
CG66ST412,"408 Currie CJ, Morgan CL, Poole CD et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research & Opinion 2006;22(8):1523–1534.",,,,,,,
CG66ST413,409  Anon. Contributed poster presentations. Value in Health 2006;9(3):A24–A173. 410 Rowlett R. How many? A dictionary of units of measurement 2001.,,,,,,,
CG66ST414,"411 Glenny AM, Altman DG, Song F et al. Indirect comparisons of competing interventions. Health Technology Assessment 2005;9(26):1–iv.",,,,,,,
CG66ST415,412 GlaxoSmithKline. Rosiglitazone maleate ZM2006/00207/00(meta-analysis)1–8. GlaxoSmithKline. 27 June 2006.,,,,,,,
CG66ST416,"413  Food and Drug Administration. Avandia (rosiglitazone maleate) NDA21-071 supplement 022 FDA. 2007. 414 National Institute for Health and Clinical Excellence. Management of type 2 diabetes – management of blood pressure and blood lipids (Guideline H). London: NICE, 2002.",,,,,,,
CG73ST1,"1    National Institute for Health and Clinical Excellence. Guidelines Manual. UK: London: National Institute for Health and Clinical Excellence, 2007.",,,,,,,
CG73ST2,"2    Department of Health. National Service Framework for Renal Services – Part Two: Chronic kidney disease, acute renal failure and end of life care. London: UK: Department of Health, 2005.",,,,,,,
CG73ST3,"3    Arora P, Obrador GT, Ruthazer R et al. Prevalence, predictors,  and  consequences  of  late  nephrology referral at a tertiary care center. Journal of the American Society of Nephrology. 1999; 10(6):1281–1286.",,,,,,,
CG73ST4,"4    Innes A, Rowe PA, Burden RP et al. Early deaths on renal replacement therapy: the need for early nephrological referral. Nephrology Dialysis and Transplantation. 1992; 7(6):467–471.",,,,,,,
CG73ST5,"5    Jungers P, Zingraff J, Albouze G et al. Late referral to maintenance dialysis: detrimental consequences.Nephrology Dialysis and Transplantation. 1993; 8(10):1089–1093.",,,,,,,
CG73ST6,"6    Ratcliffe PJ, Phillips RE, Oliver DO. Late referral for maintenance dialysis. British Medical Journal Clinical Research Ed. 1984; 288(6415):441–443.",,,,,,,
CG73ST7,"7    Sesso R, Belasco AG. Late diagnosis of chronic renal failure and mortality on maintenance dialysis. ephrology Dialysis and Transplantation. 1996; 11(12):2417–2420.",,,,,,,
CG73ST8,"8    Lameire N, Van BW. The pattern of referral of patients with end-stage renal disease to the nephrologist— a European survey. Nephrology Dialysis and Transplantation. 1999; 14 Suppl 6:16–23, 1999:16–23.",,,,,,,
CG73ST9,"9    Ansell D, Feest T, Hodsman A, and Rao, R. UK Renal Registry, The Renal Associaton, The Ninth Annual Report. Bristol, UK: UK Renal Registry, 2006.",,,,,,,
CG73ST10,"10    Drey N, Roderick P, Mullee M et al. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. American Journal of Kidney Diseases. 2003; 42(4):677–684.",,,,,,,
CG73ST11,"11    John R, Webb M, Young A et al. Unreferred chronic kidney disease: a longitudinal study. American Journal of Kidney Diseases. 2004; 43(5):825–835.",,,,,,,
CG73ST12,"12    Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine. 2004; 164(6): 659–663.",,,,,,,
CG73ST13,"13    Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine. 2004; 351(13):1296–1305 +1370.",,,,,,,
CG73ST14,"14    Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney International. 2007; 72(3):247–259.",,,,,,,
CG73ST15,"15    Royal College of Physicians. Chronic kidney diseases in adults: UK guidelines for identification, management and referral. London: RCP, 2006.",,,,,,,
CG73ST16,"16    Department of Health. Estimated Glomerular Filtration Rate (eGFR). London: DH, 2007.",,,,,,,
CG73ST17,"17    Quality and Outcomes Framework (QOF). Available from: Department of Health. Last accessed on: Feb. 28, 2008.",,,,,,,
CG73ST18,"18    Office for National Statistics. Office for National Statistics population and Vital Statistics, England And Wales. 3-12-2007. http://www.statistics.gov.uk/",,,,,,,
CG73ST19,"19    Stevens PE, O’Donoghue DJ, de Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney International. 2007; 72(1):92–99.",,,,,,,
CG73ST20,"20    Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases. 2003; 41(1):1–12.",,,,,,,
CG73ST21,"21    Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Available from: Centers for Disease Control and Prevention. Last accessed on: Feb. 28, 2008.",,,,,,,
CG73ST22,"22    Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA : the Journal of the American Medical Association. 2007; 298(17):2038–2047.",,,,,,,
CG73ST23,"23    Roderick PJ, Raleigh VS, Hallam L et al. The need and demand for renal replacement therapy in ethnic minorities in England. Journal of Epidemiology and Community Health. 1996; 50(3):334–339.",,,,,,,
CG73ST24,"24    McClellan W, Warnock DG, McClure L et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. Journal of the American Society of Nephrology. 2006; 17(6):1710–1715.",,,,,,,
CG73ST25,"25    Kidney Research UK. Summaries of the ABLE Projects. Available from: Kidney Research UK. Last accessed on: June 19, 2006.",,,,,,,
CG73ST26,"26    National Institute for Health and Clinical Excellence. Brief interventions and referral for smoking cessation in primary care and other settings. (PHI001). London: UK: National Institute for Health and Clinical Excellence, 2006.",,,,,,,
CG73ST27,"27    National Institute for Health and Clinical Excellence. Anaemia management in people with chronic kidney disease (CKD). (CG39). London: UK: National Institute for Health and Clinical Excellence, 2006.",,,,,,,
CG73ST28,"28    National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. (CG34). London: UK: National Institute for Health and Clinical Excellence, 2006.",,,,,,,
CG73ST29,"29    National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). (CG 66). London: UK: National Institute for Health and Clinical Excellence, 2008.",,,,,,,
CG73ST30,30    National Institute for Health and Clinical Excellence. Cardiovascular risk assessment: the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2008. http://www.nice. org.uk/guidance/index.jsp?action=byID&o=11628,,,,,,,
CG73ST31,"31    National Institute for Health and Clinical Excellence. Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk. 2008. London: UK, National Institute for Health and Clinical Excellence.",,,,,,,
CG73ST32,"32    Scottish Intercollegiate Guidelines Network. Chronic Kidney Disease. Edinburgh: SIGN, 2008.",,,,,,,
CG73ST33,"33    Taal, M. UK Renal Association Clinical Practice Guidelines. The Renal Association, London, 2007.",,,,,,,
CG73ST34,"34    Archibald G, Bartlett W, Brown A, Christie B, Eliott A. UK Consensus Conference on Early Chronic Kidney Disease. 2008.",,,,,,,
CG73ST35,"35    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002; 39(2:Suppl 1):S1–S266.",,,,,,,
CG73ST36,36    Caring for Australasians with Renal Impairment (CARI) Steering Committee. Proteinuria—CARI guidelines. Australian Family Physician. 2005; 34(11):942–943.,,,,,,,
CG73ST37,"37    Kidney Disease:: improving globlal outcomes (KDIGO). Available from: Kidney Disease: Improving Global Outcomes (KDIGO). Last accessed on: Feb. 28, 2008.",,,,,,,
CG73ST38,"38    Burkhardt H, Hahn T, Gretz N et al. Bedside estimation of the glomerular filtration rate in hospitalized elderly patients. Nephron Clinical Practice. 2005; 101(1):c1–c8.",,,,,,,
CG73ST39,"39    Lamb EJ, Webb MC, Simpson DE et al. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: is the modification of diet in renal disease formula an improvement? Journal of the American Geriatrics Society. 2003; 51(7):1012–1017.",,,,,,,
CG73ST40,"40    Harmoinen A, Lehtimaki T, Korpela M et al. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clinical Chemistry. 2003; 49(7):1223–1225.",,,,,,,
CG73ST41,"41    Hojs R, Bevc S, Ekart R et al. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrology Dialysis and Transplantation. 2006; 21(7):1855–1862.",,,,,,,
CG73ST42,"42    Bicik Z, Bahcebasi T, Kulaksizoglu S et al. The efficacy of cystatin C assay in the prediction of glomerular filtration rate. Is it a more reliable marker for renal failure? Clinical Chemistry & Laboratory Medicine. 2005; 43(8):855–861.",,,,,,,
CG73ST43,"43    Hayashi T, Nitta K, Uchida K et al. Clinical assessment of serum cystatin C as a marker of glomerular filtration rate in patients with various renal diseases. Clinical & Experimental Nephrology. 2000; 4(2): 133–136.",,,,,,,
CG73ST44,"44    Christensson AG, Grubb AO, Nilsson JA et al. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. Journal of Internal Medicine. 2004; 256(6):510–518.",,,,,,,
CG73ST45,"45    Mahajan S, Mukhiya GK, Singh R et al. Assessing glomerular filtration rate in healthy Indian adults: a comparison of various prediction equations. Journal of Nephrology. 2005; 18(3):257–261.",,,,,,,
CG73ST46,"46    Rigalleau V, Lasseur C, Perlemoine C et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of diet in renal disease study equation? Diabetes Care. 2005;28(4): 838–843.",,,,,,,
CG73ST47,"47    Rigalleau V, Lasseur C, Perlemoine C et al. A simplified Cockcroft-Gault formula to improve the prediction of the glomerular filtration rate in diabetic patients. Diabetes & Metabolism. 2006; 32(1):56–62.",,,,,,,
CG73ST48,"48    Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. Journal of the American Society of Nephrology. 2002; 13(8):2140–2144.",,,,,,,
CG73ST49,"49    Spinler SA, Nawarskas JJ, Boyce EG et al. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group. Annals of Pharmacotherapy. 1998; 32(12): 1275–1283.",,,,,,,
CG73ST50,"50    Poggio ED, Wang X, Greene T et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. Journal of the American Society of Nephrology. 2005; 16(2):459–466.",,,,,,,
CG73ST51,"51    Hallan S, Asberg A, Lindberg M et al. Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. American Journal of Kidney Diseases. 2004; 44(1):84–93.",,,,,,,
CG73ST52,"52    Froissart M, Rossert J, Jacquot C et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. Journal of the American Society of Nephrology. 2005; 16(3):763–773.",,,,,,,
CG73ST53,"53    Ibrahim H, Mondress M, Tello A et al. An alternative formula to the Cockcroft-Gault and the modification of diet in renal diseases formulas in predicting GFR in individuals with type 1 diabetes. Journal of the American Society of Nephrology. 2005; 16(4):1051–1060.",,,,,,,
CG73ST54,"54    Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of Internal Medicine. 2006; 145(4):247–254.",,,,,,,
CG73ST55,"55    Ricos C, Iglesias N, Garcia-Lario JV et al. Within-subject biological variation in disease: collated data and clinical consequences. Annals of Clinical Biochemistry. 2007; 44(Pt 4):343–352.",,,,,,,
CG73ST56,"56    Fraser CG, Williams P. Short-term biological variation of plasma analytes in renal disease. Clinical Chemistry. 1983; 29(3):508–510.",,,,,,,
CG73ST57,57    Holzel WG. Intra-individual variation of some analytes in serum of patients with chronic renal failure. Clinical Chemistry. 1987; 33(5):670–673.,,,,,,,
CG73ST58,58    Holzel WG. Intra-individual variation of some analytes in serum of patients with insulin-dependent diabetes mellitus. Clinical Chemistry. 1987; 33(1):57–61.,,,,,,,
CG73ST59,"59    Shepherd J, Warner M, Kilpatrick E. Stabilty of creatinine with delayed separation of whole blood and implications for eGFR. Annals of Clinical Biochemistry. 2007; 44(4):384–387.",,,,,,,
CG73ST60,"60    Ford L, Berg J. Delay in separating blood samples affects creatinine measurement using the Roche kinetic Jaffe method. Annals of Clinical Biochemistry. 2008; 45(1):83–87.",,,,,,,
CG73ST61,"61    Rapoport A, Husdan H. Endogenous creatinine clearance and serum creatinine in the clinical assessment of kidney function. Canadian Medical Association Journal. 1968; 99(9):149–156.",,,,,,,
CG73ST62,"62    Pasternack A, Kuhlback B. Diurnal variations of serum and urine creatine and creatinine. Scandinavian Journal of Clinical & Laboratory Investigation. 1971; 27(1):1–7.",,,,,,,
CG73ST63,"63    Preiss DJ, Godber IM, Lamb EJ et al. The influence of a cooked-meat meal on estimated glomerular filtration rate. Annals of Clinical Biochemistry. 2007; 44(Pt 1):35–42.",,,,,,,
CG73ST64,"64    Pinto JR, Bending JJ, Dodds RA et al. Effect of low protein diet on the renal response to meat ingestion in diabetic nephropathy. European Journal of Clinical Investigation. 1991; 21(2):175–183.",,,,,,,
CG73ST65,"65    Jacobsen FK, Christensen CK, Mogensen CE et al. Postprandial serum creatinine  increase  in  normal subjects after eating cooked meat. Proceedings of the European Dialysis & Transplant Association. 1979; 16:506–512.",,,,,,,
CG73ST66,"66    Mayersohn M, Conrad KA, Achari R. The influence of a cooked meat meal on creatinine plasma concentration and creatinine clearance. British Journal of Clinical Pharmacology. 1983; 15(2):227–230.",,,,,,,
CG73ST67,"67    Cameron JS. Common clinical presentations and symptoms in renal disease. Oxford Textbook of Medicine. In: Weatherall DJ, Ledingham JGG, Warell DA (eds), Oxford: UK: Oxford University Press, 1996: 3144–3191.",,,,,,,
CG73ST68,"68    Jones GR, Newhouse IJ, Jakobi JM et al. The incidence of hematuria in middle distance track running. Canadian Journal of Applied Physiology. 2001; 26(4):336–349.",,,,,,,
CG73ST69,"69    Ritchie CD, Bevan EA, Collier SJ. Importance of occult haematuria found at screening. British Medical Journal. 1986; 292(6521):681–683.",,,,,,,
CG73ST70,"70    Britton JP, Dowell AC, Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. British Medical Journal. 1989; 299(6706):1010–1012.",,,,,,,
CG73ST71,"71    Chan RWY, Chow KM, Tam LS et al. Can the urine dipstick test reduce the need for microscopy for assessment of systemic lupus erythematosus disease activity? Journal of Rheumatology. 2005; 32(5): 828–831.",,,,,,,
CG73ST72,"72    Chandhoke PS, McAninch JW. Detection and significance of microscopic hematuria in patients with blunt renal trauma. Journal of Urology. 1988; 140(1):16–18.",,,,,,,
CG73ST73,"73    Gleeson MJ, Connolly J, Grainger R et al. Comparison of reagent strip (dipstick) and microscopic haematuria in urological out-patients. British Journal of Urology. 1993; 72(5:Pt 1):594–596.",,,,,,,
CG73ST74,"74    Arm JP, Peile EB, Rainford DJ et al. Significance of dipstick haematuria. 1. Correlation with microscopy of the urine. British Journal of Urology. 1986; 58(2):211–217.",,,,,,,
CG73ST75,"75    Pugia MJ, Wallace JF, Lott JA et al. Albuminuria and proteinuria in hospitalized patients as measured by quantitative and dipstick methods. Journal of Clinical Laboratory Analysis. 2001; 15(5):295–300.",,,,,,,
CG73ST76,"76    Konta T, Hao Z, Takasaki S et al. Clinical utility of trace proteinuria for microalbuminuria screening in the general population. Clinical & Experimental Nephrology. 2007; 11(1):51–55.",,,,,,,
CG73ST77,"77    Gilbert RE, Akdeniz A, Jerums G. Detection of microalbuminuria in diabetic patients by urinay dipstick. Diabetes Research & Clinical Practice. 1997; 35(1):57–60.",,,,,,,
CG73ST78,"78    CortesSanabria L, MartinezRamirez HR, Hernandez JL et al. Utility of the dipstick micraltest II in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension. Revista de Investigacion Clinica. 2006; 58(3):190–197.",,,,,,,
CG73ST79,"79    Waugh JJ, Bell SC, Kilby MD et al. Optimal bedside urinalysis for the detection of proteinuria in hypertensive pregnancy: a study of diagnostic accuracy. BJOG: An International Journal of Obstetrics & Gynaecology. 2005; 112(4):412–417.",,,,,,,
CG73ST80,"80    Brown MA, Buddle ML. Inadequacy of dipstick proteinuria in hypertensive pregnancy. Australian & New Zealand Journal of Obstetrics & Gynaecology. 1995; 35(4):366–369.",,,,,,,
CG73ST81,"81    Higby K, Suiter CR, Siler KT. A comparison between two screening methods for detection of microproteinuria. American Journal of Obstetrics & Gynecology. 1995; 173(4):1111–1114.",,,,,,,
CG73ST82,"82    Meyer NL, Mercer BM, Friedman SA et al. Urinary dipstick protein: a poor predictor of absent or severe proteinuria. American Journal of Obstetrics & Gynecology. 1994; 170(1:Pt 1):137–141.",,,,,,,
CG73ST83,"83    Paruk F, Moodley J, Daya PK et al. Screening for proteinuria in hypertensive disorders of pregnancy. Journal of Obstetrics & Gynaecology. 1997; 17(6):528–530.",,,,,,,
CG73ST84,"84    Saudan PJ, Brown MA, Farrell T et al. Improved methods of assessing proteinuria in hypertensive pregnancy. British Journal of Obstetrics & Gynaecology. 1997; 104(10):1159–1164.",,,,,,,
CG73ST85,"85    Gai M, Motta D, Giunti S et al. Comparison between 24-h proteinuria, urinary protein/creatinine ratio and dipstick test in patients with nephropathy: Patterns of proteinuria in dipstick-negative patients. Scandinavian Journal of Clinical & Laboratory Investigation. 2006; 66(4):299–308.",,,,,,,
CG73ST86,"86  Agarwal R, Panesar A, Lewis RR. Dipstick proteinuria: Can it guide hypertension management? American Journal of Kidney Diseases. 2002; 39(6):1190–1195.",,,,,,,
CG73ST87,"87  Tissot E, Woronoff-Lemsi MC, Cornette C et al. Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit. Intensive Care Med. 2001; 27(12):1842–1847.",,,,,,,
CG73ST88,"88  Waugh J, Bell SC, Kilby M et al. Effect of concentration and biochemical assay on the accuracy of urine dipsticks in hypertensive pregnancies. Hypertension in Pregnancy. 2001; 20(2):205–217.",,,,,,,
CG73ST89,"89  Dube J, Girouard J, Leclerc P et al. Problems with the estimation of urine protein by automated assays. Clinical Biochemistry. 2005; 38(5):479–485.",,,,,,,
CG73ST90,"90  Ballantyne FC, Gibbons J, O’Reilly DS. Urine albumin should replace total protein for the assessment of glomerular proteinuria. Annals of Clinical Biochemistry. 1993; 30(Pt 1):101–103.",,,,,,,
CG73ST91,"91  Shihabi ZK, Konen JC, O’Connor ML. Albuminuria vs urinary total protein for detecting chronic renal disorders. Clinical Chemistry. 1991; 37(5):621–624.",,,,,,,
CG73ST92,"92  Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clinical Chemistry. 2005; 51(9):1577–1586.",,,,,,,
CG73ST93,"93  Foster MC, Hwang SJ, Larson MG et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med. 2007; 167(13):1386–1392.",,,,,,,
CG73ST94,"94  Hallan S, Astor B, Romundstad S et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med. 2007; 167(22):2490–2496.",,,,,,,
CG73ST95,"95  Cirillo M, Lanti MP, Menotti A et al. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med. 2008; 168(6): 617–624.",,,,,,,
CG73ST96,"96  Brantsma AH, Bakker SJ, de ZD et al. Extended prognostic value of urinary albumin excretion for cardiovascular events. Journal of the American Society of Nephrology. 2008; advance e-publication.",,,,,,,
CG73ST97,"97  Brantsma AH, Atthobari J, Bakker SJ et al. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? Journal of the American Society of Nephrology. 2007; 18(2): 637–645.",,,,,,,
CG73ST98,"98  Rodby RA, Rohde RD, Sharon Z et al. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. American Journal of Kidney Diseases. 1995; 26(6):904–909.",,,,,,,
CG73ST99,"99  Ruggenenti P, Gaspari F, Perna A et al. Cross sectional longitudinal study of spot morning urine protein: Creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. British Medical Journal. 1998; 316(7130):504–509.",,,,,,,
CG73ST100,"100  Gatling W, Knight C, Mullee MA et al. Microalbuminuria in diabetes: A population study of the prevalence and an assessment of three screening tests. Diabetic Medicine. 1988; 5(4):343–347.",,,,,,,
CG73ST101,"101  Hutchison AS, O’Reilly DSJ, MacCuish AC. Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. Clinical Chemistry. 1988; 34(10):2019–2021.",,,,,,,
CG73ST102,102  Marshall SM. Screening for microalbuminuria: Which measurement? Diabetic Medicine. 1991; 8(8): 706–711.,,,,,,,
CG73ST103,"103  Chaiken RL, Khawaja R, Bard M et al. Utility of untimed urinary albumin measurements in assessing albuminuria in black NIDDM subjects. Diabetes Care. 1997; 20(5):709–713.",,,,,,,
CG73ST104,"104  Gansevoort RT, Verhave JC, Hillege HL et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney International – Supplement. 2005; 67(94):S28–S35.",,,,,,,
CG73ST105,"105  Jafar TH, Chaturvedi N, Hatcher J et al. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population.[see comment]. Nephrology Dialysis and Transplantation. 2007; 22(8):2194–2200.",,,,,,,
CG73ST106,"106  Atkins RC, Briganti EM, Zimmet PZ et al. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrology Dialysis and Transplantation. 2003; 18(10):2170–2174.",,,,,,,
CG73ST107,"107  Newman DJ, Thakkar H, Medcalf EA et al. Use of urine albumin measurement as a replacement for total protein. Clinical Nephrology. 1995; 43(2):104–109.",,,,,,,
CG73ST108,"108  MacGregor MS, Traynor JP, O’Reilly DSJ et al. Assessing proteinuria in chronic kidney disease: protein–creatinine ratio versus albumin–creatinine ratio. 2007, personal correspondence.",,,,,,,
CG73ST109,109  Lum G. How effective are screening tests for microalbuminuria in random urine specimens? Annals of Clinical & Laboratory Science. 2000; 30(4):406–411.,,,,,,,
CG73ST110,"110  Chitalia VC, Kothari J, Wells EJ et al. Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein–creatinine ratio. Clinical Nephrology. 2001; 55(6):436–447.",,,,,,,
CG73ST111,"111  Bush WH, Choyke BL, Bluth RI, Casalino DD. Renal failure. National Guidelines Clearing House, 2005. www.guideline.gov",,,,,,,
CG73ST112,"112  Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. Journal of the American Geriatrics Society. 1985; 33(4):278–285.",,,,,,,
CG73ST113,"113  Garg AX, Papaioannou A, Ferko N et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney International. 2004; 65(2):649–653.",,,,,,,
CG73ST114,"114  Iseki K, Ikemiya Y, Iseki C et al. Proteinuria and the risk of developing end-stage renal disease. Kidney International. 2003; 63(4):1468–1474.",,,,,,,
CG73ST115,"115  Klausen K, Borch JK, Feldt RB et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004; 110(1):32–35.",,,,,,,
CG73ST116,"116  Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106(14):1777–1782.",,,,,,,
CG73ST117,"117  Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005; 112(7): 969–975.",,,,,,,
CG73ST118,"118  Rahman M, Pressel S, Davis BR et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.[see comment][summary for patients in Ann Intern Med. 2006 Feb 7; 144(3):I33; PMID: 16461958]. Annals of Internal Medicine. 2006; 144(3):172–180.",,,,,,,
CG73ST119,"119  Tokmakova MP, Skali H, Kenchaiah S et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004; 110(24):3667–3673.",,,,,,,
CG73ST120,"120  Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Annals of Internal Medicine. 2002; 137(7):563–570.",,,,,,,
CG73ST121,"121  Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113(5):671–678.",,,,,,,
CG73ST122,"122  Keough RMT, Kiberd BA, Dipchand CS et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. American Journal of Kidney Diseases. 2005; 46(5):845–855.",,,,,,,
CG73ST123,"123  Beddhu S, Allen BK, Cheung AK et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney International. 2002; 62(5):1776–1783.",,,,,,,
CG73ST124,"124  Kurella M, Yaffe K, Shlipak MG et al. Chronic kidney disease and cognitive impairment in menopausal women. American Journal of Kidney Diseases. 2005; 45(1):66–76.",,,,,,,
CG73ST125,"125  O’Hare AM, Bertenthal D, Shlipak MG et al. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. Journal of the American Society of Nephrology. 2005; 16(2):514–519.",,,,,,,
CG73ST126,"126  Gullion CM, Keith DS, Nichols GA et al. Impact of comorbidities on mortality in managed care patients with CKD. American Journal of Kidney Diseases. 2006; 48(2):212–220.",,,,,,,
CG73ST127,"127  McCullough PA, Jurkovitz CT, Pergola PE et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Internal Medicine. 2007; 167(11):1122–1129.",,,,,,,
CG73ST128,"128  Wattanakit K, Folsom AR, Selvin E et al. Kidney function and risk of peripheral arterial disease: Results from the Atherosclerosis Risk in Communities (ARIC) study. Journal of the American Society of Nephrology. 2007; 18(2):629–636.",,,,,,,
CG73ST129,"129  Patel UD, Young EW, Ojo AO et al. CKD progression and mortality among older patients with diabetes. American Journal of Kidney Diseases. 2005; 46(3):406–414.",,,,,,,
CG73ST130,"130  So WY, Kong AP, Ma RC et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006; 29(9):2046–2052.",,,,,,,
CG73ST131,"131  Nag S, Bilous R, Kelly  W et al. All-cause  and cardiovascular mortality in diabetic  subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years’ data from the South Tees Diabetes Mortality study. Diabetic Medicine. 2007; 24(1):10–17.",,,,,,,
CG73ST132,"132  Shlipak MG, Stehman BC, Fried LF et al. The presence of frailty in elderly persons with chronic renal insufficiency. American Journal of Kidney Diseases. 2004; 43(5):861–867.",,,,,,,
CG73ST133,"133  Kurella M, Chertow GM, Fried LF et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. Journal of the American Society of Nephrology. 2005; 16(7): 2127–2133.",,,,,,,
CG73ST134,"134  Iseki K, Kinjo K, Iseki C et al. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. American Journal of Kidney Diseases. 2004; 44(5):806–814.",,,,,,,
CG73ST135,"135  Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney International. 2006; 69(2):375–382.",,,,,,,
CG73ST136,"136  O’Hare AM, Bertenthal D, Covinsky KE et al. Mortality risk stratification in chronic kidney disease: one size for all ages? Journal of the American Society of Nephrology. 2006; 17(3):846–853.",,,,,,,
CG73ST137,"137  O’Hare AM, Choi AI, Bertenthal D et al. Age affects outcomes in chronic kidney disease. Journal of the American Society of Nephrology. 2007; 18(10):2758–2765.",,,,,,,
CG73ST138,"138  National Kidney Foundation. Kidney early evaluation program (KEEP). Available from: National Kidney Foundation, www.kidney.org.uk. Last accessed on: Feb. 27, 2008.",,,,,,,
CG73ST139,"139  Hallan SI, Dahl K, Oien CM et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey.[see comment]. British Medical Journal. 2006; 333(7577):1030–1031.",,,,,,,
CG73ST140,"140  Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. Journal of the American Society of Nephrology. 2006; 17(8):2275–2284.",,,,,,,
CG73ST141,"141  Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. Journal of the American Society of Nephrology. 2003; 14(7:Suppl 2):S131–S138.",,,,,,,
CG73ST142,"142  Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. Journal of the American Society of Nephrology. 2003; 14(11):2934–2941.",,,,,,,
CG73ST143,"143  New JP, Middleton RJ, Klebe B et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabetic Medicine. 2007; 24(4):364–369.",,,,,,,
CG73ST144,"144  Gelber RP, Kurth T, Kausz AT et al. Association between body mass index and CKD in apparently healthy men. American Journal of Kidney Diseases. 2005; 46(5):871–880.",,,,,,,
CG73ST145,"145  Stengel B, Tarver CM, Powe NR et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003; 14(4):479–487.",,,,,,,
CG73ST146,"146  Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Journal of the American Society of Nephrology. 2005; 16(7):2134–2140.",,,,,,,
CG73ST147,"147  Elsayed EF, Tighiouart H, Griffith J et al. Cardiovascular disease and subsequent kidney disease. Archives of Internal Medicine. 2007; 167(11):1130–1136.",,,,,,,
CG73ST148,"148  Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney International. 2000; 58(1):293–301.",,,,,,,
CG73ST149,"149  Borch-Johnsen K, Norgaard K, Hommel E et al. Is diabetic nephropathy an inherited complication? Kidney International. 1992; 41(4):719–722.",,,,,,,
CG73ST150,"150  Seaquist ER, Goetz FC, Rich S et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. New England Journal of Medicine. 1989; 320(18):1161–1165.",,,,,,,
CG73ST151,"151  Freedman BI, Soucie JM, McClellan WM. Family history of end-stage  renal  disease  among  incident dialysis patients. Journal of the American Society of Nephrology. 1997; 8(12):1942–1945.",,,,,,,
CG73ST152,"152  Speckman RA, McClellan WM, Volkova NV et al. Obesity is associated with family history of ESRD in incident dialysis patients. American Journal of Kidney Diseases. 2006; 48(1):50–58.",,,,,,,
CG73ST153,"153  Tillin T, Forouhi N, McKeigue P et al. Microalbuminuria and coronary heart disease risk in an ethnically diverse UK population: A prospective cohort study. Journal of the American Society of Nephrology. 2005; 16(12):3702–3710.",,,,,,,
CG73ST154,"154  Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006; 55(6):1832–1839.",,,,,,,
CG73ST155,"155  Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. British Medical Journal. 1995; 311(7020):1595–1599.",,,,,,,
CG73ST156,"156  Boulware LE,  Jaar BG,  Tarver CM  et al.  Screening for  proteinuria in  US adults:  a  cost-effectiveness analysis.[see comment]. JAMA : the Journal of the American Medical Association. 2003; 290(23):3101–3114.",,,,,,,
CG73ST157,"157  Howard K, White S, Chadban S et al. The cost-effectiveness of early detection and intervention to prevent the progression of chronic kidney disease in Australia. Melbourne: Australia: Kidney Health Australia, 2006.",,,,,,,
CG73ST158,"158  Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney International. 1984; 26(6):861–868.",,,,,,,
CG73ST159,"159  Fliser D, Franek E, Joest M et al. Renal function in the elderly: impact of hypertension and cardiac function. Kidney International. 1997; 51(4):1196–1204.",,,,,,,
CG73ST160,160  Lindeman RD. Is the decline in renal function with normal aging inevitable? Geriatric Nephrology & Urology. 1998; 8(1):7–9.,,,,,,,
CG73ST161,"161  Hemmelgarn BR, Zhang J, Manns BJ et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney International. 2006; 69(12):2155–2161.",,,,,,,
CG73ST162,"162  Halbesma N, Kuiken DS, Brantsma AH et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. Journal of the American Society of Nephrology. 2006; 17(9):2582–2590.",,,,,,,
CG73ST163,"163  Rule AD, Gussak HM, Pond GR et al. Measured and estimated GFR in healthy potential kidney donors. American Journal of Kidney Diseases. 2004; 43(1):112–119.",,,,,,,
CG73ST164,"164  Slack TK, Wilson DM. Normal renal function: CIN and CPAH in healthy donors before and after nephrectomy. Mayo Clinic Proceedings. 1976; 51(5):296–300.",,,,,,,
CG73ST165,"165  Wetzels JF, Kiemeney LA, Swinkels DW et al. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney International. 2007; 72(5):632–637.",,,,,,,
CG73ST166,"166  Rowe JW, Andres R, Tobin JD et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. Journal of Gerontology. 1976; 31(2):155–163.",,,,,,,
CG73ST167,"167  Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney International – Supplement. 2005;(97):S68–S77.",,,,,,,
CG73ST168,"168  Cruickshank JK, Mzayek F, Liu L et al. Origins of the ‘black/white’ difference in blood pressure: roles of birth weight, postnatal growth, early blood pressure, and adolescent body size: the Bogalusa heart study. Circulation. 2005; 111(15):1932–1937.",,,,,,,
CG73ST169,"169  Law CM, Shiell AW, Newsome CA et al. Fetal, infant, and childhood growth and adult blood pressure: a longitudinal study from birth to 22 years of age. Circulation. 2002; 105(9):1088–1092.",,,,,,,
CG73ST170,"170  Evans M, Fryzek JP, Elinder CG et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. American Journal of Kidney Diseases. 2005; 46(5):863–870.",,,,,,,
CG73ST171,"171  Orth SR, Schroeder T, Ritz E et al. Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. Nephrology Dialysis and Transplantation. 2005; 20(11):2414–2419.",,,,,,,
CG73ST172,"172  Hovind P, Rossing P, Tarnow L et al. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2003; 26(3):911–916.",,,,,,,
CG73ST173,"173  Orth SR, Stockmann A, Conradt C et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney International. 1998; 54(3):926–931.",,,,,,,
CG73ST174,"174  Ibanez L, Morlans M, Vidal X et al. Case-control study of regular analgesic and nonsteroidal anti- inflammatory use and end-stage renal disease. Kidney International. 2005; 67(6):2393–2398.",,,,,,,
CG73ST175,"175  Earle KK, Porter KA, Ostberg J et al. Variation in the progression of diabetic nephropathy according to racial origin. Nephrology Dialysis and Transplantation. 2001; 16(2):286–290.",,,,,,,
CG73ST176,"176  Xue JL, Eggers PW, Agodoa LY et al. Longitudinal study of racial and ethnic differences in developing end- stage renal disease among aged medicare beneficiaries. Journal of the American Society of Nephrology. 2007; 18(4):1299–1306.",,,,,,,
CG73ST177,"177  Murray MD, Black PK, Kuzmik DD et al. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. American Journal of the Medical Sciences. 1995; 310(5):188–197.",,,,,,,
CG73ST178,"178  Morlans M, Laporte JR, Vidal X et al. End-stage renal disease and non-narcotic analgesics: A case-control study. British Journal of Clinical Pharmacology. 1990; 30(5):717–723.",,,,,,,
CG73ST179,"179  Fored CM, Ejerblad E, Lindblad P et al. Acetaminophen, aspirin, and chronic renal failure. New England Journal of Medicine. 2001; 345(25):1801–1808.",,,,,,,
CG73ST180,"180  Myers GL, Miller WG, Coresh J et al. Recommendations for improving serum creatinine measurement: A report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry. 2006; 52(1):5–18.",,,,,,,
CG73ST181,"181  Jungers P, Joly D, Nguyen KT et al. Continued late referral of patients with chronic kidney disease. Causes, consequences, and approaches to improvement. Presse Medicale. 2006; 35(1:Pt 1):t–22.",,,,,,,
CG73ST182,"182  Levinsky NG. Specialist evaluation in chronic kidney disease: too little, too late. Annals of  Internal Medicine. 2002; 137(6):542–543.",,,,,,,
CG73ST183,"183  National Institute for Health and Clinical Excellence. Diagnosis and management of type 1 diabetes in children, young people and adults. (CG15). London: UK: National Institute for Health and Clinical Excellence, 2004.",,,,,,,
CG73ST184,"184  National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. (CG43). London: UK: National Institute for Health and Clinical Excellence, 2006.",,,,,,,
CG73ST185,"185  Kohzuki M, Kamimoto M, Wu XM et al. Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. Journal of Hypertension. 2001; 19(10):1877–1882.",,,,,,,
CG73ST186,"186  Hallan S, de MR, Carlsen S et al. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? American Journal of Kidney Diseases. 2006; 47(3):396–405.",,,,,,,
CG73ST187,"187  Castaneda C, Gordon PL, Uhlin KL et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Annals of Internal Medicine. 2001; 135(11):965–976.",,,,,,,
CG73ST188,"188  Eidemak I, Haaber AB, Feldt RB et al. Exercise training and the progression of chronic renal failure. Nephron. 1997; 75(1):36–40.",,,,,,,
CG73ST189,"189  Pechter U, Ots M, Mesikepp S et al. Beneficial effects of water-based exercise in patients with chronic kidney disease. International Journal of Rehabilitation Research. 2003; 26(2):153–156.",,,,,,,
CG73ST190,"190  Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. American Journal of Kidney Diseases. 2003; 41(2):319–327.",,,,,,,
CG73ST191,"191  Saiki A, Nagayama D, Ohhira M et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. International Journal of Obesity. 2005; 29(9):1115–1120.",,,,,,,
CG73ST192,"192  Solerte SB, Fioravanti M, Schifino N et al. Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. International Journal of Obesity. 1989; 13(2):203–211.",,,,,,,
CG73ST193,"193  Perneger TV, Whelton PK, Puddey IB et al. Risk of end-stage renal disease associated with alcohol consumption. American Journal of Epidemiology. 1999; 150(12):1275–1281.",,,,,,,
CG73ST194,"194  Varella L, Utermohlen V. Nutritional support for the patient with renal failure. Critical Care Nursing Clinics of North America. 1993; 5(1):79–96.",,,,,,,
CG73ST195,"195  Klahr S, Buerkert J, Purkerson ML. Role of dietary factors in the progression of chronic renal disease. Kidney International. 1983; 24(5):579–587.",,,,,,,
CG73ST196,"196  Ikizler TA, Greene JH, Wingard RL et al. Spontaneous dietary protein intake during progression of chronic renal failure. Journal of the American Society of Nephrology. 1995; 6(5):1386–1391.",,,,,,,
CG73ST197,"197  Pecoits FR, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome — the heart of the matter. Nephrology Dialysis and Transplantation. 2002; 17(Suppl 11):28–31.",,,,,,,
CG73ST198,"198  British Association for Parenteral and Enteral Nutrition. Malnutrition Universal Screening Tool (“MUST”). BAPEN www.bapen.org.uk/must_tool.html, 2003.",,,,,,,
CG73ST199,"199  Levey AS, Greene T, Beck GJ et al. Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? Journal of the American Society of Nephrology. 1999; 10(11):2426–2439.",,,,,,,
CG73ST200,"200  Giovanetti S, Maggiore Q. A low nitrogen diet with proteins of high biological value for severe chronic uremia. Lancet. 1964; 1:1000–1003.",,,,,,,
CG73ST201,"201  Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. New England Journal of Medicine. 1994; 330(13):877–884.",,,,,,,
CG73ST202,"202  Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. American Journal of Kidney Diseases. 1998; 31(4); 607–617.",,,,,,,
CG73ST203,"203  Schwarz S, Trivedi  BK, Kalantar-Zadeh K et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clinical Journal of the American Society of Nephrolology. 2006; 1(4):825–831.",,,,,,,
CG73ST204,"204  Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrology Dialysis and Transplantation. 2007; 22(10):2909–2916.",,,,,,,
CG73ST205,205  Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Seminars in Dialysis. 2007; 20(4):286–294.,,,,,,,
CG73ST206,"206  Sheikh MS, Maguire, JA et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. Journal of Clinical Investigation. 1989; 83(1):66–73.",,,,,,,
CG73ST207,207  Lancaster KJ. Dietary treatment of blood pressure in kidney disease. Advances in Chronic Kidney Disease. 2004; 11(2):217–221.,,,,,,,
CG73ST208,"208  Pedrini MT, Levey AS, Lau J et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Annals of Internal Medicine. 1996; 124(7):627–632.",,,,,,,
CG73ST209,"209  Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database of Systematic Reviews. 2006;(2):CD001892.",,,,,,,
CG73ST210,"210  Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database of Systematic Reviews. 2007;(4):CD002181.",,,,,,,
CG73ST211,"211  Ihle BU, Becker GJ, Whitworth JA et al. The effect of protein restriction on the progression of renal insufficiency. New England Journal of Medicine. 1989; 321(26):1773–1777.",,,,,,,
CG73ST212,"212  Williams PS, Stevens ME, Fass G et al. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. QJM: monthly journal of the Association of Physicians. 1991; 81(1):837–855.",,,,,,,
CG73ST213,"213  Locatelli F, Alberti D, Graziani G et al. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991; 337(8753):1299–1304.",,,,,,,
CG73ST214,"214  Rosman JBLK, Brandl M, Peris-Becht TPM et al. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. Kidney International – Supplement. 1989; 27(36):S96–S102.",,,,,,,
CG73ST215,"215  Meloni C, Tatangelo P, Cipriani S et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. Journal of Renal Nutrition. 2004; 14(4):208–213.",,,,,,,
CG73ST216,"216  Hansen HP, Tauber LE, Jensen BR et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney International. 2002; 62(1):220–228.",,,,,,,
CG73ST217,"217  Dullaart RP, Beusekamp BJ, Meijer S et al. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care. 1993; 16(2):483–492.",,,,,,,
CG73ST218,"218  Raal FJ, Kalk WJ, Lawson M et al. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. American Journal of Clinical Nutrition. 1994; 60(4): 579–585.",,,,,,,
CG73ST219,"219  Verberk WJ, Kroon AA, Lenders JW et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension. 2007; 50(6):1019–1025.",,,,,,,
CG73ST220,"220  Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of Human Hypertension. 2004; 18(3):139–185.",,,,,,,
CG73ST221,"221  Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Annals of Internal Medicine. 2005; 142(5):342–351.",,,,,,,
CG73ST222,"222  Wright JT, Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA : the Journal of the American Medical Association. 2002; 288(19):2421–2431.",,,,,,,
CG73ST223,"223  Kovesdy CP, Trivedi BK, Kalantar ZK et al. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrology Dialysis and Transplantation. 2006; 21(5):1257–1262.",,,,,,,
CG73ST224,"224  Weiner DE, Tighiouart H, Levey AS et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. Journal of the American Society of Nephrology. 2007; 18(3):960–966.",,,,,,,
CG73ST225,"225  Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. Journal of the American Society of Nephrology. 2005; 16(7): 2170–2179.",,,,,,,
CG73ST226,"226  Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. Journal of the American Society of Nephrology. 2005; 16(10): 3027–3037.",,,,,,,
CG73ST227,"227  Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Annals of Internal Medicine. 2003; 139(4):244–252.",,,,,,,
CG73ST228,"228  Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non- diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005; 365(9463):939–946.",,,,,,,
CG73ST229,"229  Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Archives of Internal Medicine. 2003; 163(13):1555–1565.",,,,,,,
CG73ST230,"230  Hovind P, Rossing P, Tarnow L et al. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney International. 2001; 60(1):277–283.",,,,,,,
CG73ST231,"231  van Bemmel T., Woittiez K, Blauw GJ et al. Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study. Journal of the American Society of Nephrology. 2006; 17(9): 2561–2566.",,,,,,,
CG73ST232,"232  Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Annals of Internal Medicine. 1995; 123(10): 754–762.",,,,,,,
CG73ST233,"233  Perneger TV, Nieto FJ, Whelton PK et al. A prospective study of blood pressure and serum creatinine. Results from the ‘Clue’ Study and the ARIC Study. JAMA : the Journal of the American Medical Association. 1993; 269(4):488–493.",,,,,,,
CG73ST234,"234  Rosansky SJ, Hoover DR, King L et al. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Archives of Internal Medicine. 1990; 150(10): 2073–2076.",,,,,,,
CG73ST235,"235  Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989; 13(5:Suppl): Suppl–93.",,,,,,,
CG73ST236,"236  Walker WG, Neaton JD, Cutler JA et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA: the Journal of the American Medical Association. 1992; 268(21):3085–3091.",,,,,,,
CG73ST237,"237  Strippoli GFM, Bonifati C, Craig M et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews. 2006;(4):CD006257.",,,,,,,
CG73ST238,"238  Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005; 366(9502): 2026–2033.",,,,,,,
CG73ST239,"239  Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine. 2001; 135(2): 73–87.",,,,,,,
CG73ST240,"240  Kent DM, Jafar TH, Hayward RA et al. Progression risk, urinary protein excretion, and treatment effects of Angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. Journal of the American Society of Nephrology. 2007; 18(6):1959–1965.",,,,,,,
CG73ST241,"241  Jennings DL, Kalus JS, Coleman CI et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabetic Medicine. 2007; 24(5):486–493.",,,,,,,
CG73ST242,"242  Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Annals of Internal Medicine. 2008; 148(1):30–48.",,,,,,,
CG73ST243,"243  Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. Journal of the American Society of Nephrology. 2007; 18(10):2766–2772.",,,,,,,
CG73ST244,"244  Dalla VM, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes, Nutrition & Metabolism – Clinical & Experimental. 2004; 17(5): 259–266.",,,,,,,
CG73ST245,"245  Marin R, Ruilope LM, Aljama P et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. Journal of Hypertension. 2001; 19(10):1871–1876.",,,,,,,
CG73ST246,"246  Ruggenenti P, Perna A, Benini R et al. Effects of dihydropyridine calcium channel blockers, angiotensin- converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology. 1998; 9(11):2096–2101.",,,,,,,
CG73ST247,"247  Anon. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997; 349(9069):1857–1863.",,,,,,,
CG73ST248,"248  Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354(9176):359–364.",,,,,,,
CG73ST249,"249  Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Archives of Internal Medicine. 2005; 165(8):947–953.",,,,,,,
CG73ST250,"250  Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.[see comment]. JAMA : the Journal of the American Medical Association. 2001; 285(21):2719–2728.",,,,,,,
CG73ST251,"251  Hendry BM, Viberti GC, Hummel S et al. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM : monthly journal of the Association of Physicians. 1997; 90(4):277–282.",,,,,,,
CG73ST252,"252  Garattini L, Brunetti M, Salvioni F et al. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. Pharmacoeconomics. 1997; 12(1):67–75.",,,,,,,
CG73ST253,"253  Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care. 1996; 19(10):1051–1061.",,,,,,,
CG73ST254,"254  Ruggenenti P, Pagano E, Tammuzzo L et al. Ramipril prolongs life and is cost effective in  chronic proteinuric nephropathies. Kidney International. 2001; 59(1):286–294.",,,,,,,
CG73ST255,"255  Schadlich PK, Brecht JG, Brunetti M et al. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics. 2001; 19(5):497–512.",,,,,,,
CG73ST256,"256  van Hout BA, Simeon GP, McDonnell J et al. Economic evaluation of benazepril in chronic renal insufficiency. Kidney International – Supplement. 1997; 63:S159–S162.",,,,,,,
CG73ST257,"257  Hogan TJ, Elliott WJ, Seto AH et al. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37–47.",,,,,,,
CG73ST258,"258  Palmer AJ, Annemans L, Roze S et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. Journal of Human Hypertension. 2004; 18(10):733–738.",,,,,,,
CG73ST259,"259  Rodby RA, Chiou CF, Borenstein J et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clinical Therapeutics. 2003; 25(7):2102–2119.",,,,,,,
CG73ST260,"260  Palmer AJ, Roze S, Valentine WJ et al. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Medical Weekly. 2006; 136(21–22):346–352.",,,,,,,
CG73ST261,"261  Coyle D, Rodby RA. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Canadian Journal of Cardiology. 2004; 20(1):71–79.",,,,,,,
CG73ST262,"262  Vora J, Carides G, Robinson P. Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom. Current Therapeutic Research, Clinical & Experimental. 2005; 66(6):475–485.",,,,,,,
CG73ST263,"263  Herman WH, Shahinfar S, Carides GW et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care. 2003; 26(3):683–687.",,,,,,,
CG73ST264,"264  Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland—an analysis of the RENAAL study. Swiss Medical Weekly. 2004; 134(31–32):440–447.",,,,,,,
CG73ST265,"265  Burgess ED, Carides GW, Gerth WC et al. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Canadian Journal of Cardiology. 2004; 20(6):613–618.",,,,,,,
CG73ST266,"266  Souchet T, Durand Z, I, Hannedouche T et al. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes & Metabolism. 2003; 29(1):29–35.",,,,,,,
CG73ST267,"267  Coyle D, Rodby R, Soroka S et al. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clinical Therapeutics. 2007; 29(7):1508–1523.",,,,,,,
CG73ST268,"268  Stafylas PC, Sarafidis PA, Grekas DM et al. A cost-effectiveness analysis of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in diabetic nephropathy. Journal of Clinical Hypertension. 2007; 9(10):751–759.",,,,,,,
CG73ST269,"269  Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Archives of Internal Medicine. 2000; 160(5):685–693.",,,,,,,
CG73ST270,"270  Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Archives of Internal Medicine. 1998; 158(1):26–32.",,,,,,,
CG73ST271,"271  Bleyer AJ, Shemanski LR, Burke GL et al. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney International. 2000; 57(5):2072–2079.",,,,,,,
CG73ST272,"272  Nakamura T, Kanno Y, Takenaka T et al. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertension Research – Clinical & Experimental. 2005; 28(5):415–423.",,,,,,,
CG73ST273,"273  Winkelmayer WC, Zhang Z, Shahinfar S et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care. 2006; 29(10):2210–2217.",,,,,,,
CG73ST274,"274  Frances CD, Noguchi H, Massie BM et al. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Archives of Internal Medicine.. 2000; 160(17):2645–2650.",,,,,,,
CG73ST275,"275  Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blockade reduces vascular injury in stroke- prone hypertensive rats. Hypertension. 1998; 31(1:Pt 2):t–8.",,,,,,,
CG73ST276,"276  Rocha R, Chander PN, Zuckerman A et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999; 33(1:Pt 2):t–7.",,,,,,,
CG73ST277,"277  Hene RJ, Boer P, Koomans HA et al. Plasma aldosterone concentrations in chronic renal disease. Kidney International. 1982; 21(1):98–101.",,,,,,,
CG73ST278,278  Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. American Journal of Kidney Diseases. 1993; 22(1):164–173.,,,,,,,
CG73ST279,"279  Rosenberg ME, Salahudeen AK, Hostetter TH. Dietary protein and the renin-angiotensin system in chronic renal allograft rejection. Kidney International – Supplement. 1995; 52:S102–S106.",,,,,,,
CG73ST280,280  Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. American Journal of Kidney Diseases. 2001; 37(4):677–688.,,,,,,,
CG73ST281,"281  Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005; 28(9):2106–2112.",,,,,,,
CG73ST282,"282  van den Meiracker AH, Baggen RG, Pauli S et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. Journal of Hypertension. 2006; 24(11):2285–2292.",,,,,,,
CG73ST283,"283  Chrysostomou A, Pedagogos E, MacGregor L et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist apironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006; 1(2):256–262.",,,,,,,
CG73ST284,"284  Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International. 2006; 70(12):2116–2123.",,,,,,,
CG73ST285,"285  Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabetic Medicine. 2004; 21(5):471–475.",,,,,,,
CG73ST286,"286  Oda H, Keane WF. Recent advances in statins and the kidney. Kidney International – Supplement. 1999; 71: S2–5, 1999 Jul.:S2–S5.",,,,,,,
CG73ST287,"287  Oda H, Keane WF. Lipids in progression of renal disease. Kidney International – Supplement. 1997; 62: S36–8, 1997 Nov.:S36–S38.",,,,,,,
CG73ST288,"288  O’Donnell MP, Kasiske BL, Kim Y et al. Lovastatin inhibits proliferation of rat mesangial cells. Journal of Clinical Investigation. 1993; 91:83–87.",,,,,,,
CG73ST289,"289  Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria (Provisional record). Annals of Internal Medicine. 2006; 145(2):117–124.",,,,,,,
CG73ST290,"290  Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. Journal of the American Society of Nephrology. 2006; 17(7):2006–2016.",,,,,,,
CG73ST291,"291  Strippoli GF, Navaneethan SD, Johnson DW et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. British Medical Journal. 2008; 336(7645):645–651.",,,,,,,
CG73ST292,292  Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383–1389.,,,,,,,
CG73ST293,"293  Cheung BM, Lauder IJ, Lau CP et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. British Journal of Clinical Pharmacology. 2004; 57(5): 640–651.",,,,,,,
CG73ST294,"294  Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326):7–22.",,,,,,,
CG73ST295,"295  Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine. 2005; 353(3):238–248.",,,,,,,
CG73ST296,"296  Kasiske BL, O’Donnell MP, Garvis WJ et al. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circulation Research. 1988; 62(2):367–374.",,,,,,,
CG73ST297,"297  Kasiske BL, O’Donnell MP, Cleary MP et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney International. 1988; 33(3):667–672.",,,,,,,
CG73ST298,"298  O’Donnell MP, Kasiske BL, Kim Y et al. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. American Journal of Kidney Diseases. 1993; 22(1):83–89.",,,,,,,
CG73ST299,"299  Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta- analysis. Kidney International. 2001; 59(1):260–269.",,,,,,,
CG73ST300,"300  Kwan BC, Kronenberg F, Beddhu S et al. Lipoprotein  metabolism  and  lipid  management  in  chronic kidney disease. Journal of the American Society of Nephrology. 2007; 18(4):1246–1261.",,,,,,,
CG73ST301,"301  Tonelli M, Collins D, Robins S et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney International. 2004; 66(3):1123–1130.",,,,,,,
CG73ST302,"302  Chonchol M, Cook T, Kjekshus J et al. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases. 49(3); 373–382.",,,,,,,
CG73ST303,"303  Rabelink TJ, Zwaginga JJ, Koomans HA et al. Thrombosis and hemostasis in renal disease. Kidney International. 1994; 46(2):287–296.",,,,,,,
CG73ST304,"304  Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. American Journal of Hematology. 1979; 7(2):107–117.",,,,,,,
CG73ST305,"305  Gordge MP, Neild GH. Platelet function in uraemia. Platelets. 1991; 2(115)",,,,,,,
CG73ST306,"306  Mezzano D, Tagle R, Panes O et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thrombosis & Haemostasis. 1996; 76(3):312–321.",,,,,,,
CG73ST307,"307  Remuzzi G, Perico N, Zoja C et al. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. Journal of Clinical Investigation. 1990; 86(5):1768–1771.",,,,,,,
CG73ST308,"308  Gordge MP, Faint RW, Rylance PB et al. Platelet function and the bleeding time in progressive renal failure. Thrombosis and Haemostasis. 1988; 60(1):83–87.",,,,,,,
CG73ST309,"309  Escolar G, Cases A, Bastida E et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb–IIIa. Blood. 1990; 76(7):1336–1340.",,,,,,,
CG73ST310,"310  Keltai M, Tonelli M, Mann JFE et al. Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. European Journal of Cardiovascular Prevention & Rehabilitation. 2007; 14(2):312–318.",,,,,,,
CG73ST311,"311  Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. Journal of the American College of Cardiology. 2004; 44(8):1587–1592.",,,,,,,
CG73ST312,"312  Krause MW, Massing M, Kshirsagar A et al. Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease. Renal Failure. 2004; 26(6):715–725.",,,,,,,
CG73ST313,"313  Gibney EM, Casebeer AW, Schooley LM et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: A National Veterans Administration study. Kidney International. 2005; 68(2):826–832.",,,,,,,
CG73ST314,"314  Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. Journal of the American Society of Nephrology. 1995; 6(4):1313–1317.",,,,,,,
CG73ST315,"315  Foley RN, Wang C, Ishani A et al. NHANES III: influence of race on GFR thresholds and detection of metabolic abnormalities. Journal of the American Society of Nephrology. 2007; 18(9):2575–2582.",,,,,,,
CG73ST316,"316  Chonchol M, Shlipak MG, Katz R et al. Relationship of uric acid with progression of kidney disease. American Journal of Kidney Diseases. 2007; 50(2):239–247.",,,,,,,
CG73ST317,"317  Nakagawa T, Kang DH, Feig D et al. Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney International. 2006; 69(10):1722–1725.",,,,,,,
CG73ST318,"318  Sanchez-Lozada LG, Tapia E, Santamaria J et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney International. 2005; 67(1):237–247.",,,,,,,
CG73ST319,"319  Nakagawa T, Mazzali M, Kang DH et al. Hyperuricemia causes glomerular hypertrophy in the rat. American Journal of Nephrology 2003; 23(1):2–7.",,,,,,,
CG73ST320,"320  Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41(6):1183–1190.",,,,,,,
CG73ST321,"321  Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. American Journal of Kidney Diseases. 2006; 47(1):51–59.",,,,,,,
CG73ST322,"322  Yamagata K, Takahashi H, Tomida C et al. Prognosis of asymptomatic hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric patients found in mass screening. Nephron. 2002; 91(1):34–42.",,,,,,,
CG73ST323,"323  Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. Journal of the American Society of Nephrology. 2007; 18(3):875–885.",,,,,,,
CG73ST324,"324  Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrology Dialysis and Transplantation. 2002; 17(8):1419–1425.",,,,,,,
CG73ST325,"325  Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney International. 2007; 71(2):134–139.",,,,,,,
CG73ST326,"326  LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. American Journal of Kidney Diseases. 2005; 45(6):1026–1033.",,,,,,,
CG73ST327,"327  Craver L, Marco MP, Martinez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1–5 – Achievement of K/DOQI target ranges. Nephrology Dialysis and Transplantation. 2007; 22(4):1171–1176.",,,,,,,
CG73ST328,"328  Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International. 2007; 71(1):31–38.",,,,,,,
CG73ST329,"329  St John A., Thomas MB, Davies CP et al. Determinants of intact parathyroid hormone and free 1,25- dihydroxyvitamin D levels in mild and moderate renal failure. Nephron. 1992; 61(4):422–427.",,,,,,,
CG73ST330,330  Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Current Osteoporosis Reports. 2005; 3(1):5–12.,,,,,,,
CG73ST331,"331  Fujii N, Hamano T, Mikami S et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrology Dialysis and Transplantation. 2007; 22(6):1601–1607.",,,,,,,
CG73ST332,"332  Kikuchi Y, Imakiire T, Yamada M et al. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrology Dialysis and Transplantation. 2007; 22(6):1593–1600.",,,,,,,
CG73ST333,"333  Miller PD, Roux C, Boonen S et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Journal of Bone & Mineral Research. 2005; 20(12):2105–2115.",,,,,,,
CG73ST334,"334  Jamal SA, Bauer DC, Ensrud KE et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone & Mineral Research. 2007; 22(4):503–508.",,,,,,,
CG73ST335,"335  Baker LR, Abrams L, Roe CJ et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney International. 1989; 35(2):661–669.",,,,,,,
CG73ST336,"336  Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. Journal of Clinical Endocrinology & Metabolism. 1988; 67(5):929–936.",,,,,,,
CG73ST337,"337  Przedlacki J, Manelius J, Huttunen K. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron. 1995; 69(4):433–437.",,,,,,,
CG73ST338,"338  Ritz E, Kuster S, Schmidt-Gayk H et al. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrology Dialysis and Transplantation. 1995; 10(12):2228–2234.",,,,,,,
CG73ST339,"339  Christiansen C, Rodbro P, Christensen MS et al. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet. 1978; 2(8092:Pt 1):700–703.",,,,,,,
CG73ST340,"340  Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. British Medical Journal. 1995; 310(6976):358–363.",,,,,,,
CG73ST341,"341  Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrology Dialysis and Transplantation. 2004; 19(4):870–876.",,,,,,,
CG73ST342,"342  Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. American Journal of Kidney Diseases. 2006; 47(2):263–276.",,,,,,,
CG73ST343,"343  Al-Aly Z, Quazi RA, Gonzalez EA et al. Changes in Serum 25-Hydroxyvitamin D and Plasma Intact PTH Levels Following Treatment With Ergocalciferol in Patients With CKD. American Journal of Kidney Diseases. 2007; 50(1):59–68.",,,,,,,
CG73ST344,344  British National Formulary (57).  2008.  UK:  BMJ Publishing  Group Ltd and RPS  Publishing. http://www.bnf.org/bnf/,,,,,,,
CG73ST345,"345  Department of Health. Creating a patient-led NHS-delivering the NHS improvement plan. London: UK: Department of Health, 2005.",,,,,,,
CG73ST346,"346  Department of Health. Supporting People with Long Term Conditions. An NHS and Social Care Model to support local innovation and integration. London: UK: Department of Health, 2005.",,,,,,,
CG73ST347,"347  Department of Health. National Service Framework for Renal Services – Part One: dialysis and Transplantation. London: UK: Department of Health, 2004.",,,,,,,
CG73ST348,"348  Ormandy P, Hulme CT, Caress AL, et al. Executive Summary: Identifying chronic kidney disease patients’ priorities and preferences for information topics. Salford: UK: Institute for Health and Social Care Research Report, Univeristy of Salford, 2007.",,,,,,,
CG73ST349,"349  Coulter A, Entwistle V, Gilbert D. Sharing decisions with patients: is the information good enough? British Medical Journal. 1999; 318(7179):318–322.",,,,,,,
CG73ST350,"350  Bekker H, Thornton JG, Airey CM et al. Informed decision making: an annotated bibliography and systematic review. Health Technology Assessment. 1999; 3(1):1–156.",,,,,,,
CG73ST351,"351  Manns BJ, Taub K, Vanderstraeten C et al. The impact of education on chronic kidney disease patients’ plans to initiate dialysis with self-care dialysis: a randomized trial. Kidney International. 2005; 68(4): 1777–1783.",,,,,,,
CG73ST352,"352  Inaguma D, Tatematsu M, Shinjo H et al. Effect of an educational program on the predialysis period for patients with chronic renal failure. Clinical & Experimental Nephrology. 2006; 10(4):274–278.",,,,,,,
CG73ST353,"353  Lindberg JS, Husserl FE, Ross JL et al. Impact of multidisciplinary, early renal education on vascular access placement. Nephrology News & Issues. 2005; 19(3):35–36.",,,,,,,
CG73ST354,"354  Levin A, Lewis M, Mortiboy P et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. American Journal of Kidney Diseases. 1997; 29(4):533–540.",,,,,,,
CG73ST355,"355  Anandarajah S, Tai T, de Lusignan S et al. The validity of searching routinely collected general practice computer data to identify patients with chronic kidney disease (CKD): a manual review of 500 medical records. Nephrology Dialysis and Transplantation. 2005; 20(10):2089–2096.",,,,,,,
CG73ST356,"356  Richards N, Harris K, Whitfield M et al. The impact of population-based identification of chronic kidney disease using estimated gloerular filtration rate (eGFR) reporting. Nephrology Dialysis and Transplantation. 2008; 23(2): 556–561.",,,,,,,
CG73ST357,"357  Richards N, Harris K, Whitfield M et al. Primary care-based disease management of chronic disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrology Dialysis and Transplantation. 2008; 23(2): 549–555.",,,,,,,
CG73ST358,"358  Hemmelgarn BR, Culleton BF, Ghali WA. Derivation and validation of a clinical index for prediction of rapid progression of kidney dysfunction. QJM: monthly journal of the Association of Physicians. 2007; 100(2):87–92.",,,,,,,
CG73ST359,"359  Weiner DE, Tighiouart H, Elsayed EF et al. The Framingham predictive instrument in chronic kidney disease. Journal of the American College of Cardiology. 2007; 50(3):217–224.",,,,,,,
CG73ST360,"360  Garg AX, Bryce AK, William FC et al. Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney International. 2002; 61(6):2165.",,,,,,,
CG73ST361,"361  Iseki K, Ikemiya Y, Kinjo K et al. Prevalence of high fasting plasma glucose and risk of developing end- stage renal disease in screened subjects in Okinawa, Japan. Clinical & Experimental Nephrology. 2004; 8(3):250–256.",,,,,,,
CG73ST362,"362  Whitfield M, Holmes M. Final report to Optimal Renal Care UK Ltd. A cost and clinical effectiveness evaluation of a “disease management programme” for chronic kidney disease (CKD). Sheffield: Sheffield School of Health and Related Research, 2007.",,,,,,,
CG73ST363,363  Government Actuary’s Department. Interim life tables. 2007. http://www.gad.gov.uk/Demography_ Data/Life_Tables/Interim_life_tables.asp,,,,,,,
CG73ST364,"364  Curtis, L. Unit Costs of Health and Social Care. Canterbury: UK: Personal Social Services Research Unit, 2007.",,,,,,,
CG73ST365,"365  Department of Health. NHS reference Costs 2005 – 2006. UK: Department of Health, 2006.",,,,,,,
CG73ST366,"366  Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its  extent  and possible explanations. BMC Health Services Research. 2005; 5(1):21.",,,,,,,
CG73ST367,"367  Klebe B, Irving J, Stevens PE et al. The cost of implementing UK guidelines for the management of chronic kidney disease. Nephrology Dialysis and Transplantation. 2007; 22(9):2504–2512.",,,,,,,
CG73ST368,368  The Information Centre for Health and Social Care. HESonline. 2007. UK: The Information Centre for Health and Social Care. www.hesonline.nhs.uk,,,,,,,
CG73ST369,"369  Palmer AJ, Valentine WJ, Ray JA. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. International Journal of Clinical Practice. 2007; 61(10):1626–1633.",,,,,,,
CG73ST370,"370  UK Transplant. Cost effectiveness of transplantation.:[1–87] Available from: UK Transplant. Last accessed on: 27 Feb, 2008.",,,,,,,
CG73ST371,"371  Baboolal K, McEwan P, Sondhi S et al. The cost of renal dialysis in a UK setting—a multicentre study. Nephrology Dialysis and Transplantation. 2008; 23(6): 1982–1989.",,,,,,,
CG73ST372,"372  de Wit GA, Merkus MP, Krediet RT et al. Health profiles and health preferences of dialysis patients. Nephrology Dialysis and Transplantation. 2002; 17(1):86–92.",,,,,,,
CG73ST379,"379 Speckman RA, McClellan WM, Volkova NV, Jurkovitz CT, Satko SG, Schoolwerth AC et al.  Obesity is associated with family history of ESRD in incident dialysis patients. American Journal 33 of Kidney Diseases. 2006; 48(1):50-58",,,,,,,
CG73ST380,"380St John A., Thomas MB, Davies CP, Mullan B, Dick I, Hutchison B et al. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal  failure. Nephron. 1992; 61(4):422-427",,,,,,,
TA288ST1,"Cummins E, Scott N, Rothnie K et al. Dapagliflozin for the treatment of type 2 diabetes. Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen, November 2012.",,,,,,,
TA288ST2,"Davis S, Sheard J. A review of the Bristol-Myers Squibb/AstraZeneca economic model on the cost-effectiveness of dapagliflozin, November 2012.",,,,,,,
TA288ST3,"Davis S. Dapagliflozin for the treatment of type 2 diabetes: Additional analyses requested by the Committee following the second meeting, April 2013.",,,,,,,
CG87ST1,"Asnani S, Kunhiraman B, Jawa A et al. (2006) Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metabolic Syndrome & Related Disorders 4: 179-84",,,,,,,
CG87ST2,"Bagust A, Beale S (2005) Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics 14: 217-30",,,,,,,
CG87ST3,"Barnett AH, Burger J, Johns D et al. (2007) Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clinical Therapeutics 29: 2333-48",,,,,,,
CG87ST4,"Berhanu P, Perez A, Yu S (2007) Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes, Obesity and Metabolism 9: 512-20",,,,,,,
CG87ST5,"Bolli G, Dotta F, Rochotte E et al. (2008) Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double- blind study. Diabetes, Obesity and Metabolism 10: 82-90",,,,,,,
CG87ST6,"Celeya JM, Fon, F, Ayala, C et al. (2007) A pharmacoeconomic evaluation for diabetes type 2 (DM 2) with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) in monotherapy. Value in Health 10 A254",,,,,,,
CG87ST7,"Davis SN, Johns D, Maggs D et al. (2007) Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 30: 2767-72",,,,,,,
CG87ST8,"DeFronzo RA, Ratner RE, Han J et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092-100",,,,,,,
CG87ST9,"Diamond GA, Bax L, Kaul S (2007) Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 147: 578-81",,,,,,,
CG87ST10,"Dormandy JA, Charbonnel B, Eckland DJ et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive",,,,,,,
CG87ST11,Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-89,,,,,,,
CG87ST12,"Fernandez M, Triplitt C, Wajcberg E et al. (2008) Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 31: 121-7",,,,,,,
CG87ST13,"Fon F, Celeya, JM, Ayala, C et al. (2007) A pharmacoeconomic evaluation for diabetes type 2 (DM 2) with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) as add-on therapy. Value in Health 10 A254",,,,,,,
CG87ST14,"Heine RJ, Van Gaal LF, Johns D et al. (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 143: 559-69",,,,,,,
CG87ST15,"Hermansen K, Kipnes M, Luo E et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity and Metabolism 9: 733-45",,,,,,,
CG87ST16,"Horvath K, Jeitler K, Berghold A et al. (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews issue 2: CD005613",,,,,,,
CG87ST17,"Jagger C, Goyder E, Clarke M et al. (2003) Active life expectancy in people with and without diabetes. Journal of Public Health Medicine 25: 42-6",,,,,,,
CG87ST18,"Kendall DM, Riddle MC, Rosenstock J et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-91",,,,,,,
CG87ST19,"Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370: 1129-36",,,,,,,
CG87ST20,"Lincoff AM, Wolski K, Nicholls SJ et al. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta- analysis of randomized trials. JAMA 298: 1180-8",,,,,,,
CG87ST21,"Mattoo V, Eckland D, Widel M et al. (2005) Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six- month, randomized, double-blind, prospective, multicenter, parallel-group study. Clinical Therapeutics 27: 554-67",,,,,,,
CG87ST22,"McEwan P, Poole, CD, Tetlow, T et al. (2007) Evaluation of the cost- effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion 23: S21-S31",,,,,,,
CG87ST23,"Montanana CF, Herrero, CH, Fernandez, MR (2007) Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal- bolus therapy of overweight type 2 diabetes patients: the PREDICTIVE-BMT trial. Diabetologia 50: S404",,,,,,,
CG87ST24,National Institute for Health and Clinical Excellence (2008) Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 66. Available from www.nice.org.uk/CG66,,,,,,,
CG87ST25,"Nauck MA, Duran S, Kim D et al. (2007a) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50: 259-67",,,,,,,
CG87ST26,"Nauck MA, Meininger G, Sheng D et al. (2007b) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 9: 194-205",,,,,,,
CG87ST27,"Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356: 2457-71",,,,,,,
CG87ST28,"Pan CY, Sinnassamy P, Chung KD et al. (2007) Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Research & Clinical Practice 76: 111-8",,,,,,,
CG87ST29,"Philis-Tsimikas A, Charpentier G, Clauson P et al. (2006) Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clinical Therapeutics 28: 1569-81",,,,,,,
CG87ST30,"Psaty BM, Furberg CD (2007) The record on rosiglitazone and the risk of myocardial infarction. New England Journal of Medicine 357: 67-9",,,,,,,
CG87ST31,"Ray JA, Boye KS, Yurgin N et al. (2007) Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Current Medical Research and Opinion 23: 609-22",,,,,,,
CG87ST32,"Raz I, Stranks S, Filipczak R et al. (2005) Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clinical Therapeutics 27: 1432-43",,,,,,,
CG87ST33,"Richter B, Bandeira-Echtler E, Bergerhoff K et al. (2008) Dipeptidyl peptidase- 4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews issue 2: CD006739",,,,,,,
CG87ST34,"Rosenstock J, Davies M, Home PD et al. (2008) A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51: 408-16",,,,,,,
CG87ST35,"Rosenstock J, Einhorn D, Hershon K et al. (2002) Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. International Journal of Clinical Practice 56: 251-7",,,,,,,
CG87ST36,"Scheen A, Charbonnel, B (2006) Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes. Diabetes 55: A134",,,,,,,
CG87ST37,"Schwarz B, Gouveia M, Chen J et al. (2008) Cost-effectiveness of sitagliptin- based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes, Obesity and Metabolism 10 Suppl 1: 43-55",,,,,,,
CG87ST38,"Scott R, Loeys T, Davies MJ et al. (2008) Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 10:959-69",,,,,,,
CG87ST39,"Secnik BK, Matza LS, Oglesby A et al. (2006) Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health & Quality of Life Outcomes 4: 80",,,,,,,
CG87ST40,"Shah PK, Mudahar, S, Aroda, V et al. (2007) Weight gain and fat distribution with pioglitazone in patients with type 2 diabetes on insulin therapy. Journal of Investigative Medicine 55 (Supplement):S95",,,,,,,
CG87ST41,"Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-95",,,,,,,
CG87ST42,"Smith I, Palmer AJ, Roze S et al. (2004) Cost-effectiveness analysis of insulin detemir compared to NPH insulin in patients with type 2 diabetes in the United Kingdom. Value in Health 7: 735-6.",,,,,,,
CG87ST43,"Tran, K., Banerjee, S., Li, H. et al. (2007) Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost- effectiveness. Ottawa: The Canadian Agency for Drugs and Technologies in Health (CADTH)",,,,,,,
CG87ST44,"Valentine WJ, Erny-Albrecht KM, Ray JA et al. (2007) Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Advances in Therapy 24: 273-90",,,,,,,
CG87ST45,"Warren E, Weatherley-Jones E, Chilcott J et al. (2004) Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment 8: iii, 1-iii,57",,,,,,,
CG87ST46,"Woehl A, Evans M, Tetlow AP et al. (2008) Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub- optimally controlled Type 2 diabetes in the United Kingdom. Cardiovascular Diabetology 7: 24",,,,,,,
CG87ST47,"Yurgin N, Secnik K, Hayes C et al. (2006) Patient reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Diabetologia 49: 474-5",,,,,,,
CG87ST48,"Zinman B, Hoogwerf BJ, Duran GS et al. (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 146: 477-85",,,,,,,
CG173ST1,"Agrawal RP, Goswami J, Jain S et al. (2009) Management of diabetic 
neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective 
double-blind randomized placebo-controlled study. Diabetes Research & 
Clinical Practice 83: 371-8. 
",,,,,,,
CG173ST2,"Arbaiza D, Vidal O (2007) Tramadol in the treatment of neuropathic cancer 
pain: a double-blind, placebo-controlled study. Clinical Drug Investigation 27: 
75-83.",,,,,,,
CG173ST3,"Arezzo JC, Rosenstock J, Lamoreaux L et al. (2008) Efficacy and safety of 
pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a 
double-blind placebo-controlled trial. BMC Neurology 8: 33. 
",,,,,,,
CG173ST4,"Backonja M, Beydoun A, Edwards KR et al. (1998) Gabapentin for the 
symptomatic treatment of painful neuropathy in patients with diabetes mellitus. 
A randomized controlled trial. Journal of the American Medical Association 
280: 1831-6.",,,,,,,
CG173ST5,"Backonja M, Wallace MS, Blonsky ER et al. (2008) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. The Lancet Neurology 7: 1106-12.",,,,,,,
CG173ST6,"Bansal D, Bhansali A, Hota D et al. (2009) Amitriptyline vs. pregabalin in 
painful diabetic neuropathy: a randomized double blind clinical trial. Diabetic 
Medicine 26: 1019-26.",,,,,,,
CG173ST7,"Beniczky S, Tajti J, Timea VE et al. (2005) Evidence-based pharmacological 
treatment of neuropathic pain syndromes. Journal of Neural Transmission 
112: 735–49. 
",,,,,,,
CG173ST8,"Bernstein JE, Korman NJ, Bickers DR et al. (1989) Topical capsaicin 
treatment of chronic postherpetic neuralgia. Journal of the American Academy 
of Dermatology 21: 265-70",,,,,,,
CG173ST9,"Beydoun A, Shaibani A, Hopwood M et al. (2006) Oxcarbazepine in painful 
diabetic neuropathy: results of a dose-ranging study. Acta Neurologica 
Scandinavica 113: 395-404. 
",,,,,,,
CG173ST10,"Biesbroeck R, Bril V, Hollander P et al. (1995) A double-blind comparison of 
topical capsaicin and oral amitriptyline in painful diabetic neuropathy. 
Advances in Therapy 12: 111-20.",,,,,,,
CG173ST11,"Bone M, Critchley P, Buggy DJ (2002) Gabapentin in postamputation 
phantom limb pain:",,,,,,,
CG173ST12,"Bouhassira D, Lanteri-Minet M, Attal N et al (2008) Prevalence of chronic pain 
with neuropathic characteristics in the general population. Pain 136:380–387.",,,,,,,
CG173ST13,"Boureau F, Legallicier P, Kabir-Ahmadi M (2003) Tramadol in post-herpetic 
neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 104: 323-
31 A randomized ",,,,,,,
CG173ST14,"Bowsher D (1997) The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. Journal of Pain & Symptom Management 13: 327-31.",,,,,,,
CG173ST15,"Breuer B, Pappagallo M, Knotkova H et al. (2007) A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clinical Therapeutics 29: 2022-30. ",,,,,,,
CG173ST16,"Cardenas DD, Warms CA, Turner JA et al. (2002) Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 96: 365-73. ",,,,,,,
CG173ST17,"Chandra K, Shafiq N, Pandhi P et al. (2006) Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. International Journal of Clinical Pharmacology & Therapeutics 44: 358-63.",,,,,,,
CG173ST18,"Cheville AL, Sloan JA, Northfelt DW et al. (2009) Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Supportive Care in Cancer 17: 451-60. ",,,,,,,
CG173ST19,"Clifford DB, Simpson DM, Brown S et al. (2012) A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. Journal of Acquired Immune Deficiency Syndromes: JAIDS 59: 126-33. ",,,,,,,
CG173ST20,"Davidoff G, Guarracini M, Roth E et al. (1987) Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study. Pain 29: 151-61. ",,,,,,,
CG173ST21,"Dieleman JP, Kerklaan J, Huygen FJ et al. (2008) Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 31: 137: 681–8. ",,,,,,,
CG173ST22,"Dogra S, Beydoun S, Mazzola J et al. (2005) Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. European journal of pain (London, England) 9: 543-54. ",,,,,,,
CG173ST23,"Donofrio P, Capsaicin study group (1992) Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 15: 159-65. ",,,,,,,
CG173ST24,"Dworkin RH, Turk DC, Farrar JT, et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9–19. ",,,,,,,
CG173ST25,"Dworkin RH, Corbin AE, Young JP, Jr. et al. (2003) Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.[see comment]. Neurology 60: 1274-83. ",,,,,,,
CG173ST26,"Eisenberg E, Lurie Y, Braker C et al. (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57: 505-9.",,,,,,,
CG173ST27,"Falah M, Madsen C, Holbech JV et al. (2012) A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. European Journal of Pain 16: 860-9. ",,,,,,,
CG173ST28,"Finnerup NB, Sindrup SH, Bach FW et al. (2002) Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 96: 375-83. ",,,,,,,
CG173ST29,"Finnerup NB, Sindrup SH, Bach FW et al. (2009) Lamotrigine in spinal cord injury pain: a randomized controlled trial. Spinal Cord 47: 861-7. ",,,,,,,
CG173ST30,"Freynhagen R, Strojek K, Griesing T et al. (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115: 254-63. ",,,,,,,
CG173ST31,"Gao Y, Ning G, Jia WP et al. (2010) Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chinese Medical Journal 123: 3184-92. ",,,,,,,
CG173ST32,"Gilron I, Bailey J.M., Tu D et al. (2012) Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 374: 1252-61. ",,,,,,,
CG173ST33,"Gimbel JS, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial.[see comment]. Neurology 60: 927-34. ",,,,,,,
CG173ST34,"Goldstein DJ, Lu Y, Detke MJ et al. (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116: 109-18. ",,,,,,,
CG173ST35,"Gordh TE, Stubhaug A, Jensen TS et al. (2008) Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 138: 255-66. ",,,,,,,
CG173ST36,"Graff-Radford SB, Shaw LR, Naliboff BN (2000) Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clinical Journal of Pain 16: 188-92. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 102 of 138 ",,,,,,,
CG173ST37,"Grosskopf J, Mazzola J, Wan Y et al. (2006) A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica 114: 177-80. ",,,,,,,
CG173ST38,"Guan Y, Ding X, Cheng Y et al. (2011) Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. Clinical Therapeutics 33: 159-66. ",,,,,,,
CG173ST39,"Hahn K, Arendt G, Braun JS et al. (2004) A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Journal of Neurology 251: 1260-6. ",,,,,,,
CG173ST40,"Hanna M, O'Brien C, Wilson MC (2008) Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain 12: 804-13. ",,,,,,,
CG173ST41,"Harati Y, Gooch C, Swenson M et al. (1998) Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.[see comment]. Neurology 50: 1842-6. ",,,,,,,
CG173ST42,"Holbech J.V., Otto M., Bach FW et al. (2011) The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. European Journal of Pain: Ejp 15: 608-14. ",,,,,,,
CG173ST43,"Huse E, Larbig W, Flor H et al. (2001) The effect of opioids on phantom limb pain and cortical reorganization. Pain 90: 47-55. ",,,,,,,
CG173ST44,International Association for the Study of Pain (2007) IASP taxonomy [online; accessed 30 April 20139] ,,,,,,,
CG173ST45,"Irving GA, Backonja MM, Dunteman E et al. (2011) A Multicenter, Randomized, Double-Blind, Controlled Study of NGX-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia. Pain Medicine 12: 99-109. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 103 of 138 ",,,,,,,
CG173ST46,"Jensen TS, Backonja MM, Hernandez Jimenez S et al. (2006) New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes & Vascular Disease Research 3: 108–19. ",,,,,,,
CG173ST47,"Jung BF, Johnson RW, Griffin DR et al. (2004) Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62: 1545–51. ",,,,,,,
CG173ST48,"Kalso E, Tasmuth T, Neuvonen PJ (1996) Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 64: 293-302. ",,,,,,,
CG173ST49,"Kautio AL, Haanpaa M, Saarto T et al. (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. Journal of Pain & Symptom Management 35: 31-9. ",,,,,,,
CG173ST50,"Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367: 1618–25. ",,,,,,,
CG173ST51,"Khoromi S., Patsalides A., Parada S et al. (2005) Topiramate in Chronic Lumbar Radicular Pain. The Journal of Pain 6: 829-36. ",,,,,,,
CG173ST52,"Khoromi S, Cui L, Nackers L et al. (2007) Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 130: 66-75. ",,,,,,,
CG173ST53,"Kieburtz K, Simpson D, Yiannoutsos C et al. (1998) A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 51: 1682-8. ",,,,,,,
CG173ST54,"Kim JS, Bashford G, Murphy TK et al. (2011) Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain 152: 1018-23. ",,,,,,,
CG173ST55,"Kochar DK, Garg P, Bumb RA et al. (2005) Divalproex sodium in the management of post-herpetic neuralgia: A randomized double-blind placebo-controlled study. QJM - Monthly Journal of the Association of Physicians 98: 29-34. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 104 of 138 ",,,,,,,
CG173ST56,"Kochar DK, Jain N, Agarwal RP et al. (2002) Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study.[see comment]. Acta Neurologica Scandinavica 106: 248-52. ",,,,,,,
CG173ST57,"Kochar DK, Rawat N, Agrawal RP et al. (2004) Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM : monthly journal of the Association of Physicians 97: 33-8. ",,,,,,,
CG173ST58,"Leijon G, Boivie J (1989) Central post-stroke pain--a controlled trial of amitriptyline and carbamazepine. Pain 36: 27-36. ",,,,,,,
CG173ST59,"Lesser H, Sharma U, Lamoreaux L et al. (2004) Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63: 2104-10. ",,,,,,,
CG173ST60,"Levendoglu F, Ogun CO, Ozerbil O et al. (2004) Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 29: 743-51. ",,,,,,,
CG173ST61,"Low PA, Opfer-Gehrking TL, Dyck PJ et al. (1995) Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 62: 163-8. ",,,,,,,
CG173ST62,"Luria Y, Brecker C, Daoud D et al. (2000) Lamotrigine in the treatment of painful diabetic neuropathy: A randomized, placebo-controlled study. Progress in Pain Research and Management 16: 857-62. ",,,,,,,
CG173ST63,"Max MB, Schafer SC, Culnane M et al. (1988) Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 38: 1427-32. ",,,,,,,
CG173ST64,McCarberg B (2006) Pharmacotherapy for neuropathic pain: The old and the new. Advanced Studies in Medicine 6: 399–408. ,,,,,,,
CG173ST65,"McCleane G (1999) 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial.[see comment]. Pain 83: 105-7. ",,,,,,,
CG173ST66,"McCleane G (2000) Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 105 of 138 ",,,,,,,
CG173ST67,"Mikkelsen T, Werner MU, Lassen B et al. (2004) Pain and sensory dysfunction 6 to 12 months after inguinal herniotomy. Anesthesia Analgesia 99: 146–51. ",,,,,,,
CG173ST68,"Mishra S, Bhatnagar S, Goyal GN et al. (2012) A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. American Journal of Hospice & Palliative Medicine 29: 177-82. ",,,,,,,
CG173ST69,"Moon DE, Lee DI, Lee SC et al. (2010) Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clinical Therapeutics 32: 2370-85. ",,,,,,,
CG173ST70,"Moore RA, Edwards JE, McQuay HJ (2005) Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain 116: 322–31. ",,,,,,,
CG173ST71,"Morello CM, Leckband SG, Stoner CP et al. (1999) Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159: 1931-7. ",,,,,,,
CG173ST72,"Norrbrink C, Lundeberg T (2009) Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clinical Journal of Pain 25: 177-84. ",,,,,,,
CG173ST73,"Nurmikko TJ, Serpell MG, Hoggart B et al. (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133: 210-20. ",,,,,,,
CG173ST74,"Otto M., Bach FW, Jensen T.S. et al. (2008) Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 139: 275-83. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 106 of 138 ",,,,,,,
CG173ST75,"Paice JA, Ferrans CE, Lashley FR et al. (2000) Topical capsaicin in the management of HIV-associated peripheral neuropathy. Journal of Pain and Symptom Management 19: 45-52. ",,,,,,,
CG173ST76,"Rao RD, Michalak JC, Sloan JA et al. (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110: 2110-8. ",,,,,,,
CG173ST77,"Rao RD, Flynn PJ, Sloan JA et al. (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112: 2802-8. ",,,,,,,
CG173ST78,"Raskin J, Pritchett YL, Wang F et al. (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine 6: 346-56. ",,,,,,,
CG173ST79,"Raskin P, Donofrio PD, Rosenthal NR et al. (2004) Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63: 865-73. ",,,,,,,
CG173ST80,"Rauck RL, Shaibani A, Biton V et al. (2007) Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clinical Journal of Pain 23: 150-8. ",,,,,,,
CG173ST81,"Revicki DA, Wood M (1998) Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord. 48: 25–36. ",,,,,,,
CG173ST82,"Rice ASC, Maton S (2001) Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 94: 215-24. ",,,,,,,
CG173ST83,"Richter RW, Portenoy R, Sharma U et al. (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. The journal of pain: official journal of the American Pain Society 6: 253-60. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 107 of 138 ",,,,,,,
CG173ST84,"Rintala DH, Holmes SA, Courtade D et al. (2007) Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury.[erratum appears in Arch Phys Med Rehabil. 2008 Jun;89(6):1206]. Archives of Physical Medicine & Rehabilitation 88: 1547-60. ",,,,,,,
CG173ST85,"Robinson LR, Czerniecki JM, Ehde DM et al. (2004) Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. Archives of Physical Medicine & Rehabilitation 85: 1-6. ",,,,,,,
CG173ST86,"Rog DJ, Nurmikko TJ, Friede T et al. (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65: 812-9. ",,,,,,,
CG173ST87,"Rosenstock J, Tuchman M, Lamoreaux L et al. (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110: 628-38. ",,,,,,,
CG173ST88,"Rossi S, Mataluni G, Codeca C et al. (2009) Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. European Journal of Neurology 16: 360-6. ",,,,,,,
CG173ST89,"Rowbotham M, Harden N, Stacey B et al. (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280: 1837-42. ",,,,,,,
CG173ST90,"Rowbotham MC, Goli V, Kunz NR et al. (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.[erratum appears in Pain. 2005 Jan;113(1-2):248]. Pain 110: 697-706. ",,,,,,,
CG173ST91,"Sabatowski R, Galvez R, Cherry DA et al. (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109: 26-35. ",,,,,,,
CG173ST92,"Satoh J, Yagihashi S, Baba M et al. (2011) Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 108 of 138 ",,,,,,,
CG173ST93,"Scheffler NM, Sheitel PL, Lipton MN (1991) Treatment of painful diabetic neuropathy with capsaicin 0.075%. Journal of the American Podiatric Medical Association 81: 288-93. ",,,,,,,
CG173ST94,Schmader KE (2002) Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. The Clinical Journal of Pain 18: 350–4. ,,,,,,,
CG173ST95,"Selvarajah D, Gandhi R, Emery CJ et al. (2010) Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 33: 128-30. ",,,,,,,
CG173ST96,"Shaibani A, Fares S, Selam JL et al. (2009) Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. Journal of Pain 10: 818-28. ",,,,,,,
CG173ST97,Shipton E (2008) Post-surgical neuropathic pain. ANZ Journal of Surgery 78: 548–55. ,,,,,,,
CG173ST98,"Siddall PJ, Cousins MJ, Otte A et al. (2006) Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.[see comment]. Neurology 67: 1792-800. ",,,,,,,
CG173ST99,Simpson DA (2001) Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease 3: 53-62. ,,,,,,,
CG173ST100,"Simpson DM, Olney R, McArthur JC et al. (2000) A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54: 2115-9. ",,,,,,,
CG173ST101,"Simpson DM, McArthur JC, Olney R et al. (2003) Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60: 1508-14. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 109 of 138 ",,,,,,,
CG173ST102,Simpson DM et al. (2008) Controlled trial of high-concentration capsaicin patch in painful HIV neuropathy. Neurology 70: 2–2313. ,,,,,,,
CG173ST103,"Simpson DM, Schifitto G, Clifford DB et al. (2010) Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74: 413-20. ",,,,,,,
CG173ST104,"Sindrup SH, Andersen G, Madsen C et al. (1999) Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 83: 85-90. ",,,,,,,
CG173ST105,"Sindrup SH, Bach FW, Madsen C et al. (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60: 1284-9. ",,,,,,,
CG173ST106,"Smith BH, Torrance N, Ferguson JA et al. (2012) Towards a definition of refractory neuropathic pain for epidemiological research. An international Delphi survey of experts. BioMed Central Neurology 12:29. ",,,,,,,
CG173ST107,"Smith BH, Torrance N (2010) Neuropathic pain. In: Croft PR, editor. Chronic pain epidemiology: from aetiology to public health. Oxford: Oxford University Press, p 209–233. ",,,,,,,
CG173ST108,"Smith DG, Ehde DM, Hanley MA et al. (2005) Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. Journal of Rehabilitation Research & Development 42: 645-54. ",,,,,,,
CG173ST109,"Stacey BR, Barrett JA, Whalen E et al. (2008) Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. Journal of Pain 9: 1006-17. ",,,,,,,
CG173ST110,"Sullivan SD, Lew DP, Devine EB et al. (2002) Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics 20:1079–89.Tandan R, Lewis GA, Krusinski PB et al. (1992) Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 15: 8-14. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 110 of 138 ",,,,,,,
CG173ST111,"Tasmuth T, Hartel B, Kalso E (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain: Ejp 6: 17-24. ",,,,,,,
CG173ST112,"Thienel U, Neto W, Schwabe SK et al. (2004) Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurologica Scandinavica 110: 221-31. ",,,,,,,
CG173ST113,"Tolle T, Freynhagen R, Versavel M et al. (2008) Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. European journal of pain (London, England) 12: 203-13. ",,,,,,,
CG173ST114,"Torrance N, Smith BH, Bennett MI et al. (2006) The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. The Journal of Pain 7:281–289. ",,,,,,,
CG173ST115,"van SR, Feister HA, Young JP, Jr. et al. (2006) Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Current Medical Research & Opinion 22: 375-84. ",,,,,,,
CG173ST116,"Vestergaard K, Andersen G, Gottrup H et al. (2001) Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 56: 184-90. ",,,,,,,
CG173ST117,"Vinik AI, Tuchman M, Safirstein B et al. (2007) Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies.[see comment]. Pain 128: 169-79. ",,,,,,,
CG173ST118,"Vranken JH, Dijkgraaf MG, Kruis MR et al. (2008) Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 136: 150-7. ",,,,,,,
CG173ST119,"Vranken JH, Hollmann MW, van der Vegt MH et al. (2011) Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain 152: 267-73. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 111 of 138 ",,,,,,,
CG173ST120,"Vrethem M, Boivie J, Arnqvist H et al. (1997) A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clinical Journal of Pain 13: 313-23. ",,,,,,,
CG173ST121,"Wade DT, Makela P, Robson P et al. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 10: 434-41. ",,,,,,,
CG173ST122,"Watson CP, Evans RJ (1992) The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain 51: 375-9. ",,,,,,,
CG173ST123,"Watson CP, Tyler KL, Bickers DR et al. (1993) A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clinical Therapeutics 15: 510-26. ",,,,,,,
CG173ST124,"Watson CP, Vernich L, Chipman M et al. (1998) Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 51: 1166-71. ",,,,,,,
CG173ST125,"Webster LR, Tark M, Rauck R et al. (2010) Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurology 10: 92. ",,,,,,,
CG173ST126,"Webster LR, Malan TP, Tuchman MM et al. (2010) A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Journal of Pain 11: 972-82. ",,,,,,,
CG173ST127,"Wernicke JF, Pritchett YL, D'Souza DN et al. (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67: 1411-20. ",,,,,,,
CG173ST128,"Wilby J, Kainth A, Hawkins N et al. (2005) Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technology Assessment 9: 1–157. Neuropathic pain – pharmacological management: NICE clinical guideline 173 (November 2013) Page 112 of 138 ",,,,,,,
IPG257ST1,"Close N, Alejandro R, Hering B et al. (2007) Second annual analysis of the collaborative islet transplant registry. Transplantation Proceedings 39: 179-182. ",,,,,,,
IPG257ST2,"Shapiro AM, Ricordi C, Hering BJ et al. (28-9-2006) International trial  of the Edmonton protocol for islet transplantation.[see comment]. New England Journal of Medicine 355: 1318-1330.  ",,,,,,,
IPG257ST3," Ryan EA, Paty BW, Senior PA et al. (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54: 2060-2069. ",,,,,,,
IPG257ST4,Poggioli R. (2006) Quality of life after islet transplantation. American Journal of Transplantation 6: 371-378. ,,,,,,,
IPG257ST5, Bucher P. (2004) Morbidity associated with intraportal islet transplantation. Transplantation Proceedings 36: 1119-1120. ,,,,,,,
IPG257ST6,"Hafiz MM, Faradji RN, Froud T et al. (27-12-2005) Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 80: 1718-1728. ",,,,,,,
IPG257ST7," Molinari M, Al Saif F, Ryan EA et al. (2005) Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. American Journal of Transplantation 5: 2799-2804. ",,,,,,,
IPG257ST8,"Barshes NR, Agee EE, Zgabay T et al. (2006) West Nile virus encephalopathy following pancreatic islet transplantation. American Journal of Transplantation 6: 3037-3037. ",,,,,,,
IPG257ST9,"Toso C, Shapiro JAM, Bowker S et al (2007) Quality of life after islet cell transplantation : impact of the number of islet transfusions and metabolic outcome. Transplantation 84: 664-667 ",,,,,,,
TA71ST1,"Coronary artery stents: rapid systematic review & economic evaluation, February 2003",,,,,,,
TA71ST2,"Assessment report – addendum A – data no longer confidential, June 2003",,,,,,,
TA71ST3,"Assessment report – addendum B - further analysis requested by the Appraisal Committee, May 2003",,,,,,,
TA152ST1,"Hill R, Boland A, Dickson R, et al. Drug-eluting stents: a systematc review and economic evaluation, November 2005",,,,,,,
